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"It was the best of times, it was the worst of times, it was the age of wisdom, it was the age 
of foolishness, it was the epoch of belief, it was the epoch of incredulity, it was the season of 
Light, it was the season of Darkness, it was the spring of hope, it was the winter of despair, we had 
everything before us, we had nothing before us, we were all going direct to Heaven, we were all 
going direct the other way […]” 
A Tale of Two Cities (Charles Dickens) 
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English summary 
 
Selective modulation the Protein Kinase CK2: discovery, syntheses and characterization of non-
ATP site inhibitors. 
 
The protein kinase CK2 is a tetrameric enzyme composed of a dimer of regulatory 
subunits (β) and two catalytic subunits, CK2α and/or CK2α’. The catalytic subunit of CK2 is 
constitutively active, while the regulatory subunit modulates the selectivity toward a subset of 
substrate proteins. CK2 is a ubiquitous Ser/Thr protein kinase involved in the control of various 
signaling pathways, and dysregulation of CK2 promotes cancer development. CK2 has been 
proved to be a valuable target in cancer treatment.  
Our objective was to target CK2 outside the ATP-pocket. Two independent classes of 
compounds were studied: 
 Based on a first hit with a low potency (IC50 = 30 µM) but a non-ATP competitive 
mechanism of action, several 2-aminothiazole derivatives were synthesized to lead to a 
potent (IC50 = 0.6 µM) and cell efficient allosteric inhibitor of CK2. Using single mutation 
scanning, CD spectrometry, STD-NMR and docking experiments, the binding site of our 
compounds was precisely defined outside the ATP-pocket, at the interface of the 
glycine-rich loop and the αC-helix. 
 
 Inhibitors of the α/β interaction were studied from a small cyclic peptide to the 
development of small molecules through Virtual Ligand Screening. Structures Activity 
Studies were conducted on the synthesized derivatives and cellular based assays to 
evaluate the α/β inhibitors were set up. 
The two classes of compounds developed herein are valuable tools to understand the 
physiological regulation of the protein kinase CK2, and potential new opportunities in cancer 
treatment. 
 
Key words: Oncology, Medicinal chemistry, Biology, Protein Kinase 
  
6 
 
German summary 
 
Selektive Modulation der Proteinkinase CK2: Entdeckung, Synthese und Charakterisierung 
von nicht ATP-kompetitiven Hemmstoffen. 
Das Protein Kinase CK2 ist ein tetrameres Enzym, das aus einem Dimer von 
regulatorischen Untereinheiten (β) und zwei katalytischen Untereinheiten (CK2α und/oder CK2α’) 
besteht. Die katalytische Untereinheit der CK2 ist konstitutiv aktiv, während die regulatorische 
Untereinheit die Auswahl einiger der durch CK2 phosphorylierten Substrate steuert. CK2 ist eine 
ubiquitäre Proteinkinase, die an der Kontrolle zahlreicher Signalwege beteiligt ist. Eine 
Fehlregulation der CK2 fördert die Tumorenstehung. Es konnte gezeigt werden, dass CK2 eine 
vielversprechende Zielstruktur für die Entwicklung neuer Therapeutika ist. Unser Ziel war es, neue 
Hemmstoffe der Proteinkinase CK2 zu entwickeln, die an anderen Stellen als dem aktiven 
Zentrum angreifen.  
Zwei Serien von Verbindungen sind untersucht worden: 
 Basierend auf einem ersten schwach aktiven “Hit” (IC50 = 30 µM), der einen nicht-ATP-
kompetitiven Wirkmechanismus aufwies, wurden einige neue 2-Aminothiazol-Derivate 
synthetisiert. Dadurch wurden allosterische Inhibitoren mit einer deutlich gesteigerte 
Potenz (IC50 = 0,6 µM) und einer beachtlichen Zellaktivität erhalten. Mittels eines CK2-
Punktmutanten-Screenings, Zirkulardichroismus-Spektrometrie, STD-NMR und molekularer 
Docking-Simulationen konnte die Bindestelle unserer Hemmstoffe außerhalb der ATP-
Bindetasche, zwischen der Glycin-reichen Schleife und der αC-Helix, lokalisiert werden. 
 
 Desweiteren wurden niedermolekulare Inhibitoren der α/β-Interaktion entwickelt, 
ausgehend von einem zyklischen Peptid sowie von Hitverbindungen aus einem virtuellen 
Screening. Neue Verbindungen wurden synthetisiert und die Struktur-
Wirkungsbeziehungen analysiert; zusätzlich wurde ein Zellassay zur Überprüfung des 
postulierten Wirkmechanismus etabliert. 
Die beiden entwickelten Verbindungsklassen sind interessante Werkzeuge, um die 
physiologische Regulation der Proteinkinase CK2 näher zu analysieren; überdies stellen sie 
Ausgangspunkte für die Entwicklung neuartiger Krebstherapeutika dar. 
Stichworte: Onkologie, Medizinische Chemie, Biologie, Protein Kinase  
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French summary 
 
Modulation sélective de la Protéine Kinase CK2 : Identification, synthèse et caractérisation 
d’inhibiteurs ne ciblant pas le site ATP. 
 
La Protéine Kinase CK2 est une enzyme tétramérique composé d’un dimère de sous-unité 
régulatrice (β) et de deux sous-unités catalytiques, CK2α et/ou CK2α’. La sous-unité catalytique 
de CK2 est constitutivement active alors que la sous-unité régulatrice régule seulement la 
sélection des substrats phosphorylés par CK2. CK2 est une Ser/Thr protéine kinase ubiquitaire 
impliquée dans le contrôle de nombreuses voies de signalisations. La dérégulation de CK2 
promeut le développement des cancers et il a été démontré que CK2 est une cible pertinente 
dans le traitement des cancers. 
Notre objectif était de cibler la protéine kinase CK2 de manière indépendante du site 
actif. Deux séries de composés ont été étudiés : 
 Basé sur un premier hit faiblement actif (CI50 = 30 µM) mais inhibant CK2 de manière non-
ATP compétitive, des dérivés comportant le noyau 2-aminothiazole ont été synthétisés et 
un composé actif (CI50 = 0,6 µM) et efficace in cellulo a été obtenu. Grace à des 
expériences sur des mutants ponctuels de CK2, des expériences de dichroïsme circulaire, 
de la STD-RMN et de la modélisation moléculaire, le site de fixation de nos inhibiteurs a 
été précisément défini à l’interface de la boucle riche en glycine et de l’hélice-αC. 
 
 Des inhibiteurs de l’interaction α/β ont été étudiés à partir d’un peptide cyclique jusqu’au 
développement de petites molécules via un screening virtuel. Des études de relations 
structure-activité ont été réalisé sur la série de composés synthétisées et des tests 
cellulaires ont été mis en place afin d’évaluer ces composés. 
 
Les deux classes de molécules décrites sont des outils intéressants pour comprendre la 
régulation physiologique de la protéine kinase CK2 et des opportunités prometteuses dans le 
traitement de certains cancers. 
 
Mots-clés: Oncologie, Chimie Médicinale, Biologie, Protéine Kinases 
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1.1 Cancer and cell signaling 
 
1.1.2 Epidemiology 
Cancers were responsible for 5660 thousands deaths in the world in 1990 and 8236 
thousands in 2013, representing 15% of human mortality in 2013 (Fig 1). Deaths caused by cancer 
are generally increasing, mainly because of ageing of the world’s population. Notably, death 
rates for cancers are not homogeneous, from cancer types but also from geographical area.1,2 
 
 
Fig 1: Percentages of death causes in the world in 1990 and 2013 (Reprinted from the Lancet GBD 
20132, Copyright (2016), with permission from Elsevier). 
In 2008, 12.7 million cancer cases and 7.6 million cancer deaths were estimated to have 
occurred. For females, the most frequent cancer is breast cancer with 23% of total cancer cases 
and 14% of cancer deaths. For males, lung cancer is the most frequent with 17% of the cases and 
23% of deaths. Notably, mortality rates are similar in developing countries and in developed 
countries.3 
 
1.1.3 Cancer definition 
Sometimes, cancers are classified by the organ at the source of neoplasm but there are 
actually more than 100 distinct types of cancer and different types of cancer can exist in one 
organ. Nevertheless, all subtypes of tumors share six common hallmarks (Fig 2): (i) sustaining 
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proliferative signaling, (ii) inducing angiogenesis, (iii) insensitivity to anti-growth signals, (iv) 
evading apoptosis, (v) activating invasion and metastasis, (vi) enabling replicative immortality. 
These six characteristics are the common denominator of cancer cells.4 
 
Fig 2: Hallmarks of cancer (Reprinted from Hanahan, D. et al.4, Copyright (2016), with permission 
from Elsevier) 
More than one deregulation is required to transform a normal human cell into cancer 
cells. Globally, a succession of genetic changes, each one providing a step promoting a growth 
advantage, is required for the acquisition of the six characteristics of cancer cells. Each genetic 
change is responsible of a small deregulation in cell signaling, leading to tumor development.5 
 
  
22 
 
1.2 Protein kinases in cell signaling 
1.2.1 Cell signaling 
Cell signaling is the global system that enables cells to react properly to environmental 
factors. Indeed, cells are controlled by various internal or external factors. In order to respond to 
these stimuli, cells have to be able to detect them and to react specifically to them. A network 
of proteins is responsible of the signal carrying from the environment into the cells. Each protein 
inside the cell signaling network controls a specific part of the signal transduction. Together, they 
control specific responses to one stimulus. 
 
1.2.2 Deregulation in cancer development 
Cell signaling is responsible of the control of the cellular functions. Cell signaling regulates 
cell proliferation, cell differentiation, apoptosis, cell survival, cell mobility, cell cycle, metabolism, 
transcription, translation… In consequence, any small deregulation of this machinery could be 
the starting point of a complete change in cell behavior. In some cases, pro-survival and anti-
apoptotic features can be acquired in normal cells that could be then transformed into cancer 
cells. Thus, deregulation of cell signaling is a common feature of cancer cells. 
 
1.2.3 Protein Kinases 
Protein Kinases are one of the major classes of protein involved in cell signaling. Protein 
kinases are a group of enzymes able to transfer a phosphate group from a phosphate donor 
such as ATP or GTP to a protein substrate (Fig 3). In living cells, phosphorylation is a reversible 
mechanism as dephosphorylation is operated by another class of proteins named protein 
phosphatases. Phosphorylation is a very well controlled mechanism enabling cells to react in a 
time frame of milliseconds to seconds. Indeed, each protein kinase is able to phosphorylated 
specific substrates at specific amino acids. According to recent estimations, at least 30% of 
proteins in eukaryotic cells are phosphorylated.6 Addition of phosphate groups can alter protein 
activity, stability, cellular localization and interactions. Consequently, protein phosphorylation is a 
key regulator of cellular physiology, and abnormal phosphorylation contributes to diseases such 
as cancer, diabetes and neurodegeneration. 
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Fig 3: Schematic representation of protein phosphorylation. 
 
1.2.4 Human kinome 
The completion of the human genome sequence allows the classification of all the 518 
kinases that represent about 1.7% of the human genome.7 The entire set of human protein 
kinases are called human kinome and could be divided into eight major subfamilies (Fig 4): 
 TK for Tyrosine Kinase which phosphorylates almost exclusively tyrosine residues, 
 TKL for Tyrosine Kinase-Like which are similar to TK but phosphorylates serine/threonine 
substrates, 
 STE that are homologs of the yeast STE genes, 
 CK1 for Cell Kinase 1, 
 AGC for protein kinase A, G and C (PKA, PKC, PKG), 
 CAMK for Calmodulin/Calcium regulated Kinases, 
 CMGC named after CDK, MAPK, GSK3 and CLK families, 
 RGC for Receptor Guanylate Cyclases. 
Notably, some protein kinases do not belong to any of the major branches of the human 
kinome. As an example, CK2α is phylogenetically close to the CMGC family with similarities with 
DYRK, CLK and CDK but CK2α is located on a different branch in the kinome (Fig 4). 
 
 
24 
 
 
Fig 4: The Human Kinome (From Manning, G. et al.7). Each kinase is at the tip of a branch and the 
similarity between various kinases is inversely related to the distance between their positions. 
CK2α and CK2α’ are surrounded in red. Illustration reproduced with the courtesy of Cell Signaling 
Technology, Inc. (www.cellsignal.com). 
Notably, protein kinases are present in all living organisms but with structural differences, 
as examples: 
 Eukaryotic Protein Kinases (EPK) in eukaryotes, probably more than 28,000 different 
EPK, exist, 
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 EPK-Like Kinase (ELK) are present in prokaryotes, 18,699 ELKs have been identified, 
 Histidine kinases are also present in bacteria but they are structurally different to 
EPK or ELK.8,9 
 
1.2.5 Protein Kinase structures 
Protein kinase A (PKA) was the first protein kinase structure resolved by crystallization and 
X-ray diffraction in 1991.10 Rapidly, a large number of protein kinase structures have been 
determined and all share the same structural core features (Fig 5a). All of them are composed of 
two lobes. The N-terminal lobes are mainly composed of five β strands, and one crucial and well 
conserved C-helix, which is very important for the overall structure organization. Indeed, it has 
been reported that displacement of the C-helix is the major way for allosteric kinase inhibition 
(see paragraph 1.4.3). The C-terminal lobe is mainly composed of helices rendering it more rigid 
than the N-terminal lobe. The ATP binding site is localized at the interface of the two lobes, in a 
very well conserved pocket. The adenosine moiety of ATP binds in a hydrophobic pocket and 
makes special H-bonds with the hinge region. Close to the adenosine binding site, a 
“gatekeeper” residue controls the access to a second pocket used by several marketed 
inhibitors to improve their selectivity (Fig 5b,c). The triphosphate moiety of ATP binds with the help 
of two magnesium ions between the glycine-rich loop (also called P-loop) and the magnesium-
binding loop. Therefore, the third phosphate group is exposed and ready to be transferred to a 
protein substrate. The catalytic loop is an important regulator of kinase activity and, in the 
majority of kinases, this loop can adopt two conformations: open or closed. The closed 
conformation is the basal and inactive position. This conformation could be switched to the 
open or active conformation by a specific event, such as a phosphorylation in the catalytic loop 
or an activating-protein binding.11 
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(a) 
 
 
 
Fig 5: Structure of the conserved protein kinase core. (a) General bilobal kinase structure based 
on PKA (Reprinted from Taylor, S. S. et al.12, Copyright (2016), with permission from Elsevier). 
 
Study of the spatial conservation of residues among kinases revealed that two groups of 
amino acid are spatially very well conserved. Due to their spine pattern going through the 
catalytic site and the key elements of kinase regulation, they were called catalytic spine and 
regulatory spine, respectively (Fig 6). Both of them are anchored on the F-helix. Based on the 
protein kinase A sequence: the catalytic spine is composed of 8 amino-acids, V57, A70, M128, 
L172, L173, I174, L227, M231 and the regulatory spine is composed of 5 amino-acids, L95, L106, 
F185, Y164, D220.15 In contrast to active kinase structures, these residues were not found to be 
well positionned in inactive kinase structures, underlining the relevance of these two spines in 
kinase regulation.16 
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Fig 6: Structural representation of the Catalytic spine (C-spine) and Regulatory spine (R-spine) 
anchored on the F-helix (based on PKA) (From Kornev, A. P. et al.15, Copyright (2016) National 
Academy of Sciences, USA). 
 
1.2.6 Protein Kinases as therapeutic targets 
 The 518 protein kinases of the human kinome represent less than 2% of the whole human 
genome7 but there are considered to represent 22% of the druggable genome.17 
Because of their crucial roles in cell signaling, protein kinases are considered as the 
second major drug target after G-Protein-Coupled Receptors. However, since the seminal 
discovery of R. Erikson, showing that the transforming factor of Rous sarcoma virus was a protein 
kinase (v-Src),18 it took more than twenty years for the approval in 2001 by the authorities of the 
first selective small molecule kinase inhibitor targeting Bcr-Abl and called imatinib (Fig 7).19 
 
αF 
C-spine 
R-spine 
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Fig 7: Key events in the development of protein-kinase inhibitors (Reprinted by permission from 
Macmillan Publishers Ltd: [Nat. Rev. Drug Discov.] from Cohen, P.19 copyright (2016)) 
 
Imatinib (Gleevec®, Novartis) is an orally available inhibitor of Bcr-Abl and the first kinase 
inhibitor approved by the FDA and EMA for the treatment of chronic myelogenous leukaemia. 
Since, tremendous efforts of many laboratories have been focused on the identification of new 
kinase inhibitors and an increasing number of these inhibitors has been approved to treat several 
diseases (Table1). In 2013, imatinib was elected as the most innovative drug in oncology in the 
last 25 years, based on a physicians’ survey.20 
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Table 1: Small molecule kinase inhibitors approved by EMA, classified by approval year until 
2013.21,22 
Target Molecule name Trade name 
Year of EMA 
approval 
Company 
Bcr-Abl imatinib Gleevec® 2001 Novartis 
EGFR erlotinib Tarceva® 2005 Roche 
Bcr-Abl, Src, c-KIT 
dasatinib Sprycel® 2006 
Bristol-Myers 
Squibb 
VEGF pegaptanib Macugen® 2006 OSI/Pfizer 
VEGFR, PDGFR, BRAF, 
c-Kit… 
sorafenib Nexavar® 2006 Bayer 
VEGFR, PDGFR sunitinib Sutent® 2006 Pfizer 
HER2 lapatinib Tyverb® 2008 GlaxoSmithKline 
Bcr-Abl nilotinib Tasigna® 2009 Novartis 
EGFR gefitinib Iressa® 2009 AstraZeneca/Teva 
VEGFR, PDGFR, c-Kit pazopanib Votrient® 2010 GlaxoSmithKline 
VEGFR, PDGFR, c-KIT axitinib Inlyta® 2012 Pfizer 
ALK, HGFR, c-MET crizotinib Xalkori® 2012 Pfizer 
JAK ruxolitinib Jakavi® 2012 Novartis 
VEGFR, EGFR, RET, BRK vandetanib Caprelsa® 2012 AstraZeneca 
BRAF vemurafenib Zelboraf® 2012 Roche 
Bcr-Abl bosutinib Bosulif® 2013 Pfizer 
ErbB afatinib Giotrif® 2013 
Boehringer 
Ingelheim 
Bcr-Abl, BEGFR, 
PDGFR, FGFR, EPH, Src, 
c-KIT, RET, TIE2, FLT3 
ponatinib Iclusig® 2013 
ARIAD 
Pharmaceuticals 
RET, VEGFR, PDGFR regorafenib Stivarga® 2013 Bayer 
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1.3 Protein kinase CK2 
 
1.3.1 Overview 
Protein Kinase CK2 was discovered in 1954 during a study conducted by G. Burnett and E. 
Kennedy.23 CK2 activity was revealed by the ability of the soluble extract of rat liver mitochondria 
to phosphorylate a protein, the casein, rather than small metabolites. In consequence, they 
suspected the presence of a possible protein phosphokinase.  
In 1979, G. Hathaway and J.Traugh24 purified two kinases from rabbit reticulocytes. Due to 
their ability to phosphorylate casein in vitro, they named them Casein Kinase 1 and Casein 
Kinase 2. Casein Kinase 2 was able to use either ATP (Km = 10 µM) or GTP (Km = 40 µM) as 
phosphate donors. Moreover, a highly purified preparation of CK2 analyzed by denaturing gel 
electrophoresis showed proteins of molecular weights of 42, 38 and 24 kDa. This finding suggests 
a heterogeneous subunit structure of CK2.  
In the 80’s, several groups worked on other kinases such as the dog cardiac Troponin-T 
kinase by C. Villar-Palasi and A. Kumon in 198125 or as the Glycogen Synthase Kinase 5 (GSK-5) by 
the group of P. Parker in 198226. Later, researchers realized that these two supposed kinases were 
however one, the protein kinase CK2. 
 At that time, the confusion came from two points. First, based on its ability to 
phosphorylate -casein in vitro, Casein Kinase 2 was misnamed at its discovery since casein is not 
an in vivo substrate of CK2. Second, CK2 phosphorylates a pleiotropic number of substrates and 
cumulative literature described more than 300 in vivo substrates of CK2, involved in all aspects of 
the cell signaling network.27 Consequently, several questions rise from these findings: How CK2 
could be a good therapeutic target with so many substrates? What does make protein kinase 
CK2 a “special” kinase? 
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1.3.2 Structural specificities 
 
1.3.2.1 The holoenzyme (CK222) 
 
 
Fig 8: Structure of the holoenzyme form of the protein kinase CK2 (1JWH).28,29 In green and in 
blue: the two catalytic subunits (α). In magenta and in yellow: the dimer of regulatory subunits (β) 
linked by a “zinc finger binding motif” (the two red spheres). 
 
CK2 is a multimeric kinase (Fig 8). The CK2 holoenzyme complex (125 kDa) is composed of 
a dimer of two β-subunits (regulatory subunits) and two α- or α’-subunits (catalytic subunits). The 
-subunit (40 kDa) shares general features of protein kinases but the β2-subunit (45 kDa) is a 
unique protein with no sequence similarity with any other proteins. 
In contrast to the majority of multimeric kinases like PKA or CDKs, that requires the 
binding/or unbinding of their regulatory subunit for activity, the β subunit does not turn on/off the 
kinase activity but instead, modulates its substrate selection of CK2 in a complex and not fully 
understood manner. 
 
 
 
 
 
 α α 
β β 
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1.3.2.2 The  CK2 catalytic subunit 
The catalytic subunit shares general features of human kinases such as a large C-terminal 
lobe mainly composed of -helix and a smaller N-terminal lobe mainly composed of β-sheets. 
Nevertheless, CK2α exhibits some structural specificities (Fig 9):30,31 
 An activation segment locked in an active state, responsible of the constitutive 
activity of CK2, 
 A good plasticity of the hinge/αD region, 
 An unusual “DWG” motif instead of the usual “DFG”. 
 
Fig 9: Structure of the catalytic subunit of CK2 from Zea mays in complex with AMPPNP and 
magnesium ions31–33 (From Niefind, K. et al.31, with permission of Springer). (B) represent the same 
than (A) but after a 90° rotation around a vertical axis. The activation segment and the αC-helix 
drawn in black are from the inactive conformation of CDK2 to show a possible inactive state of 
CK2. 
A global comparison of X-ray structures of CK2 with the structures of CDK2 (Fig 10) 
revealed some interesting differences in their structural flexibility. Indeed, the N-terminal segment, 
the αC-helix, the catalytic loop and the activation segment of CK2α are rigid and always 
observed in the same conformation whereas flexibility of these regions was observed in CDK2 
structures. In the other hand, the glycine-rich loop, the β4/β5 loop, the hinge region and the αI-
helix are the main flexible part of CK2α whereas these regions are rigid in CDK2 structures. The 
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complete different flexibility profile obtained for CK2 and CDK2 supports the specificity of CK2 
regulation, in comparison with other kinases.31 
The activation segment (Mg-binding loop, β9, activation loop, P+1 loop) of CDK2 is very 
flexible. Upon cyclin binding, the positions of these key regulatory elements change and so, 
induce CDK2 activation. In the opposite, the activation segment of CK2α is rigid and is not 
modified upon CK2β binding. Indeed, in contrast to the majority of other protein kinases,34 the 
activation segment of CK2α is locked in the active conformation. No phosphorylation event is 
required to switch this activation segment in the active state because specific interactions of the 
N-terminal segment with the activation loop lock it in the fully productive conformation.30 
 
Fig 10: Representation of structural invariable and variable region for human CK2 in comparison 
with CDK2 (From Niefind, K. et al.31, with permission of Springer). All possible 3D structures were 
superposed and an average structure was determined. Then, average deviation represented by 
RMSD shows the structural variability of each part of the kinase structure. Specific rigid region are 
represented in grey and variable regions are represented by a peak. 
The hinge region (H115-D120) connects the two lobes of CK2. This region plays a central 
role in ATP/GTP binding by forming several hydrogen bonds with adenine or guanine.32 The hinge 
region is closely connected to the αD-helix and two different conformations can be observed: 
open or closed and the amino acid Phe121 is the flag used to determine the conformation. 
Indeed, Phe121 can be observed “in” the C-spine making it complete (closed form) or “out” the 
C-spine (open form) (Fig 11). The equivalent residue of Phe121 in PKA catalytic spine is the 
residue Met128. But, on the contrary of PKA spines, in CK2 structures, ATP seems to favor the open 
conformation of the hinge/D region, making the catalytic spines uncompleted. Therefore, 
based on X-ray structures, CK2 seems to be active with an uncomplete C-spine.35–37 
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The DFG motif is composed of three amino-acids (Aspartic acid 175, Phenylalanine 176, 
Glycine 177 in PKA). This motif is very well conserved in EPKs. The aspartic acid is crucial for 
magnesium binding but the most important residue of this motif is the central phenylalanine. 
Indeed, the phenylalanine can twist from the “in” or active conformation to the “out” or inactive 
conformation.38 In drug design, this special feature is a frequent strategy to target the ATP pocket 
in an inactive state. For example, imatinib targets the ATP pocket of Bcr-Abl in the DFG-out 
conformation.39,40 In the entire human kinome, CK2 (and ’) is the only kinase that does not 
have the DFG motif but instead a DWG one. The presence of a large residue tryptophan in 
position 176 instead of a phenylalanine induces stronger contacts and interactions with other 
residues of the environment. In consequence, the DWG-motif is stabilized in the “in” (active) 
conformation. The “out” conformation was never observed in X-ray structures of CK2. However, 
kinetic experiments with CK2 mutant (W176F) and CK2 wild type revealed that they both have 
the same Vmax value. This result is not consistent with the fact that Trp176 is responsible of the fully 
active state of CK2 and that the mutated CK2 to Phe176 supports the release of ADP as 
expected.41,42 
 
1.3.2.3 The CK2’ catalytic subunit isoform 
 
A second isoform of CK2 was identified and named CK2’. Both isoforms coexist in cells 
but CK2’ is present in a larger quantity in the brain and testicles.43 On the contrary of CK2, 
mice with CK2’ knockout are viable, but sterile.44 Overall comparison of amino-acid sequences 
revealed only very few differences, mainly in the C-terminal segment (Fig 12).45 The affinity 
between CK2’ and CK2β is, of note, weaker (about 12-fold) than the affinity between CK2 
and CK2β.46 
Bischoff et al.45 shown that the differences in C-terminal segment and the affinity for CK2β 
are linked. In CK2’, the prolongation of the N-terminal β-sheet by a β-strand and the presence 
of a tryptophan residue (Trp34) in a conserved hydrophobic cavity (localized between the β4/β5 
loop and the helix-C) stabilized the β4/β5 loop in the open conformation. This conformation is 
required for CK2β binding but authors proposed that the rigidity of the β4/β5 loop in CK2’ could 
prevent adaptation under β-binding, and is consequently responsible for the lower affinity. The 
second important point underlined in their study is that the “in” conformation of the hinge/D 
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region observed for CK2’ whereas the “out” conformation is observed in the large majority of 
CK2 structures. Nevertheless, more crystallization experiments are required to conclude if this 
observation is a generality or a rare case.45 
 
Fig 12: Sequence alignment of CK2 and CK2’. Lower case letters are used to underline non-
identical position and the C-term structurally non-determined region (Reprinted from Bischoff, N. 
et al. 45, Copyright (2016), with permission from Elsevier). 
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1.3.2.4 The CK2β regulatory subunit 
The regulatory subunit of CK2 (β2) is a unique protein composed of a dimer of β protein 
linked by the strong interaction of two zinc chelating fingers motif (Fig 13). The zinc-binding motif 
(F106-P146) is only composed of β-sheets and loops whereas the other part of the protein also 
harbors -helix.47 Each CK2β subunit of the dimer is able to bind to one α-subunit through an 
interaction with the loop (L187-H193) of the CK2β tail (Fig 13). 
 
Fig 13: Schematic representation of a β-subunit dimer (1JWH).28,29 One β monomer is represented 
in green and dark green for its zinc-binding motif and the second one in blue and dark blue, 
respectively. The two zinc ions are represented by red spheres. Acidic loop is represented in dark 
red. The -interacting loops with the two -interaction hot-spots (Y188 and F190) are represented 
in orange. 
The α/β interface has been well studied to understand the mode of formation of the 
holoenzyme and, in particular, if it is a permanent or a transient complex. The identification of 
α/β interaction modulators would be the Grail that will enable scientists working on protein kinase 
CK2 to understand the cellular role of this protein/protein interaction.  
Since the first crystal structure of CK2 holoenzyme was solved,28 several studies have 
pointed out important features of the α/β interface. The size of this interface is between 771 Å² 
and 1099 Å², depending on the crystal structure and interface type (symmetric or asymmetric).48 
The affinity between CK2 and CK2β is very high, with a dissociation constant measured 
between 4 and 13 nM.48,49 
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CK2β stabilizes CK2 as shown by the Differential Scanning Calorimetry experiment (Fig 
14, A). The CK2 melting point increased from 45.6°C to 54.7°C in presence of the β dimer. On 
the other side, the melting point of the β-subunit is only slightly decreased from 60.6°C to 60.2°C.49 
The interaction between the two subunits of CK2 is mainly directed by the “interaction 
loop” or “CK2β tail” (L187-H193) of β-subunit and the “remote cavity” or “/β interaction pocket” 
defined by the strands β1 to β5 of the -subunit (Fig 14, B and D).  
In the regulatory subunit, the two hot spots responsible for a substantial part of the affinity 
are Tyr188 and Phe190. Thus, mutations of these residues to alanine induce a strong decrease in 
/β affinity.50 CK2β tail is preformed to bind to CK2, as the conformation of the β tail is identical 
in the bound or unbound state (Fig 14, C).49 
In the catalytic subunit, the hot spots are Leu41 and Phe54, localized on the β1 and β2 
strands. In the bound form, these residues are in close interaction with the β-hairpin loop of the β-
subunit. The β4/β5 loop is another key element of the /β interaction and this loop can adopt 
different conformations, depending of the / interaction pocket occupancy (Fig 14, D). The 
β4/β5 loop is closed in the absence of the β subunit but an “open” conformation was observed 
in presence of the β subunit28,48 or in presence of a cyclic peptide that mimics the β tail.51 
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(B) 
 
 
 
Fig 14: Key elements of the CK2 /β interaction. (A) DSC curves of hsCK21-335 (red), hsCK2β1-
193(blue), and the corresponding holoenzyme (black) (From Raaf, J. et al.49, with the permission of 
John Wiley and Sons). (B) Structural overview of the /β interface. CK2α is represented in green 
and the hot spots (L41 and F54) in orange. CK2β is colored in blue and the two hot spots (Y188 
and F190) in dark blue (based on 4DGL52) (C) Superposition of the CK2β tail bound or unbound to 
CK2 (From Niefind, K. et al.31, with permission of Springer). (D) Structural overview of the /β 
interaction with a focus on the two conformations of the β4/β5 loop (From Niefind, K. et al.31, with 
permission of Springer). 
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1.3.3 CK2 implication in pathophysiology 
1.3.3.1 CK2 overexpression in cancers 
As a multifunctional/multi-substrates enzyme, CK2 occupied a central position in cell 
signaling. Therefore, CK2 role in cancer development has been extensively investigated. The 
expression level and activity of CK2 have been widely studied in diverse tumor types and it has 
been determined that CK2 is globally a marker of poor survival prognosis for patients.  
Indeed, in 2004, CK2 overexpression has been shown to be a marker of poor prognosis in 
squamous cell carcinoma of the lungs. A survey on 16 patients shown that after 90 months, only 
10% of patients with a high CK2α level survive whereas 50% of patients with a normal CK2 
expression were alive (Fig 15, A).53 
In 2007, a survey on 131 patients with prostate cancer has shown than CK2 is 
overexpressed in prostate cancer cells in comparison with normal prostate cells. Moreover, 
nuclear localization of CK2 is correlated with high-grade tumors and poor prognostic factors.54 
The same year, a second implication of CK2 was found in Acute Myeloid Leukemia 
(AML) as a survey on 48 patients has shown that CK2 overexpression is correlated with a poor 
survival prognosis (Fig 15, B).55 
In 2010, CK2 expression was studied in breast carcinoma and revealed that CK2 is 
individually a poor prognosis marker. Moreover, CK2 was chosen together 11 other markers to 
bring an accurate classification for 86% of the tumors on 905 patients.56 
In 2011, overexpression of CK2 in nuclei of colorectal tumor tissues have been correlated 
to bad prognosis for patients and as an independent prognostic marker for human colorectal 
cancer (Fig 15, C).57 
In 2013, the analysis of 537 glioblastomas has demonstrated that CSNK2A1 gene 
encoding CK2 was overexpressed in 33.7% of glioblastomas and even in more than 50% of 
classical glioblastomas whereas CK2’ expression was not changed. Only a slight modification 
was observed in CK2β expression (7.3% of gene deletion). Moreover, downregulation of CK2, by 
siRNA or inhibitors, counteracted glioblastoma development.58 
In 2014, 187 patients with gastric carcinoma were studied and CK2 expression was a 
marker of survival prognosis (Fig 15, D). CK2 was involved in phosphorylation of DBC1 and the 
inhibition of both CK2 and DBC1 decreased proliferation of cancer cells.59 
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In 2015, a small cohort study revealed that CK2 was upregulated in Renal Cell 
Carcinoma tumor samples. Moreover, 786-O cells were used as model of RCC and CK2 inhibition 
by CX-4945 treatment underlined the potential of CK2 as a target to cure RCCs.60 
(A) 
 
(B) 
  
(C)
 
(D) 
Fig 15: Clinical implication of the protein kinase CK2. (A) Survival rate in function of the 
expression level of CK2 in squamous cell carcinoma (Reprinted from O-charoenrat, P. et al.53, 
with permission from AACR). (B) Survival rate of patient with Acute Myeloid Leukemia (AML) 
depending of their CK2 expression level (Reprinted from Kim, J. S. et al.55, with permission from 
AACR). (C) Survival analysis of patients with human colorectal cancer. Low nuclear CK2 means 
labeling index ≤40% for nuclear CK2 by immunoreactivity and high nuclear CK2 means >40% 
(From Lin, K.-Y. et al.57, with the permission of John Wiley and Sons). (D) Implication of CK2 in 
gastric carcinoma, immunohistochemical expression of CK2 in normal tissue, low and high 
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CK2 gastric carcinoma and patient survival depending of the expression level of CK2 (From 
Bae, J. S. et al.59, with the permission of John Wiley and Sons). 
 
1.3.3.2 CK2 implication in cell signaling 
The correlation between CK2 overexpression and prognosis in a large number of 
cancers is in relation with the multiple consequences of this overexpression in cells (Fig 16).61 
 
Fig 16: Consequences of a high CK2 expression. 
CK2 overexpression induces favorable conditions for tumor development by acting on 
several cell signaling pathways implicated in cancer. 
CK2 is involved in the regulation of NF-κB pathway at multiple levels. CK2 phosphorylates 
IκB leading to its degradation and the release of NF-κB.62 Moreover, CK2 can directly 
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phosphorylate NF-κB p65 subunit, inducing the augmentation of the transcriptional activity of NF-
κB in vivo.63,64 
CK2 is able to promote the Wnt signaling by several actions. CK2 phosphorylates 
Disheveled (Dvl), β-catenin on Thr393 and LEF-1 on Ser42 and Ser61. These events lead to the 
stabilization of β-catenin and to the promotion of β-catenin/LEF-1 complex formation (Fig 17, 
B).61,62 In parallel, CK2 phosphorylates α-catenin (Ser641), thus destabilizing the α-catenin/β-
catenin complex that inhibits β-catenin. Therefore, CK2 favors the transcription of survival 
genes.65 
CK2 activates the PI3K/Akt pathway by a direct phosphorylation of Akt in position Ser129 
and Ser473. Morevover, CK2 also acts upstream by a negative control on PTEN, which is a natural 
blocker of the PI3K/Akt pathway. Laterally, CK2 enhances the protection of Akt by HSP90 
activation/stimulation. Thus, CK2 favors survival signals.61 
Consequenly, CK2 inhibition has been proved to be a valuable way to treat cancer cells. 
Indeed, CK2 acts as a major support to prosurvival and antiapoptotic signals by acting on the 
NF-κB, Wnt and Akt pathway (Fig 17). CK2 is not directly involved in these pathways but acts as a 
side regulator through activation or inhibition of key enzymes.66 
 
 
Fig 17: Role of CK2 in regulation of NF-κB (A), β-catenin (B) and Akt (C) signaling (Reprinted from 
Ruzzene, M. et al.66, Copyright (2016), with permission from Elsevier). 
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 In addition, CK2 is involved in the multidrug resistance phenomenon.67 CK2 inhibition has 
been demonstrated to be efficient to restore sensitivity toward imatinib of imatinib-resistant 
LAMA84 cells68, as well to induce apoptosis in various drug resistant cell lines.69 Moreover, a large-
scale proteomic study on the phosphorylation stoichiometries in lung cancer cells and gefitinib-
resistant lung cancer cells has rencently demonstrated that CK2 and EGFR are the two kinases 
with wider implication in drug resistance pathway.70 Thus, CK2 appears to be an interesting 
target to counteract drug resistance phenomena. 
 
1.3.3.3 Functional role of CK2β 
CK2β knockout experiments have been used to determine the role of the regulatory 
subunit in different models. 
In Saccharomyces cerevisiae, the knockout of one or the two different regulatory 
subunits (CK2β1 and CK2β2) induces only salt sensitivity and a partial blockage in the adaptation 
to the G2/M checkpoint arrest but no difference in growth or viability was observed, so showing 
that yeasts can survive in the absence of CK2β.71,72 
CK2β deletion in mice leads to early embryonic lethality, leading to mutant embryos with 
a reduced size. A decrease in cells proliferation was observed but not in apoptosis markers. Thus, 
in contrast to yeast, mammals require a normal level of CK2β to survive.73 Moreover, conditional 
CK2β knockout in embryonic central nervous system led to defects in proliferation and 
differentiation, the latter underlining the major role of CK2β in central nervous system 
development.74 
CK2β deletion in mammary epithelial cells (MCF10A) leads to phenotypic changes. 
Indeed MCF10A epithelial cells transfection with siRNA targeting CSNK2B gene induces a 
mesenchymal phenotypes. Immunofluorescence images have shown a decrease in E-Cadherin 
expression, an increase in the N-Cadherin level and a reorganization of the actin filaments. These 
observations are characteristics of an increase in cell mobility (Fig 18).75,76 
Moreover, unbalanced level of CK2 subunits (lower expression level of β-subunit) in breast 
tumour samples has been correlated with EMT markers such as decrease in E-Cadherin and 
Occludin expression and increase in N-Cadherin, Vimentin, αSMA and Snail1 expression.76 
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Fig 18: Immunofluorescence images of MCF10A WT and ΔCK2β with E-Cadherin, N-Cadherin or 
Phalloidin antibodies in combination with Hoechst-33342 (Reprinted by permission from 
Macmillan Publishers Ltd: [Oncogene] from Deshiere, A. et al.76, copyright (2016)). 
Biochemical approaches have been used to identify proteins interacting with CK2β. CK2β 
partners could be classified in two categories: 
 CK2 dependent partners which bind specifically to CK2β, 
 CK2 independent partners which bind specifically to CK2β only when CK2 is not 
bound to the regulatory subunit.  
Several CK2 dependent binding partners of CK2β were characterized, some of them 
only in vitro such as p90Rsk, PKCζ, topoisomerase II, p27KIP1, CD5, FGF-2, Nopp 140 and L41 but few 
of them were also characterized as CK2β binding partners in vivo (Table 2). Interestingly, four 
serine/threonine kinases, c-Mos, Chk1, A-Raf and AMPKα2 were characterized as CK2α 
independent binding partners of CK2β. The β-subunit binding site on these kinases is localized in 
the same area than on CK2. Moreover CK2β is able to modulate their activity like the one of 
CK2.77 As a remark, activation of AMPK2 by CK2β suppressed EMT.78 
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Table 2: In vivo CK2β binding partners. 
Interaction 
partner 
Function Reference 
CK2α dependent binding partners of CK2β  
p53 Tumor supressor 79–81 
p21WAF1/CIP1 CDK inhibitor 81,82 
Cdc25B Phosphatase, CDK activator 83 
L5 Ribosomal protein 81,84 
HHV-6IE2 
Human herpesvirus 6 immediate-early 
protein 
85 
CK2α independent binding partners of CK2β  
c-Mos 
Serine/Threonine protein kinase, MAPK 
activation 
81,86,87 
Chk1 
Serine/Threonine protein kinase, regulator of 
DNA damage, induced G2 arrest 
88 
A-Raf 
Serine/Threonine protein kinase, mitogenic 
signaling, cell proliferation 
81,84,89 
AMPKα2 
AMP-activated protein kinase, 
heterotrimeric serine/threonine 
kinase, cellular energy homeostasis, 
EMT 
78 
 
A possible consequence of the multiple interactome of CK2β is proposed in Fig 19. If the 
amount of CK2 (or/and CK2’) in one cell compartment is equal or higher to the quantity of 
CK2β, the holoenzyme form (α2β2) is predominant and CK2 mainly interacts with proteins that 
could bind to the holoenzyme form. In the contrary, if the regulatory subunit is present in excess, 
free β dimer could bind to other kinases such as c-Mos, Chk1, A-Raf and regulate them (Fig 19, 
b), or to other proteins such as p53, p21, p27 (Fig 19, c)… In consequence, the equilibrium 
between CK2 and CK2β expression has to be very well controlled in subcellular compartments 
and any dysregulation may lead to dramatical alteration in cell signaling pathways.90 
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Fig 19: Possible mechanisms of cell signaling modulation by CK2 as a function of CK2β 
expression (Reprinted from Bolanos-Garcia, V. M. et al.90, Copyright (2016), with permission from 
Elsevier). (a) In the presence of an excess of CK2β, CK2 is preferentially in the holoenzyme form 
and interacts with holoenzyme’s substrate. (b) Free CK2β could interact and modulate other 
kinases (such as c-Mos, A-Raf, Chk1…) in the same way than for CK2. (c) CK2β could bind to 
other proteins independently of CK2 and maybe modulates them by activation/inactivation, 
stabilization… 
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1.3.4 Known CK2 inhibitors 
For a long time, CK2 was considered as an “undruggable kinase”.91 Indeed, despite the 
long period since the discovery of CK2 in 195423, its full characterization in 80s and the first x-ray 
structure of CK2 solved in 199830, only one potent ATP competitive inhibitor, CX-4945, underwent 
clinical trials.92 
Various chemical structures have been identified as CK2 inhibitors, through various 
approaches93–96 and the majority of them could be classified in several general families (Fig 20): 
 Benzimidazole derivatives including TBB, TBI and DMAT, 
 Anthraquinone derivatives based on the natural product emodin, 
 Coumarin derivatives such as ellagic acid, 
 Indolo-quinazoline derivatives such as IQA, 
 Benzo-naphthyridine derivatives, with CX-4945 in phase II clinical trial, 
 Atypical inhibitors such as GIGB-300 (also in clinical trials), POMs, 
azonaphthalenes, peptide-like α/β interaction inhibitors and bi-substrate inhibitors. 
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Fig 20: Selected examples of CK2α modulators based on their chemical scaffold or mechanism of action. 
4,5,6,7-tetrabromo-N,N-
dimethyl-1H-benzo[d]imidazol-2-
amine 
(DMAT)
Ki = 0.04 µM
5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-
carboxylic acid 
(CX-4945)
IC50 = 0.0015 µM
4,5,6,7-tetrabromo-1H-
benzo[d][1,2,3]triazole 
(TBB)
Ki = 0.4 µM
4,5,6,7-tetrabromo-1H-
benzo[d]imidazole 
(TBI)
Ki = 0.3 µM
(3R,4S,5R)-2-(5,6-dichloro-1H-
benzo[d]imidazol-1-yl)-5-
(hydroxymethyl)tetrahydrofuran-3,4-diol 
(DRB)
IC50 = 23 µM
Benzimidazole scaffold
1,3,8-trihydroxy-6-
methylanthracene-9,10-dione 
(Emodin)
Ki = 1.5 µM
1,2,5,8-tetrahydroxyanthracene-
9,10-dione 
(Quinalizarin)
Ki = 0.06 µM
Anthraquinone
2,3,7,8-
tetrahydroxychromeno[5,4,3-
cde]chromene-5,10-dione 
(Ellagic acid)
Ki = 0.02 µM
7-hydroxy-3H-phenoxazin-3-one 
(Resorufin)
Ki = 0.8 µM
2-(5-oxo-5,6-dihydroindolo[1,2-
a]quinazolin-7-yl)acetic acid 
(IQA)
IC50 = 0.39 µM
Indolo-quinazoline scaffold
Coumarin scaffold
Benzo-naphthyridine scaffold Atypical inhibitors
WMSPRHLGT-Tat
(GIGB-300)
(Cyclic peptide)
(E)-3-hydroxy-4-((1-hydroxynaphthalen-2-yl)diazenyl)-7-
nitronaphthalene-1-sulfonic acid (Azonaphthalene 4)
IC50 = 0.4 µM
(POM)
[P2Mo18O62]
6-
Ki < 0.01 µM
5-((3-ethynylphenyl)amino)pyrimido[4,5-c]quinoline-8-
carboxylic acid
(CX-5011)
IC50 = 0.0023 µM
(K137-E4)
IC50 = 0.025 µM
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The following discussion will focus on CX-4945, which is the most developed CK2 inhibitor 
and some of the atypical inhibitors will be discussed in paragraph 1.4.4 and 1.5.4. 
 
1.3.4.1 CX-4945 and in vitro selectivity  
CX-4945 is the prototype of CK2 inhibitor and is in clinical Phase II for the treatment of 
several cancers. This molecule, developed by Cylene Pharmaceuticals®, belongs to the family of 
benzo-naphthyridine. It is a very potent inhibitor of CK2 (IC50 = 14.7 nM) and one of the most 
selective.97 Indeed, CX-4945 has a Gini coefficient98 of 0.667 on a panel of 235 protein kinases. In 
comparison, other CK2 inhibitors have lower Gini coefficient, 0.612 for quinalizarin, 0.60 for TBCA, 
and even lower than 0.4 for TBB, DMAT or TIBI (Table 3).97 
However, an off-target inhibitory activity of Cdc2-like kinases (Clks) was recently reported 
for CX-4945.99 The Clk family of kinases is involved in the regulation of alternative splicing through 
the phosphorylation of serine/arginine rich (SR) proteins: CX-4945 is actually more potent on Clk-2 
(IC50 = 3.8 nM) than on CK2 (IC50 = 14.7 nM). Furthermore, CX-4945 causes the inhibition of 
cellular SR protein phosphorylations at low micromolar concentrations in a CK2 independent 
manner.99 Although the consequences of this off-target remain to be clearly understood, this 
recent result underlines the fact that potent and selective CK2 inhibitors are difficult to obtain 
through targeting the ATP binding pocket. Another study describes several CX-4945 off-targets 
with the respective IC50 of 1 nM on CK2α and CK2α’, 17 nM on DAPK3, 35 nM on FLT3 and on 
TBK1, 41 nM on Clk3, 45 nM on HIPK3, 46 nM on Pim-1 and 56 nM on CDK1/cyclinB.92 
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Table 3: Selectivity of CK2 inhibitors expressed with Gini coefficients in comparison with some 
approved kinase inhibitors.98 
Target 
Inhibitor 
Number of PK 
tested 
Gini coefficient 
CK2 
CX-4945 (0.5 µM)100 102 0.62 
CX-4945 (0.5 µM)100 235 0.67 
Quinalizarin (1 µM)101 78 0.62 
TBCA (0.5 µM)102 300 0.60 
TBB (10 µM)103 70 0.38 
DMAT (10 µM)103 70 0.34 
TIBI (10 µM)103 70 0.31 
Bcr-Abl Imatinib (0.5 µM)102 300 0.77 
Bcr-Abl Dasatinib (0.5 µM)102 300 0.74 
PDGFR/VEGFR Sunitinib (0.5 µM)102 300 0.52 
 
1.3.4.2 Cellular effects of CX-4945 
CX-4945 induces cell death in various cell lines with an average EC50 of 5.5 µM in 43 cell 
lines originated from different cancers (Fig 21). Moreover, extensive studies in breast cancer cell 
lines have shown an apparent correlation between the efficacy of CX-4945 and the level of 
CK2 expression. Cell lines with a higher level of CK2 (mRNA and protein) are more sensitive 
toward CX-4945:92 this last point underlined the importance of CK2α inhibition to treat cancers 
that are dependent on abnormal high CK2 level. 
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Fig 21: Cell viability assay results on a panel of 43 cancer cell lines. The baseline represents the 
average EC50 (5.5 µM), cell lines with a negative logEC50 are more sensitive than average, and 
positive less sensitive (Reprinted from Siddiqui-Jain, A. et al.92, with permission from AACR). 
CX-4945 inhibits CK2 activity in various cell lines in the micromolar range. A decrease of 
Akt phosphorylation (Ser129, specific to CK2) was observed. Moreover, CX-4945 induces a 
decrease in phosphorylation of p21 (Thr145), PTEN (Ser370 and Ser380) but at a concentration 
about 10-fold higher.69,92,104 
Xenograft model experiments were conducted and showed CX-4945 efficiency to 
induce breast and pancreatic tumor regression without any weight loss for mice (Fig 22). 
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Fig 22: Effect of CX-4945 in BT-474 (A) and BxPC-3 (B) xenograft models. CX-4945 or Sodium 
Phosphate Buffer (vehicle) were administrated by oral gavage twice a day (Reprinted from 
Siddiqui-Jain, A. et al.92, with permission from AACR). 
 Recently, a study dealing with human head and neck squamous cell carcinomas 
revealed a possible resistance mechanism to CX-4945 treatment, both in cellular-based assay 
and in xenograft models. Resistance to CX-4945 involved an increase in the reporter gene 
activity of p21, p53, AP-1 and IL-8, as well as an increase of Ki67. The resistance is, of note, clearly 
dependent on the cell lines.105 
To date, CX-4945 remains the most promising CK2 inhibitor efficient in vitro, in cell-based 
assay and in vivo. Nevertheless, the recently described off-targets (Clk, for example) and 
resistance pathways could be a serious drawback in clinical development. Notwithstanding, CX-
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4945 validates CK2 as a target of interest to treat several cancer types. Consequently, new 
potent and more selective CK2 inhibitors are still required to make CK2 inhibition a success story 
in cancer treatment. 
1.3.4.3 Overview of CK2 inhibitors binding sites 
 The major part of the described CK2 modulators bind to the ATP cleft (Fig 23) but several 
compounds have been characterized as non-ATP competitive modulators of CK2 and they can 
be classified in four groups: 
 Allosteric inhibitors of CK2 including azonaphthalene class of compounds, POMs, 
CFTR fragment peptide… 
 /β interaction inhibitors which are Protein Protein Interaction Inhibitors (PP2I) more 
than kinase inhibitors. This group includes DRB (5,6-dichlorobenzimidazole 1-β-D-
ribofuranoside) and a cyclic peptide (Pc) derived from the C-terminal tail of CK2β. 
 Substrate inhibitors represented by one small peptide named CIGB-300, nowadays in 
phase II clinical trials. CIGB-300 does not interact directly with CK2 but with its 
substrates. Indeed, this small peptide is able to bind selectively to a CK2 
phosphorylation site of CK2 substrate, thus preventing CK2 phosphorylation in vitro. 
The main target of CIGB-300 in vivo is B23/nucleophosmin.106–108 
 The last class aim to develop a dual site inhibitor, by coupling TBBi to an amino-acid 
sequence rich in aspartate residues. This molecule is able to bind simultaneously in the 
ATP pocket and in the substrate binding site, as  shown by a very high affinity for CK2 
(Ki = 0.5 nM).109 
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Fig 23: Schematic representation of the different inhibitors binding sites on CK2 structure (based 
on 2PVR cristallographic file110). 
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1.4 Allostery and non-ATP competitive inhibitors 
1.4.1 Allostery definition 
The word “allosteric” was first described in 1961, after the 26th Cold Spring Harbor 
Symposium on Quantitative Biology dedicated to “cellular regulatory mechanisms”. The word 
allosteric was used in the report of this conference by Monod and Jacob.111 This statement 
followed years of research on feedback inhibition of biosynthetic pathway in bacteria by the 
end product of the synthetic chain112–115 and on the hemoglobin subunit cooperation to bind 
oxygen molecules. These two authors proposed to call “allosteric inhibition” the phenomenon of 
end-product inhibition “where the inhibitor is not a steric analogue of the substrate”: they 
guessed that this statement implied a different binding site. 
Following this seminal research, the first model describing the allostery concept was 
proposed in 1965 and was called Monod-Wyman-Changeux (MWC) by the name of its 
inventors.116 The MWC model tried to define the main criteria of allosteric inhibition in multimeric 
proteins. A part of the new concepts focused on the change of protein conformation that 
induced the inhibition. They supposed that the protein could exist in both active and inactive 
form and that an allosteric inhibitor favors the inactive conformation whereas the natural 
substrate favors the active conformation.117 One year later, a second model was proposed by 
Koshland, Nemethy and Filmer (KNF model). The major difference with the MWC model is that 
monomers of the oligomer structure are not connected to each other and so, each monomer 
could have a different conformation. The binding of one ligand induced a conformational 
modification favorable to the binding of the ligand in the adjacent subunit.118 In 1984, the first 
model describing allosteric regulation without conformational change was proposed by Cooper 
and Dryden.119 
Allosteric regulations of proteins are very interesting, due to the opportunity to modulate 
with increased selectivity previously targeted enzyme and to target some of the previously “non-
druggable” proteins. This last point is very similar to what researchers try to achieve with Protein-
Protein Interactions Inhibitors (PP2Is), as they wish to bring new targets in drug discovery.120 
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1.4.2 Kinase inhibitor classes and allostery 
The first kinase inhibitors were ATP-competitive. They targeted the canonical ATP cleft but 
soon, the poor selectivity of these inhibitors was discovered (eg for staurosporine). Indeed, a 
good selectivity is very difficult to achieve through ATP-site targeting because of the numerous 
proteins that binds ATP molecules. On the other hand, high potency was obtained with ATP 
competitive inhibitors because of the easy targeting of the large hydrophobic ATP pocket. In 
addition, by exploiting specific features, several well potent and selective ATP-competitive 
inhibitors are already in clinical use, such as imatinib (Bcr-Abl)121, gefitinib (EGFR)122, sunitinib 
(VEGFR, PDGFR)123 or dabrafenib (B-Raf)124. To efficiently target some refractory kinases, allosteric 
inhibitors were considered and several out-of-the-box inhibitors were identified and will be 
discussed thereafter. 
Researchers defined four categories (Fig 24) to classify the different kinase inhibitors, 
depending on their mechanisms of action: 
 
 Type I: ATP-competitive inhibitors that strictly bind into the ATP pocket and maintain 
the kinase in an active conformation but prevent the ATP-Mg complex binding are 
defined as class I inhibitor. Staurosporine and dasatinib are two examples of this class. 
 
 Type II: encompass the inhibitors that bind to the ATP cleft and simultaneously to a 
hydrophobic pocket located between the DFG motif in the “out” position and the 
αC-helix. The binding to this double pocket enable a greater selectivity. Imatinib and 
sorafenib are type II inhibitors. Recently, a new special class named 1/2 was added 
for the molecules that bind to the same pockets than type II inhibitors but with the 
DFG in the “in” position. 
 
 Type III: inhibitors that do not compete with ATP and bind to a true allosteric pocket, 
inducing an inactive conformation. Most of them act through αC-helix displacement 
or by locking the DFG motif in an inactive conformation. 
 
 Type IV: compounds that are also “type III-like” allosteric inhibitors but which bind to a 
pocket distant from the ATP cleft.  
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Fig 24: Schematic representation of kinase inhibitor types (Reprinted by permission from 
Macmillan Publishers Ltd: [Nat. Chem. Biol.] from Foda, Z. H. et al.125, copyright (2016). (A) Type I: 
small molecule (orange) binds to ATP pocket (grey) with the DFG motif on the activation loop 
(blue) in the “in” position. (B) Type II: small molecule binds to the ATP pocket but with the DFG 
motif in the “out” position. (C) Type III (and IV): allosteric inhibitor (red) binds in a different pocket 
near the ATP pocket or far from it.  
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1.4.3 Examples of non-ATP competitive inhibitors of protein kinases 
 
 
Fig 25: Few examples of kinase inhibitors in their binding sites (Reprinted from Nussinov, R. et al. 
126, Copyright (2016), with permission from Elsevier). (A) Orthosteric inhibitor (Gefitinib in red) 
bound to active EGFR kinase (PDB ID: 3UG2). (B) Allosteric inhibitor (PD318088 in cyan) and ATP 
(in red) bound to inactive MEK1 (PDB ID: 1S9I). (C) ATP competitive inhibitor (imatinib in red) 
bound to inactive p38 (PDB ID: 3HEC). (D) Allosteric inhibitor (in red) bound to CHK1 (PDB ID: 
3JVR). (E) Allosteric inhibitor bound to the interface of Akt and PH domain (PDB ID: 3O96).  
 
1.4.3.1 ANS pocket 
Cyclin-Dependent Kinases (CDKs) are key regulators of the cell cycle and they are 
deregulated in numerous pathologies. Despite numerous efforts to find good CDK inhibitors, and 
several of these molecules that underwent into clinical trials, research groups did not succeed to 
develop an efficient compound. All of the developed molecules were ATP-competitive inhibitors 
and one of their major drawbacks was their selectivity. Recently, a new pocket was identified on 
CDK2 and named ANS pocket, as this compound (8-anilino-1-naphtalene sulfonate) was the 
only molecule described to bind into this pocket. 
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ANS is a commonly used fluorescent probe. In the process of searching for new 
compounds able to compete with cyclins for CDK2 binding, Betzi et al. have set up an assay 
based on ANS displacement. They realized later that ANS specifically binds to CDK2 with a Kd of 
37 µM and X-ray structures revealed a specific pocket able to bind two ANS molecules (Fig 26). 
ANS inhibits CDK2 through αC-helix displacement, thus locking the inactive state of CDK2.127,128 
 
(A)
 
(B)
 
(C) 
 
Fig 26: ANS pocket in CDK2. (A) Schematic representation of the ANS pocket without or in 
presence of the two ANS molecules. A small ATP competitive compound can bind in the same 
time than ANS without any competition (Reprinted with permission from Betzi, S. et al.128, 
Copyright (2016) American Chemical Society). (B) CDK2 X-ray structure with two ANS molecules 
bound (PDB ID: 3PXF) (Reprinted from Palmieri, L. et al.129, Copyright (2016), with permission from 
Elsevier). (C) Schematic representation of the ANS interactions into their binding sites in CDK2 
(Reprinted with permission from Betzi, S. et al.128, Copyright (2016) American Chemical Society).  
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1.4.3.2 PIF pocket 
The AGC protein kinase family is one of the most evolutionary conserved groups that 
represents 12% of human kinome (61 kinases and 2 pseudo kinases).130 The C-terminal segment of 
AGC kinases presents a unique hydrophobic motif which fold back in a hydrophobic pocket 
localized between β4, β5 loop and α-B-, α-C-helix. This pocket, named PIF pocket, played a 
central role in AGC protein kinases regulation (Fig 27, A).131 Despite the general presence of the 
PIF pocket in AGC kinases, PDK1 is the kinase in which the PIF pocket has the most crucial role. 
Indeed, in PDK1, binding of the C-terminal segment does not only turn on/off the kinase activity 
but modulates the protein kinase substrate selection. 
 
(A) 
 
(B) 
 
(C) 
 
(D) 
 
Fig 27: PIF pocket in PDK1. (A) General X-ray structure of AGC kinases (from PKA, PDB ID: 1ATP) 
with the C-terminal extension in blue and the two hydrophobic residues bound to the PIF pocket 
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(Reprinted from Arencibia, J. M. et al.130, Copyright (2016), with permission from Elsevier). (B) 
General view of the C-helix central role between the active site, the PIF pocket of PDK1 and the 
activation loop (Reprinted by permission from Macmillan Publishers Ltd: [Nat. Chem. Biol.], From 
Hindie, V. et al.132, copyright (2016)). (C) and (D) Superimposition of PDK1-ATP (blue) and PDK1-
ATP-PS48 (off-white) showing key interacting amino-acids (Reprinted by permission from 
Macmillan Publishers Ltd: [Nat. Chem. Biol.], From Hindie, V. et al.132, copyright (2016). 
 
The crucial role of the PIF pocket in PDK1 makes it a promising target for therapeutic 
drugs. 2-(3-Oxo-1,3-diphenylpropyl)malonic acid and its derivatives were identified as small 
molecules targeting the PIF pocket of PDK1. They act as in vitro activators of PDK1 and selective 
substrate inhibitors in cell assays.133–135 These molecules selectively bind to the hydrophobic 
pocket localized behind the αC-helix and stabilize key residues implicated in kinase activity (Fig 
27). 
The PIF pocket is also present in PKCζ and 4-benzimidazolyl-3-(4-chloro-phenyl)butanoic 
acid family of compounds targets this pocket. Compounds of this class are allosteric inhibitors of 
PKCζ with a very good selectivity whereas they are weak activator of PDK1.136 
 
1.4.3.3 Akt pocket 
Another member of the AGC group has interesting features for allosteric inhibition, the 
protein kinase Akt (also named Protein Kinase B, PKB). Akt plays a key role in survival and 
proliferation regulation. All three human isoforms (Akt1, Akt2 and Akt3) of Akt share an N-terminal 
Pleckstrin Homology (PH) domain which takes part in Akt regulation. Indeed, the kinase in its PH 
“out” form is ready to be activated by phosphorylation whereas the PH “in” form is inactive.  
The importance of Akt makes this kinase a promising target for cancer treatment. One of 
the compound screenings undergone to find Akt inhibitors revealed two molecules with a mixed-
competitive effect toward ATP. These molecules inhibit Akt in a PH-dependent manner. Indeed, 
the IC50 of these compounds are in the micromolar range in the presence of the PH domain 
whereas they are completely inactive in the absence of the PH domain. This effect is opposite to 
the one observed with staurosporine, which is active in both cases but with preference for Akt in 
the absence of the PH domain.137 
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Medicinal chemistry and structural optimization drove researchers to find improved 
compounds with nanomolar potency and high selectivity (Fig 28, B and C).138,139 X-ray structures 
revealed a new pocket formed in the presence of the PH domain. Furthermore, a disorganization 
of the C-helix was observed in presence of small molecules bound in this pocket. The Akt 
pocket is localized at the interface of the kinase domain and of the PH-domain making the 
presence of the PH-domain a strict requirement for inhibitor binding (Fig 28, A).140 
 
 
                              (A) 
 
 
(B) 
 
 
 
 
IC50 (Akt1) = 58 nM 
IC50 (Akt2) = 210 nM 
IC50 (Akt3) = 2119 nM 
(C) 
 
IC50 (Akt1) = 5 nM 
IC50 (Akt2) = 18 nM 
IC50 (Akt3) = 170 nM 
 
Fig 28: Overview of Akt1 pocket. (A) Structural overview of Akt1 pocket with the Pleckstrin 
Homology (PH) domain in red (Reprinted from Palmieri, L. et al.129, Copyright (2016), with 
permission from Elsevier) (B) Chemical structure of the allosteric Akt inhibitor VIII139. (C) Chemical 
structure of the allosteric Akt inhibitor described by Ashwell et al138. 
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1.4.3.4 P-loop pocket 
The P-loop pocket (or MEK pocket) is localized between the P-loop (Mg-binding loop) 
and the C-helix in Mitogen-activated protein kinase kinase (MEKs). Several small molecules 
have been found to bind to the MEK pocket: the first one PD184352 was described in 1999.141 
Based on mutation experiments, a putative binding site was considered142 and later confirmed 
by X-ray structure determination (Fig 29).143 
Interestingly, all of the type III inhibitors of MEKs have been crystallized in presence of an 
ATP analog. Hydrogen bonds could be observed between inhibitors and phosphates of the 
nucleotide and synergetic effect for binding was observed for some of these type III inhibitors.144 
 
(A) 
 
 
(B) 
 
 
Fig 29: Structural view of the MEK-pocket localized between the DFG-motif and the C-helix. (A) 
General 3D view of the MEK-pocket (PDB ID: 1S9J) (Reprinted from Palmieri, L. et al.129, Copyright 
(2016), with permission from Elsevier). (B) View, from the N-terminal lobe, of the ATP molecule 
bound to the catalytic site and of PD318088 compound bound to the allosteric MEK pocket. 
Brown surface represents the most hydrophobic residues and green the most hydrophilic 
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(Reprinted by permission from Macmillan Publishers Ltd: [Nat. Struct. Mol. Biol.] from Ohren, J. F. et 
al.143, copyright (2016)). 
Following these results, several highly selective MEK1/MEK2 inhibitors were discovered and 
one of them, trametinib145(Fig 30) was approved by FDA in 2013 for the treatment of patients with 
BRAF V600E mutated metastatic melanoma. Nowadays, trametinib is used in combination with 
dabrafenib to overcome resistances.146 
Trametinib (allosteric MEK1/MEK2 inhibitor) Dabrafenib (B-Raf inhibitor) 
 
 
Fig 30: Chemical structure of trametinib and dabrafenib. 
Recently, findings about the binding mode of an ERK inhibitor named SCH772984 
revealed that it shares some features with MEK Type III inhibitors. SCH772984 was firstly described 
as a potent and selective ERK inhibitor but its mechanism of action remained unknown.147 Then, 
Chaikuad et al. supposed that a Type II mechanism of action could be the reason of the overall 
good efficacy of this inhibitor. Experiments enabled them to determine the exact and unique 
binding mode of this molecule. Indeed, SCH772984 binds to the ATP pocket and, at the same 
time, to the P-loop pocket providing specific properties such as slow binding kinetics. Piperazine-
phenyl-pyrimidine moiety of this compound binds to the specific P-loop pocket near the αC-helix 
with the P-loop Tyr36 shifted to the “in” position whereas the indazole moiety binds classically in 
the ATP pocket (Fig 31). Interestingly, SCH772984 binding mode is different in off-targeted kinases 
such as Haspin where it binds with a classical type I mechanism.148 
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(A)
 
(B) 
 
(C) 
 
Fig 31: SCH772984 binding mode to ERK1/2 using the dual ATP/P-loop pocket. (A) Schematic 
representation of SCH772984 bound to ERK1/2. Adenine pocket is underlined with a blue shadow, 
ribose and phosphates pocket with a red shadow and the P-loop pocket with a brown shadow 
(Reprinted by permission from Macmillan Publishers Ltd: [Nat. Chem. Biol.] from Chaikuad, A. et 
al.148, copyright (2016)). (B) ERK1/2 surface representation with SCH772984 (PDB ID: 4QTA) 
(Reprinted by permission from Macmillan Publishers Ltd: [Nat. Chem. Biol.] from Chaikuad, A. et 
al.148, copyright (2016)).  (C) Chemical structure of SCH772984. 
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1.4.4 Allosteric inhibitors and CK2 
As described in paragraph 1.3.2.2, CK2 is considered as always active.30 This statement is 
based on the observation of the same active conformation in all X-ray structures of CK2. 
Moreover, no regulation mechanisms such as phosphorylation are required for CK2 activity. 
Nevertheless, during attempts to crystallized CK2 in the presence of small molecule (DRB or 
glycerol) in the /β interaction pocket, Raaf et al. obtained the first CK2α structure in an inactive 
conformation. In this structure, the conformation of the ATP-binding loop (or glycine-rich loop, or 
P-loop) differs from the canonical one. Indeed, Tyr50 of the P-loop collapses in the ATP pocket, 
preventing ATP binding, instead of making interaction with Lys74 and Lys77 of the C-helix (Fig 
32).149 This structure opens the question about the “always active conformation” and it is fair to 
expect that specifically designed small molecules could favor this inactive conformation and act 
as allosteric inhibitors. Moreover, by looking at the β-factor of the CK2 structures, it is clear that 
the ATP-binding loop is one of the most flexible parts of CK2, together with the β4/β5 loop. This 
point is confirmed by the global overview of CK2 structures, already discussed in paragraph 
1.3.2.2 (Fig 10).31 A displacement of the ATP-binding loop by a small molecule seems to be a 
likely event. 
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(A) 
 
 (B) 
 
Fig 32: Glycine-rich loop conformation in active CK2 (PDB ID: 2PVR) and in inactive CK2 (PDB 
ID: 3FWQ) (Reprinted from Raaf, J. et al.149, Copyright (2016), with permission from Elsevier). (A) 
Representation of the ATP binding pocket occupied by ATP (grey) in active CK2 and by Arg47 
and Tyr50 (yellow) in inactive conformation. (B) Specific interactions of Tyr50 with Lys74 and Lys77 
in active conformation (grey) and absence of interactions in inactive CK2 (yellow). 
 
As already mentioned, almost all CK2 inhibitors described until now target the ATP pocket 
and are ATP-competitive inhibitors (TBB, TBI, CX-4945…). Nevertheless, one exception, the 
azonaphthalene class of compounds, is particularly interesting, even if the binding site was not 
precisely determined (Fig 33). Indeed, this family of small molecules has been described as non 
ATP-competitive inhibitors of CK2. SAXS experiments disclosed that, in the presence of an 
azonaphthalene derivative (Fig 33, C), a striking deformation of the kinase structure takes place 
in the region near the P-loop, C-helix and activation segment has been observed (Fig 33, A). 
Moreover, three CK2 mutants Lys71A, Lys76A and Leu178A were found less sensitive toward 
azonaphthalene inhibition than WT-CK2 (Fig 33, B).150 Lys71 and Lys76 residues are localized in 
the C-helix and they make interactions with the P-loop. Leu178 is located at the beginning of 
the activation segment, close to the ATP pocket. These results support the concept that the 
binding site of azonaphthalene series is localized in the area between C-helix and the 
activation segment. 
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 (A) 
 
 (B)
 
(C) 
 
Fig 33: Overview of the azonaphthalene class of compounds. (A) Surimposition of X-ray structure 
(PDB ID: 1PJK) in red ribbon and SAXS ab initio shape restoration for CK2 and CK2 + 
azonaphthalene (From Moucadel, V. et al.150, with the permission of Impact Journals, LLC). (B) 
Inhibitory effect of 0.4 µM azonaphthalene on CK2 mutated in the residues: 10, 24, 61, 71, 74, 76, 
80, 123, 138, 160, 178, 195, 253, 268, 308, 311 to alanine (From Moucadel, V. et al.150). (C) 
Chemical structure of the lead compound azo of the azonaphthalene class.  
 
Few other non ATP-competitive inhibitors have been described such as polyoxometalates 
(POMs).151 Studies also supported their binding site to be located in the same region of CK2 
than azonaphthalenes but, as POMs could not be classified as drug-like small molecules, the 
following discussion will not deal with this class of compounds. 
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A last class of dual site inhibitors is of particular interest. They were obtained by coupling 
the commonly used TBBi (ATP competitive inhibitor) to a small acidic peptide containing multiple 
aspartate residues. As the result, they were able to interact both with the ATP-site and with the 
substrate binding site of CK2, leading to very potent compounds. The most potent inhibitor 
ARC-1502 showed a tremendous affinity for CK2α with a Ki of 0.5 nM, more than 2500-fold better 
than the initial ATP competitive inhibitor (Ki = 1.34 µM). As expected, the acidic peptide part of 
ARC-1502 binds to the substrate binding region of CK2 (PDB ID: 4FBX) but the low resolution of 
this part of the molecule in the X-ray structure prevents a better understanding of its the binding 
mode.109 Following this work, novel dual-site inhibitors were obtained by coupling the ATP-
competitive inhibitor K137 to small peptide sequences. The most potent compound (K137-E4) 
was linked to four glutamic acid residues and exhibited an IC50 of 25 nM for CK22β2. The 
glutamic acid residues interact with the residue involved in binding of n+1 (R191, R195, K198) and 
n+3 (K74, K77) of the substrate proteins. Interestingly, K137-E4 was lacking cell membrane 
permeability: this molecule was therefore able to inhibit selectively the ecto-CK2 activity. In 
consequence, K137-E4 appears to be a valuable tool to understand the physiological role of the 
ecto-CK2.152 
In conclusion, previous studies support the potential interest of the P-loop, the αC-helix 
and the activation segment to be targeted by small molecules to induce CK2α inactivation. 
Nevertheless, up to now, no precise allosteric pocket has been defined on CK2α and allosteric 
drug-like inhibitors have not been identified yet. 
In this part of the manuscript, /β interaction inhibitors that could be considered as 
allosteric modulators of CK2 have not been discussed. Information about this strategy for CK2 
modulation will be detailed in paragraph 1.5.4. 
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1.5 Protein-Protein Interaction Inhibitors 
1.5.1 Definitions and importance 
Protein-Protein Interactions (PPI) have been extensively studied because of their crucial 
role in protein regulation. Indeed, a simple interaction between two proteins is the most common 
way to regulate their activity through protection toward degradation, translocation, activation, 
inactivation, degradation… Human protein-protein interaction network, also called interactome, 
consists of the whole set of interactions between proteins that could occur in a given 
organism.153 The size of the human interactome is estimated to have 130,000 binary interactions 
and, consequently, 130,000 possible targets to modulate cell signaling.154 A web database 
called “Interactome Database”155 reports all described binary interactions. 
Protein-protein interaction enables scientists to target proteins that were considered 
undruggable such as p53/mdm2, EphA4/ephrinB, HPV E2/E1… 
 
1.5.2 Specific difficulties in PP2I discovery 
Protein-protein interaction inhibitors (PP2Is) faced different difficulties compared to 
“usual” orthosteric enzyme inhibitors. In contrast to enzyme inhibitors, there are no natural small 
molecule which could act as ligands as starting scaffolds, nor well-defined pockets, nor 
convenient enzymatic assays to evaluate these small molecules… Large and flat interfaces, lack 
of cavities, competition with large protein, smooth interface are the main difficulties for the 
design of new PP2Is. 
Most of the proteins interact through the intermediate of a large surfaces,156,157 with a 
common surface size of about 1,500 to 3,000 Å². To the opposite, interactions between proteins 
and small molecules are much smaller, with an average surface interaction equals from 300 to 
1,000 Å². However, alanine scanning mutagenesis of residues located in protein interfaces 
revealed that, despite the large number of residues implicated in the interaction, only few of 
them are responsible of the major part of the affinity. Most of the time, one to three hydrophobic 
residues located at the center of the interactions are responsible of the majority of the affinity, 
and so, they are called hot spots.158 In consequence, small molecules targeting only these key 
elements could be sufficient to modulate the protein-protein interaction.159–161 
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Another important feature of protein-protein interfaces is their global flatness. 
Nevertheless, surface flexibility allows adaptation to small molecule binding. Indeed, side chain 
or loop movements can reveal small pockets that are not observable at a first glance on the 
protein structure. Transient pockets could be revealed in flat protein surface during 10 ns 
molecular dynamic simulation, as shown with Bcl-XL, IL-2 and MDM2. In these three examples, 
transient pockets opened during simulation, confirming the situation obtained in crystal structures 
of these proteins with small molecules inhibitors. This statement underlined the drugability of the 
“appearantly flat” protein interfaces.162 
Most of PP2Is come from compound library screenings. Nevertheless, screenings for PP2Is 
are considered arduous, due to the low hit rate that is generally obtained from large library 
screening. One source of this problem could be that compound libraries have been designed to 
target classical enzyme active sites whereas protein-protein interfaces required different 
chemical structures properties. In consequence, specific libraries have been designed to target 
protein interactions.163,164 In addition to screenings, fragment-based approaches using various 
methods such as NMR, SPR or enzymatic assays are often used to identify PP2Is.165 Since the 
success of the molecule ABT-737, discovered by NMR fragment screening and now in clinical 
trials,166,167 several other protein-protein interactions such as ZipA/FtsZ,168 pVHL/HIF-1α169 and Bcl-
XL170 have been studied by NMR. Elisa Barile et al. have recently published a very interesting 
review which described in details all the NMR methods used for the identification and 
optimization of PP2Is.171 
Lipinski’s “rule of five” (HDonor< 5, HAcceptor< 10, MW < 500, LogP< 5) is a global feature 
leading to a good absorption and so, to a good in vivo efficiency. These rules are commonly 
accepted as general guidelines to follow in drug discovery programs.172 However, for PP2Is, a 
consensus is generally accepted: due to the size of protein-protein interfaces, larger molecules 
are required. A comparison between molecular descriptors of PP2Is and a subset of classical 
drugs enables a verification of this statement (Fig 34):173 
 Molecular weight: the average molecular weight of PP2Is is bigger than for other 
drugs but most of PP2Is have a molecular weight under 500 g/mol. 
 logP: none of the described PP2Is has a negative logP and they have a general logP 
greater than classical drugs (75% of PP2Is have a logP under 5). 
 Hydrogen bond formation: both subsets of molecules respect Lipinski’s rules 
concerning the number of hydrogen bond acceptors and the number of hydrogen 
bond donors. 
72 
 
 Topological Polar Surface Area (TPSA): TPSA is considered to be less than 140 Å² and 
both families of molecules respect this statement, even if PP2Is share a larger TPSA 
than classical drugs. 
This comparison confirms the global need of larger molecules to address protein-protein 
interfaces but most of the PP2Is still respect the Lipinski’s rule of five and in consequence could 
be promising candidates. 
  
  
  
Fig 34: Distribution of several molecular descriptors calculated on a family of 66 PP2Is and 557 
drugs. Minimum value, first quartile, median, third quartile and maximum values are represented 
(Reprinted from Sperandio, O. et al.173, Copyright (2016), with permission from Elsevier). 
 
1.5.3 Successful stories 
Protein-protein interactions can be classified in two subtypes depending of the natural 
secondary structure type: 
 Helix-mediated interaction: an α-helix is the natural binder of the targeted protein, 
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 Loop-mediated interaction: a loop, often more flexible and related to macrocycles, is 
the natural binder of the protein. 
 
1.5.3.1 Helix mediated interaction inhibitors 
A survey on all PDB structures shows that only 15% of PDB entries consist of multiprotein 
complexes and, in this subgroup, 62% of the interactions have an helix at the interface.174 
Naturally, helix mimetics are the best option to find inhibitors of such interactions175 and this could 
be obtained: 
 From helix stabilization, using side-chain cross links by covalent bonds or hydrogen 
bonds, 
 From β-foldamers, composed of amino-acid analogs able to adopt an helix 
conformation, 
 From small molecule scaffolds which are helical surface mimetics. This category is 
advantageous because they are composed of small organic molecules and not of 
peptide derivatives.176 
Several successful molecules have been developed as helix competitors. One of the 
most famous cases of protein-protein interaction, the p53/MDM2 interaction, is mediated by an 
helix. Indeed, one α-helix of the N-terminal transactivation domain of p53 binds to MDM2, thus 
preventing p53 tumor suppressor effect. In 2004, Vassilev et al. published the first in vivo effective 
small molecule inhibitor of the p53/MDM2 interaction: Nutlin-3a.177 These results were the proof-of-
concept that inhibition of this interaction in a murine model restored the p53 tumor suppressor 
activity. Following this result, researchers focused their works to find other efficient chemical 
structures targeting this interaction.178,179 Nowadays, 5 molecules are already in clinical trials and 
some more are going to enter such trials (Fig 35).180 
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Nutlin-3a177 
HTRF IC50 = 88 nM 
MTT IC50 = 1.5 µM 
RG7172181 
HTRF IC50 = 18 nM 
MTT IC50 = 0.4 µM 
 
 
RG7388182 
HTRF IC50 = 6 nM 
MTT IC50 = 0.03 µM 
SAR405838183 
Ki = 0.88 nM 
 
AMG-232184 
SPR Kd = 0.045 nM 
 
p53 peptide bound to Mdm2179 (PDB ID: 
1YCR) Kd = 60 nM185 
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Fig 35: Examples of p53/MDM2 inhibitors and representation  of the natural residues involved in 
the interaction (From Shangary, S. et al.186, with the Annual Review of Pharmacology and 
Toxicology). 
Small molecule inhibitors of p53/MDM2 interaction mimic the key residue (Phe19, Trp23, 
Leu26) of the p53 helix which binds to MDM2 (Fig 36). Medicinal chemistry optimization has led to 
small molecules with stronger affinities for MDM2 than p53 (60 nM). 
 
  
 
 
RG7388 
AMG-232 
Fig 36: Structure of RG7388 (Reprinted with permission from Ding, Q. et al.182, Copyright (2016) 
American Chemical Society) and AMG-232 (Reprinted with permission from Sun, D. et al.184, 
Copyright (2016) American Chemical Society) bound to MDM2 protein. Amino-acid names 
written in white correspond to the position of the key residue of p53 bounds to MDM2. 
Even if p53/MDM2 is probably the most well studied protein-protein interaction and with 
the greatest number of drugs in development, some other inhibitors have been successfully 
developed for other interactions (Bcl-XL/BAK or BAD, HPV E2/E1, ZipA/FtsZ, IL-2, α-tubulin/β-
tubulin…). Extensive and recent reviews concerning PP2Is have been published by Tracy L. Nero 
et al.187, Madhu Aeluri et al.178, Lech-Gustav Milroy et al.188 
 
1.5.3.2 Loop-mediated interaction inhibitors 
Despite the fact than α-helix interactions composed the major part of protein-protein 
interactions described in the PDB databank, non-helical and non-strand loops are the drivers of 
many protein-protein interactions.189 A computational approach was described by Jason 
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Gavenonis et al. to identify loops (“hot loops”) which are important for affinity in protein 
interfaces. Among all identified loops, computational alanine scanning was used to determined 
hot spots and loops that include more than one hot spot. Using this method, 1407 hot loops were 
identified in the PDB databank, which represents 5.6% of all interfaces loops. Among this 
subgroup, 19% of the hot loops represent more than 75% of the predicted energy of the all 
interface, 36% more than 50% of the predicted energy interface and 67% more than 25%. This 
study highlights the importance of these hot loops in protein-protein interactions. Interactions 
mediated by loops can also be targeted for drug development190 and some examples are 
presented below. 
EphA4 protein belongs to the Eph family of tyrosine kinase, composed of 16 members, 
which can bind to different glycosylphosphatidylinositol-anchored ephrin-A or transmembrane 
ephrin-B to regulate various biological responses.191 Modulation of EphA4/ephrin interaction is a 
promising target to cure several diseases such as cancers or amyotrophic lateral sclerosis. 
The interaction between EphA4 and ephrin-B is mediated by a loop of ephrin-B that binds 
to a groove of EphA4.192 As frequently observed, the first modulator of EphA4/ephrin-B interaction 
was a small peptide. Actually, three different peptides were discovered by phage display 
screening as EphA4 binders.193 Further investigations led to the identification of the binding site of 
these peptides and revealed their competition with ephrin for EphA4 binding. Moreover, these 
peptides are selective for EphA4 among Eph receptors (Fig 37, A and B).194 
Two small molecules were later identified as inhibitors of EphA4/ephrin interaction by 
using an ELISA-based screening for the interaction between EphA4 and Biot-KYL peptide.195 
These small molecules have moderate affinity (about 20 µM) for EphA4, probably because of the 
absence of an interaction with the complete interface of EphA4/ephrin. Nevertheless, they 
remain good starting point for further drug optimization. Competition experiments, combined 
with NMR experiments and docking simulations, enabled the determination of a putative binding 
site consistent with affinity and ability to prevent ephrin binding (Fig 37, C and D).196 
By using the same screening approach, another structurally unrelated compound was 
discovered as EphA4/ephrin inhibitor: lithocholic acid. This compound has a moderate affinity for 
EphA4 (Ki = 49 µM), despite a higher molecular weight. Other bile acids such as cholic acid, 
deoxycholic acid and chenodeoxycholic acid did not show any effect on EphA4/ephrin 
interaction. However, lithocholic acid showed an effect on all EphA and EphB proteins, which 
was consistent with a lack of selectivity and a common mechanism to bind ephrins (Fig 37, E).197 
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Another example is brought by compound 76D10, which was characterized as an 
inhibitor of EphA/ephrin interaction with a better potency (4.4 µM) but with an irreversible 
mechanism. Moreover, the instability of 76D10 prompted Roberta Noberini et al.195 to suppose 
that the degradation product of 76D10 was the true active compound. They were not able to 
identify this product but speculated about an oxidation mechanism (Fig 37, F).  
Bainan Wu et al.198 used a high-throughput screening by using a NMR approach to find 
inhibitors of the EphA4/ephrin-B interaction. From a library of fragments related to peptide 
structure, few weak inhibitors were identified. Afterwards, structural improvements through 
medicinal chemistry strategies led them to a potent and specific inhibitor of EphA4/ephrin-B 
interaction. Compound 22 is able to inhibit the interaction between EphA4 and ephrin-B with an 
IC50 of 3.7 µM and a good selectivity among Eph receptors. They speculated that a smaller 
molecule even less potent than compound 22 could be obtained by setting aside amino acid 
derivatives for more effective compound.198 
All the studies dealing with EphA4/ephrin-B interaction represent a good overview of the 
strategy to find potent and selective PP2Is, from the characterization of the interaction (the first 
active peptides) and the difficult translation to small molecules by classical screening. The use of 
innovative methods, adapted to the identification of potent and active PP2I, was most of the 
time necessary. 
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(A) (B) 
 
KYL peptide 
KYLPYWPVLSSL 
KD = 0.8 µM (ITC) 
APY peptide 
APYCVYRGSWSC 
KD = 1.5 µM (ITC) 
VTM peptide 
VTMEAINLAFPG 
KD = 4.7 µM (ITC) 
(C)  (D) 
 
Compound 1 
KD = 20 µM (ITC) 
 
 
Compound 2 
KD = 26 µM (ITC) 
 
      EphA4/Compound 1         EphA4/Compound 2 
(E) 
 
Lithocholic acid (LCA) 
Ki = 49 µM 
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(F) 
 
76D10 
IC50 = 2.6 µM 
(G) 
 
Compound 22 
KD = 1.2 µM (ITC) 
Fig 37: EphA4 interaction. (A) Amino acid sequences of the three peptides active on 
EphA4/ephrin-B interaction. (B) Docking model of KYL peptide in EphA4, based on NMR and 
mutagenesis experiments (From Lamberto, I. et al.194, with the permission of Portland Press 
journals). (C) Chemical structures of two small molecule inhibitors of the EphA4/ephrin-B 
interaction. (D) Docking model of EphA4 binding site of the two small molecules (from (C)), 
based on NMR experiments. Residues Ile31 & Met32 in the D-E loop are represented in brown, 
Ile131 & Gly132 of the J-K loop are represented in violet and Gln43 in the β-strand is colored in 
blue (From Qin, H. et al.196 with the permission of Portland Press journals). (E) Chemical structure of 
lithocholic acid, a moderate inhibitor of Eph/ephrin interaction. (F) Chemical structure of a 
putative irreversible inhibitor of EphA4/ephrin interaction. (G) Chemical structure of the peptide 
derivative 22, inhibitor of the EphA4/ephrin-B interaction and docking model of compound 22 
and EphA4. Ephrin-B2 loop is represented by a yellow ribbon (From Barile, E. et al.171, with the 
permission of ACS Publication ). 
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XIAP antagonists target another loop-mediated interaction and exhibited interesting 
results. Inhibitors of Apoptosis Proteins (IAPs) are overexpressed in many cancers and they 
prevent apoptosis by caspase inhibition. XIAP antagonists could reverse caspases inhibition and 
induce apoptosis. Smac is a natural XIAP antagonist and the nature of the interaction between 
Smac and XIAP was determined by NMR.199 Later, synthetic molecules with nanomolar inhibitory 
activities were obtained, based on tripeptide derivatives (Fig 38).200 A combinatorial screening 
strategy based on tri-phenylurea scaffold was also used to successfully find cellular effective XIAP 
antagonists.201 
 
 
XIAP antagonist 
KD = 5 nM 
Fig 38: Structure of tripeptide-based small molecule with XIAP antagonist properties. 
 Menin/MLL interaction is also a successful example to find potent inhibitors of loop-
mediated interactions. Mixed Lineage Leukemia (MLL) fusion protein requires the interaction with 
Menin protein to promote oncogenic activity. Inhibitors of this interaction will induce apoptosis 
and block proliferation. Initial PP2I hits were found by HTS and then developed by medicinal 
chemistry optimization to lead to several compounds with sub-micromolar IC50 (Fig 39).202 
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MI-2 
 
 
IC50 = 0.45 µM 
LE = 0.35 
Fig 39: Chemical structure of a small molecule inhibitor of Menin/MLL interaction. 
 
Research firstly focused on α-helix mediated interaction and a lot of protein-protein 
interaction inhibitors which mimic α-helix have been identified.175,178,188 However, a large 
proportion of protein-protein interaction is mediated by loops and only several examples of 
inhibitors targeting loop mediated interaction have been identified. Without any doubt, the 
number of PP2Is that interact with loop interactions will increase in the near future. 
 
1.5.4 PP2I and CK2 
As described in paragraph 1.3.2.1, CK2 is a multimeric protein, composed of a dimer of 
regulatory subunit (β subunit) that could bind two catalytic subunits ( and/or ’ subunit). The 
regulatory subunit changes the substrate selection of CK2. Moreover, in vitro experiments have 
shown that the regulatory subunit activates and stabilizes CK2. Association and dissociation of 
the catalytic subunit to beta dimer (β2) is an in vivo dynamic process but the driver of this 
phenomenon has not been identified yet.203 
Interactions between CK2 and CK2β have been well characterized and already 
described in paragraph 1.3.2.4. The first crystal structure of CK2 holoenzyme (PDB ID: 1JWH) was 
published in 2001. The interface between α and β subunit was described as asymmetric, id the 
two / interactions in the holoenzyme are not identical, with an average interaction surface of 
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860Å².28 More recently, a new structure of /β interaction was resolved (PDB ID: 4DGL), showing a 
symmetric interaction with a surface about 1000Å² and a KD of 4 nM.48 The interaction is 
mediated by the interaction loop of the regulatory subunit which binds to the N-terminal lobe of 
CK2. The main two hot spots of the interaction loop are Tyr188 and Phe190.50 In the other side, 
the two corresponding hot spots of the -subunit for β binding are Leu41 and Phe54 (Fig 40, A).204 
Despite the strong affinity between CK2 and CK2β, the fact that /β complex is transient make 
it a good target for protein-protein interaction inhibitors design. 
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(A)
 
(B) 
 
 
 (C) 
 
(D)                                        W16 
 
(E) 
DRB 
 
(F) 
 
Fig 40: Modulators of CK2/β interaction. (A) Structural overview of the /β interface. CK2 is 
represented in green and the two hot spots (L41 and F54) in orange. CK2β is colored in blue and 
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the two hot-spots (Y188 and F190) in dark blue (based on PDB ID: 4DGL29). (B) Chemical structure 
of Pc and results of alanine mutagenesis scanning on Pc affinity for CK2. (C) Pc is represented in 
green except for the hot spots in blue and the disulfide bridge between the two cysteines in 
yellow. Amino-acid numbering is based on CK2β sequence, glycine residues are not labeled 
(based on PDB ID: 4IB5).29,51 (D) Chemical structure of W16 compound. (E) Chemical structure of 
5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB). (F) DRB in the /β interaction pocket. 
Surface is colored depending of the β-factor, blue for rigid and green for flexible. Positions of the 
CK2 hot spots are underlined by their labels (based on PDB ID: 3H3029). 
 
In 2007, Béatrice Laudet et al.50 described a small cyclic peptide derived from a loop 
localized in the C-terminal part of CK2β. This peptide competes with CK2β to bind on CK2. This 
small peptide, called Pc, was designed after mutagenesis experiments that revealed the key 
residues (Tyr188 and Phe190) involved in α/β interaction. These two hot spots are located at the 
extremity of a 90° β-hairpin loop formed by residues R186LYGFKIH193: Pc mimics this sequence. 
Then, glycine and cysteine residues were added to cyclize the peptide, and by this way, to lock 
the peptide conformation. The resulting cyclic peptide inhibited the phosphorylation of CK2β-
dependent peptide substrate with an IC50 of 3 µM whereas no inhibition was observed on CK2β-
independent substrates. Moreover, Pc is able to disrupt the CK22β2 complex with the same 
potency. Alanine scanning mutagenesis experiments were conducted with Pc and confirmed 
the crucial role of YGF motif, which binds deeper inside the /β pocket (Fig 40, B).50 In 2013, 
Jennifer Raaf et al. were able to co-crystallize CK2 and Pc (PDB ID: 4IB5). The structure 
confirmed the expected binding mode and underlined the importance of the YGF motif in Pc 
binding.51 Recently, during the development of an HTS assay to identify inhibitor of /β 
interaction, the Pc peptide was improved. Based on docking experiments, central phenylalanine 
was replaced by para-iodo-phenyl alanine and the KD of the novel I-Pc was improved: 0.24 µM, 
measured by ITC, instead of 0.56 µM for the initial Pc.205 
In 2008, two small molecules were published as /β interaction modulators. Béatrice 
Laudet et al. published indolo analogs of podophyllotoxine, also named the W family of 
compounds, with the W16 as the hit compound. This molecule was described as an /β 
interaction inhibitor but CK2 is inhibited by W16 with the same potency, probably by protein 
aggregation. In consequence, this compound was not suitable for further optimizations (Fig 40, 
D).206 In 2008, Jennifer Raaf et al.207 published the first crystal structure of CK2 with a small 
molecule in the /β interaction pocket (also called remote pocket). In attempts to crystallize 
CK2 and 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB, Fig 40, F) known as CK2 
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inhibitor, they obtained a crystallographic structure with two molecules of DRB: one in the ATP 
pocket and one in the /β interaction pocket (Fig 40, F). Biochemical assays have confirmed the 
dual binding mode of DRB but despite the binding of DRB in the /β interaction pocket, no 
significant effect on the association or dissociation of the holoenzyme was observed in presence 
of DRB. This lack of efficiency is probably due to the weak affinity of DRB for CK2 (Fig 40, E, F).207 
Several groups have put a lot of efforts to find a cellular efficient inhibitor of CK2/CK2β 
interaction that will enable a deeper understanding of the role of this interaction in living 
organism. Nonetheless, such an inhibitor has not been published yet. 
  
86 
 
 
 
 
 
2. Aim of the thesis 
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Cancer cell growth relies on activated oncogenes as well as on deregulated non-
oncogenes.208 The Protein Kinase CK2 is one of the deregulated non-oncogenic proteins which 
supports cancer development through activation of pro-survival, anti-apoptotic and proliferative 
signals (See Introduction 1.3.3.1-2. for further details).61,66 CK2 is an ubiquitous Ser/Thr protein 
kinase, composed of a dimer of regulatory subunit () and two catalytic subunits ( and/or ’).28 
The catalytic subunit of CK2 is constitutively active, while the regulatory subunit modulates the 
selectivity toward a subset of substrate proteins.77 The central position of CK2 in the control of 
various cell signaling pathways requires a fine internal control of CK2 activity. However, little is 
known about the cellular regulation of CK2 and the role of the regulatory subunit in the substrate 
selection. Additionally, previous studies promoted the interest of targeting CK2 to counteract 
cancer development, and one ATP-competitive inhibitor is currently in clinical trial, CX-4945, (5-
(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, silmitasertib).209 
Nevertheless, off-targets and resistances to CX-4945 have been recently revealed (see 
Introduction 1.3.4.1-2. for further details).99 
In contrast to ATP-competitive inhibitors, only few small molecules were reported to target 
allosteric binding sites on the catalytic domain of kinases, which can be explained by the fact 
that these allosteric inhibitors exploit unique binding sites and isoform–specific regulatory 
mechanisms.210 Besides the fact that allosteric kinase inhibitors usually present higher selectivity, 
these molecules do not compete with the high cellular ATP concentration. Indeed, for kinases 
with relatively high ATP binding affinities (Km = 1–20 μM), it could be difficult to develop ATP-
competitive inhibitors, which could be selective and, at the same time, potent enough to exhibit 
cellular activity.211 
The aim of this work was: 
A) to develop novel non ATP-competitive inhibitors of CK2. Two distinct hit compounds 
from previous in silico screening campaigns (Fig 41) had to be optimized using 
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different medicinal chemistry approaches. Series of analogs had to be designed, also 
supported by molecular docking. Finally the inhibitory activity and binding affinity 
toward CK2 had to be determined;  
 
Fig 41: Class 1 and class 2 hit compounds from previous in silico-screening campaigns. 
 
B) to confirm and further investigate the mechanism of action of the optimized non-ATP 
competitive inhibitors. Based on the original hits, two distinct chemical classes (1 & 2) 
of compounds had been developed in part A, and were supposed to modulate CK2 
activity by different mechanisms. The following modes of action were postulated and 
had to be investigated using diverse cell-free and cell-based assays: 
i. Allosteric modulators of CK2α could overcome the selectivity issues observed in the case 
of CX-4945 and we believed that they could exert a better in vivo potency than ATP-
competitive inhibitors. It was hypothesized that compounds deriving from class 1 (Fig 41) 
might bind to a novel allosteric site, outside the ATP binding pocket and could lock the 
“always active” CK2α conformation into an inactive state. The goal of our study was to 
verify the allosteric mechanisms of our optimized inhibitors and eventually identify the 
binding site using a combination of single-alanine mutagenesis, temperature-dependent 
circular dichroism, saturation-transfer difference NMR experiments and molecular 
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modeling. Finally, consequences of the novel mechanism of action on the regulation of 
CK2 in cells were to be investigated.  
ii. Protein–protein interaction inhibitors (PP2Is) targeting the CK2α/CK2β interaction: 
compounds deriving from class 2 (Fig 41) were supposed to block the interaction 
between the regulatory subunit () and the catalytic subunit () because the  binding 
pocket had been used as a template for the in silico screening from which the class 2 
secondary hit was identified. Since the / subunit interaction is dynamic212, optimized 
derivatives of this compound might be useful to obtain a deeper understanding of the 
mechanisms that control this interaction and their physiological consequences in cells 
and whole organisms. The goal was to synthesize a small library of class 2 analogs and to 
evaluate their activity in biochemical and cell-based assays. Another objective was the 
characterization of the effects of optimized compounds. Moreover, a complementary 
study of the CK2 activity in cells of a previously described cyclic peptide was planned, in 
order to assess whether the novel and unique approach of modulating CK2 by small PP2Is 
could have potential therapeutic applications.    
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3. Results
91 
 
3.1 Modulation of protein kinase CK2 activity in cells through novel 
non-ATP competitive inhibitors 
CK2 is an ubiquitous Ser/Thr protein kinase involved in the control of various signaling 
pathways and is thought to be constitutively active. In the present study, we identified a novel 
class of CK2 inhibitors, which displayed a non ATP-competitive mode of action and stabilized an 
inactive conformation of CK2 in solution. Single mutation scanning, CD spectrometry and STD-
NMR experiments demonstrated that the compounds bind in an allosteric pocket outside the 
ATP-binding site. Our data strongly suggested that the putative binding site was located at the 
interface between the αC helix and the flexible glycine-rich loop. The optimized compound 7 
showed a micromolar potency to reduce CK2 substrate phosphorylation both in enzymatic 
assays and in cell–based experiments. Furthermore, a substrate–dependent CK2 inhibition as well 
as modulation of the CK2α subcellular localization was observed upon compound 7 treatment. 
Thus, compound 7 is a novel tool to investigate conformation–dependent mechanisms of CK2 
regulation in cells and may be further developed into anti-cancer drugs exploiting a novel mode 
of CK2 inhibition.   
3.1.1 Scientific rationale 
The protein kinase CK2 has an exceptional position within the human kinome due to the 
significant proportion of the cellular phosphoproteome that can be attributed to this kinase.27 This 
ubiquitously expressed protein kinase is involved in the activation of several pro-oncogenic 
pathways that are critical for cell proliferation, differentiation and survival.213 Numerous reports 
underlined the relationship between CK2 overexpression and poor survival rates in lung 
carcinoma, prostate cancer, acute myeloid leukemia, breast carcinoma, colorectal tumors, 
glioblastomas and gastric carcinoma.67 The crucial role of CK2 as a cancer driver makes it an 
interesting target in cancer therapy, and CK2 inhibition proved to be an effective method to 
induce tumor regression.92  
CK2 is a tetrameric enzyme composed of a dimer of regulatory subunits (β) and two 
catalytic subunits, CK2α and/or CK2α’.28 The catalytic subunit of CK2 is considered as 
constitutively active30 and can phosphorylate more than 300 substrates27 while the regulatory 
subunit modulates the selectivity toward a subset of substrate proteins.77 
Most of the known CK2 inhibitors bind to the ATP pocket and show an ATP-competitive 
behavior in enzymatic assays91 CX-4945 (5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-
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carboxylic acid, silmitasertib) is one of the most potent CK2 inhibitors (IC50 = 14 nM) and is 
currently in phase II clinical trials.209 X-ray crystallographic analysis revealed that CX-4945 binds to 
the ATP-binding pocket of CK2α in the active conformation.214 Although CX-4945 is rather 
selective, it was recently reported to be actually more potent against Clk (Cdc2-like kinase) 2 
(IC50 = 4 nM), a kinase involved in the regulation of alternative splicing.99 This recent result 
underlines the fact that potent and selective CK2α inhibitors are difficult to obtain through 
targeting the ATP binding pocket. Therefore, research efforts are spent to identify inhibitors that 
exploit specific regulatory mechanism to suppress the catalytic activity of the kinase. Besides the 
potential pharmacological benefit, such allosteric ligands are often invaluable tools to 
investigate the underlying allosteric mechanism that allows the catalytic domain to switch 
between the active and the inactive state. It was previously reported that azonaphthalene dye–
derived compounds inhibit the catalytic activity of CK2α in a non-ATP-competitive manner, 
however, the exact binding site and a potential mechanism of inhibition remained elusive 150. 
Besides, inorganic PolyOxoMetalate complexes (POMs), e. g., [P2Mo18O62]6-, were described as 
potent allosteric inhibitors of CK2α, exhibiting nanomolar IC50s and great selectivity in a panel of 
29 kinases.151 However, POMs lack cellular activity and there is little perspective to develop them 
further as in vivo active agents. 
  In the present study, we describe the identification of a novel, cellularly active class of 
non ATP-competitive CK2 inhibitors. Using different methodologies, we provide evidence that the 
compounds target an alternative binding pocket distinct from the ATP binding site. 
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3.1.2 Hit compound 1 is a non-ATP competitive inhibitor of CK2 
 
Figure 1. Chemical structures of compounds 1-7. IC50 (S.D. < 20 %) and Ki are depicted for 
compound 1, 5 and 7. For the others, CK2α inhibition percentages in presence of 10 µM of 
respective compound are depicted with S.D. values given in brackets. aKi values were 
determined from graphical plotting of the Lineweaver-Burk plot slopes.  
 
Compound 1 (Figure 1) was identified as a part of a Virtual Ligand Screening (VLS) 
campaign against non-ATP binding sites on CK2.215,216 Michaelis-Menten kinetic experiments were 
performed on top ranking VLS hits in order to confirm the non-ATP-competitive mechanism of 
their action. Despite its relatively weak potency (IC50 = 7 µM on CK2α), this evaluation sparked 
1 
IC50 = 7.0 µM
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our interest in compound 1 because it exhibited an unusual mixed-type mechanism of inhibition 
(Figure 2A) and a constant potency in the presence of increasing ATP concentrations (Figure 
S1A). Moreover, raising the concentration of the peptide substrate did not impair CK2 inhibition 
by 1, ruling out that the compound competed with substrate binding (Figure S1B). Furthermore, 
monomeric CK2α showed the same sensitivity toward inhibition by compound 1 as the 
preformed tetrameric complex CK2α2β2 (Figure 2B). In addition, CK2 inhibition by compound 1 
was not affected by increasing concentrations of CK2β (Figure 2C). These results clearly 
demonstrated that the regulatory β-subunit did not influence the inhibition by compound 1, 
suggesting that 1 does not bind in the α/β interaction pocket on the α-subunit. Next, the 
selectivity of 1 was evaluated against a panel of 44 selected kinases. The selectivity profile was 
encouraging: besides CK2α, only three other kinases from the panel were inhibited by more than 
50 % in the presence of 50 µM of compound 1: EGFR (74 % inhibition), EphA4 (55 %) and Pim-1 (54 
%). Two additional kinases, MuSK (38 %) and PDGFRα (35 %) were inhibited by more than 30 % 
(Table S1). 
 
Figure 2. Analysis of the mode of inhibition of compound 1. A. Lineweaver-Burk inhibition plot of 
human recombinant CK2α by compound 1 at various ATP concentrations. The Ki was 
determined by plotting the slopes at varying inhibitor concentrations. B. CK2α and CK2α2β2 
activity in the presence of increasing concentrations of compound 1. C. Effect of increasing 
CK2β concentrations on the inhibition of fixed amounts of CK2α by compound 1 (20 µM).  
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3.1.3 Structural requirements of the new inhibitors for CK2 affinity 
Based on these promising results, a small set of compound 1 derivatives was synthesized 
(Scheme S1) to establish preliminary structure–activity–relationships (SAR) and possibly optimize 
the potency toward CK2. The compound structures are depicted in Figure 1. Conversion of the 
carboxylic acid function in compound 1 to an ester, or deletion of it, resulted in a strong 
decrease in affinity for CK2 (Figure 1, compounds 2 and 3), suggesting that the binding involved 
ionic interactions with a basic residue. The presence of a phenyl group at position 4 of the 
aminothiazole core was also found to be crucial, as indicated by the complete lack of activity of 
the truncated analog 4 (Figure 1). While modulation of the electron density of this 4-phenyl did 
not change the inhibitory activity compared with that of the unsubstituted congener 5 (cf. 1, 2 
and 6 in Figure 1), increasing the lipophilicity by a bromo-substituent significantly enhanced the 
affinity to reach the sub-micromolar range (Ki = 0.7 µM, compound 7, Figure 1). Thus, the SAR 
obtained with the 4-phenyl ring suggested that binding of this moiety to CK2 was driven by 
hydrophobic interaction with a lipophilic pocket (Figure 1).  
The selectivity of the most potent compound 7 was then evaluated against a panel of 32 
selected kinases, specifically enriched by closely related kinases from the CMGC family but also 
including kinases from other branches of the kinome (Table S2). In addition to CK2α, six others 
kinases were inhibited by more than 60 % in the presence of 50 µM of compound 7 EphA4 (73 %), 
GSK3β (71 %), CK1γ1 (69 %), ACVR1 (66 %), Clk4 (61 %) and MLCK (61 %). Notably, Clk2, the main 
off-target of the ATP-competitive compound CX-4945, was inhibited by only 33 %. 
3.1.4 Identification of a putative allosteric pocket  
Enzyme kinetic experiments (Figure 2 and Figure S1) suggested an alternative mechanism 
of action relying on a potential binding site outside the ATP pocket. To find a clue about the 
potential location of an alternative binding pocket for small molecules, we analyzed the 
available CK2α crystal structures. A study by Niefind et al.31 suggested that the glycine-rich loop 
is one of the most variable regions in X-ray structures of CK2α, suggesting a putative flexibility of 
this loop in solution. This feature was also supported by metadynamics studies simulating 
conformational transitions 217 and by recent structural studies.218 In most CK2α crystal structures, 
the glycine-rich loop conformation is maintained by two hydrogen bonds linking the Tyr50 of this 
loop and two lysine residues (Lys74, Lys77) of the basic cluster (compare e.g., PBD entries 3PE1 
and 3Q9Z). In order to find alternative conformations of the glycine-rich loop, we analyzed all 72 
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crystal structures (and individual chains within these structures) of the human enzyme available in 
the PDB as of November 2014. Two crystal structures (PDB entries: 3FWQ and 3JUH) were 
identified, in which the key hydrogen bonds fixing Tyr50 are lacking. In consequence, Tyr50 has 
fully collapsed in the ATP binding site of the 3FWQ structure.149 The second structure (PDB code: 
3JUH), also presents Tyr50 turned away from its usual location to an intermediate position toward 
the ATP binding site (Figure 3A).33 Thus, it can be assumed that CK2 exists in conformational states 
that allow a movement of the glycine-rich loop. Further examination of the X-ray structures in PDB 
entries 3FWQ and 3JUH revealed a hydrophobic pocket, large enough to accommodate a small 
molecule, which, in the active conformation, is partially occluded by Tyr50 and the glycine-rich 
loop (Figure 3B). This putative allosteric pocket was located between the glycine-rich loop and 
the C-helix, delimited by residues Tyr50, Lys71, Val73, Lys74 and Lys77. To investigate if this region 
might be targeted by our compounds, nine GST-CK2α single-point alanine mutants covering this 
area were tested in enzymatic assays in the presence of a fixed concentration of 7. All CK2 
mutants displayed reasonable catalytic activity, which was at least 30 % of that of the wild type. 
Three mutants (Lys74Ala, Lys77Ala and His160Ala) were found to be more resistant to inhibition by 
compound 7 than the wild type, and therefore selected for dose–response experiments. These 
studies showed that the IC50 values of compound 7 were significantly increased for the Lys74Ala 
(1.8-fold), the Lys77Ala (3.2-fold), and the His160Ala mutant (2.3-fold) (Figure 4). It is reasonable to 
assume that the lysine residues interact with the carboxylate of 7, and that in each lysine mutant, 
the remaining nearby lysine residue can compensate in part for the loss of electrostatic 
interactions, thus attenuating the drop in binding affinity. Taken together, our results from enzyme 
inhibition kinetics, site–directed mutagenesis and SAR analysis were consistent with the binding of 
our new compounds to an allosteric site, composed of a carboxylate coordination site formed 
by the basic cluster containing Lys74/77, and an adjacent hydrophobic cavity which 
accommodates the 4-phenyl moiety. As suggested by the 3D structures (PDB entries 3JUH and 
3FWQ, see above), the hydrophobic pocket was most likely located between the αC helix, 3rd β-
strand of the N-terminal lobe, the activation loop and the glycine-rich loop of the kinase (Figure 
3). 
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Figure 3. A. Superposition of four CK2 structures (3PE, magenta; 3FWQ, blue; 3JUH, cyan; 3Q9Z; 
green). The ATP-binding site is occupied by CX-4945 in 3PE1 and by AMPPNP in 3JUH and 3Q9Z 
(not shown for clarity). B. A separated view from front or top of each structure is depicted. The 
pockets were identified using ICM pocket finder and represented with a mesh surface. The 
putative allosteric pocket is partially available in 3PE1, fully accessible in 3FWQ and 3JUH but 
completely absent in the conformation crystallized in 3Q9Z. 
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Figure 4. Percentage of inhibition of GST-CK2 wild-type and single alanine mutants in the 
presence of compound 7 (4 µM). IC50s were determined for GST-CK2α wild-type and mutants 
with reduced sensitivity toward inhibition (S.D. < 20 %). The fold increase in the respective IC50 
over that of the wild-type is indicated at the bottom. nd: not determined. 
 
3.1.5 Compounds 5 and 7 induce a thermal destabilization of CK2α  
Binding of the allosteric inhibitor was expected to stabilize a conformation in which the 
interactions between Tyr50 and Lys74/77 do no longer link the glycine-rich loop with the αC-helix, 
thereby leading to an increase in the glycine-rich loop flexibility. Hence we hypothesized that the 
inactive conformation stabilized by our inhibitors might be less protected against thermal 
denaturation than the apo enzyme or the complex with ATP binding site–directed compounds. 
Indeed, using CD spectroscopy to monitor the transition to the unfolded state, we observed a 
clear reduction of the melting temperature (Tm) in the presence of compounds 5 or 7 compared 
with the enzyme alone (Table 1). In contrast, the ATP-competitive reference compound CX-4945 
stabilized the protein structure, resulting in an increased Tm. An enhancement of the thermal 
stability was consistently reported for small ligands targeting the ATP binding site, comprising the 
classical ATP-competitive inhibitors but also the so-called type II inhibitors, which induce a local 
conformational change involving the DFG-motif – although not many thermal shift assay data 
are available in the latter case.219,220 Hence, the differential effect of our compounds was a 
further hint that they were not directed to the ATP-binding site.  
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Table 1. Unfolding temperatures of CK2 in the presence of compound 5, 7 or CX-4945 as 
monitored by TdCD. 
Sample Tm (°C) 
CK2 53.2 (± 0.3) 
CK2 + 5 (50 µM) 50.3 (± 0.3) 
CK2 + 7 (6.25 µM)a 52.0 (± 0.2) 
CK2 + CX-4945 (6.25 µM)a 55.4 (± 0.2) 
The midpoint unfolding temperatures (Tm) shown are averages of three independent 
experiments (± S.D.). The CK2 concentration was 5 µM. aConcentrations were limited by the 
compound solubility in methanol. 
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3.1.6 The binding sites of compound 5 and the ATP-competitive inhibitor CX-4945 do not 
overlap 
To provide further evidence for a binding of our compounds to an alternative, allosteric 
pocket, we performed binding NMR experiments, which permit to analyze binding events in 
solution. Compound 5 was chosen for Saturation Transfer Difference (STD) experiments221 due to 
its good solubility in water. Competition experiments between compounds 5 and CX-4945 
revealed that they could bind simultaneously to CK2, proving that they were addressing two 
distinct binding sites (Figure 5A). By comparison, further STD experiments showed that the 7-
azaindole, a fragment substructure known to bind the ATP-site of kinases, did not interact with 
CK2 in the presence of CX-4945 (Supplementary Figure S2).  
STD experiments can also discriminate protons of the inhibitor buried in the protein 
structure from protons of the compound exposed to the solvent, permitting the so-called STD–
based epitope mapping.221 Hence, STD factors were calculated for the different protons of 
compound 5. Clearly, the benzoic acid moiety was found to be exposed to the solvent, as 
indicated by weak STD factors, while the remaining proton of the thiazole and the proton at 
position 10 of the adjacent phenyl ring displayed larger STD factors, indicating that these 
molecule parts were fully buried in the CK2 structure (Figure 5B-C).  
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Figure 5. STD–based evidence for the simultaneous binding of compounds 5 and CX-4945, 
epitope mapping for compound 5 and correlation with the docking model. A. 1D (black) and 
STD (red) NMR experiments of compound 5 (500 µM, approx. 700 x Ki) recorded in the presence 
of the kinase inhibitor CX-4945 (100 µM, approx. 105 x Ki) with 5 µM CK2, showing that CX-4945 
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does not displace compound 5 binding. B. The STD factors measured for compound 5 upon 
binding to CK2 are indicated for the different protons as observed in the 1H-NMR spectrum. C. 
Representation of the STD factors with a green scale on the chemical structure of 5. D. Double 
docking poses of compound 5 (magenta, in the putative allosteric pocket) and CX-4945 (blue, in 
the ATP-binding pocket). Residues interacting with compound 5 are depicted and named, 
except for Arg80, which is hidden by compound 5. E. Top view of the double docking poses of 
compound 5 and CX-4945. The mesh represents the so-called Lee-Richards surface 222: the 
imaginary surface where ligand atom centers should be placed for optimal interactions with the 
receptor; it is colored by preferred ligand atom properties, with green, white, red, and blue 
standing for aliphatic, aromatic, H-bond acceptor and H-bond donor, respectively. F. 3D 
docking model of ATP and 5 simultaneously bound to CK2 (PDB: 1JUH). The proximity between 
ligands is energetically unfavorable. Accordingly, the docking score for compound 5 in the 
presence of bound ATP (-28.64 ICM score units) was much less favorable than its score in the 
absence of ATP (-37.42 ICM score units). G. Binding of AMP-PNP to CK2. 1D (black) and STD 
(red) NMR experiments of AMP-PNP (500 µM) is shown in the absence and in the presence of 
compound 5 (500 µM) with 5 µM CK2. The binding of compound 5 prevents the interaction of 
AMP-PNP with CK2.    
3.1.7 In silico prediction of the binding mode 
To obtain more detailed insight in the binding mode of the CK2 inhibitors, we performed 
docking simulations using the coordinates of PBD entries 3JUH and 3FWQ. The backbone 
conformation of the CK2 structure in 3JUH33 was found to be most compatible with the 
proposed mode of interaction. Hence, the final docking model was prepared from this structure 
by reverting Val66Ala and Met163Leu mutations in the ATP binding pocket of the crystal structure 
back to their wild-type amino-acids, followed by a conformational refinement of the side chains 
near the proposed pocket in the presence of the docked compounds. 
Compounds 1–7 were docked into this final model, alone and in combination with either 
ATP or CX-4945. A representative docking pose for compound 5 is depicted in Figure 5D-E. 
Interestingly, the predicted binding modes of all compounds 1–7 did not differ between the apo- 
and CX-4945–bound CK2. In all cases, basic residues in the C-helix (Lys74, Lys77 and Arg80) 
and the activation segment (Arg191) were found to coordinate the carboxyl–substituted phenyl 
ring of the compounds via a network of favorable hydrogen bonds and salt bridges. The overall 
binding model was consistent with the SAR and the pattern of exposed/buried protons as 
determined by the STD-NMR (cf. Figure 5B-C). Furthermore, the decreased sensitivity of the K74A 
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and K77A mutants toward the inhibitor (Figure 4) was in full accordance with a role for the C-
helix and the activation segment in binding the carboxylate; however, the decreased sensitivity 
of the H160A mutant could not be explained by a direct contact with the inhibitor. It is 
conceivable that, in this mutant, the formation of the allosteric pocket might be impeded, thus 
increasing the energetic barrier for inhibition by our compound.  
While the conformation of the protein structure model based on PDB entry 3JUH was 
compatible with a simultaneous docking of CX-4945 and either of the compounds 1-7, docking 
of ATP was only successful with the apo-model; when attempted in the presence of either of the 
docked compounds 1-7, a minor steric clash occurred with the terminal phosphate group of ATP 
(Figure 5F). The latter was consistent with the prevention of AMP-PNP binding in the presence of 5 
as observed in the STD-NMR (Figure 5G). 
3.1.8 Compound 7 retains its cell-free potency in cell–based CK2 inhibition assays  
As mentioned above, dysregulated CK2 is considered as pro-oncogenic and was 
validated as a pharmaceutical target for anti-cancer therapies 66. Specifically, the importance 
of CK2 activity for the development of clear-cell renal cell carcinomas (ccRCCs) has been 
described recently 60. Therefore, the ccRCC cell line 786-O was chosen as an in vitro model to 
evaluate the anti-cancer activity of compounds 1-7. In the cytotoxicity assay, all of the 
compounds affected the cell viability after a 24 h treatment. The most potent inhibitor 7 also 
effected the strongest reduction in 786-O cell viability (EC50: 25 µM). This cellular efficacy was 
remarkable since in the same assay, the canonical ATP-competitive inhibitor CX-4945 exhibited 
an EC50 of 6.1 µM, reflecting only a 4-fold higher activity than 7 (Figure S3), in spite of its much 
higher cell-free potency (IC50: 5 nM). 
Next, we performed Western Blot analyses to investigate whether CK2 activity was 
indeed inhibited by our compounds in living cells. CK2 is responsible for the phosphorylation of α-
catenin on residue Ser641,223 and Akt1 on residue Ser129.224 Therefore, these two phospho-
acceptor sites were chosen as selective reporters of CK2 cellular activity. After a 24 h treatment 
of 786-O renal carcinoma cells with compound 7, a strong decrease in both -catenin (Ser641) 
and Akt1 (Ser129) phosphorylation was observed (Figure 6A), confirming that CK2 was a cellular 
target of this inhibitor. Subsequent dose–response experiments showed that 7 inhibited the 
phosphorylation of α-catenin (Ser641) and Akt1 (Ser129) with EC50s of 6 µM and 16 µM, 
respectively (Figure 6B). These EC50s were in good agreement with the concentration required to 
reduce the viability of 786-O cells by half (25 µM), also arguing that the inhibition of the CK2–
dependent signaling was functionally linked to the observed cell death induction. Interestingly, 
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we noted only a modest 5-fold drop in potency for 7 between the cell-free assay (IC50: 3.4 µM) 
and the suppression of Akt phosphorylation in living cells (EC50: 16 µM). In comparison, the 
reference compound CX-4945 exhibited a cell-free potency of 5 nM and a cellular efficacy of 1 
µM for both substrates (Figure S6), indicating a striking 200-fold drop in potency. This finding was in 
accordance with the distinct mechanism of action identified for 7. As indicated by its observed 
mixed-type of mechanism for CK2 inhibition, this compound did not directly compete with ATP. 
Therefore the high cellular ATP concentration should not affect the binding of 7 to CK2 to the 
same degree as would be expected for CX-4945.  
 
Figure 6. Inhibition of cellular CK2 activity by compound 7. A. 786-O cells were incubated with 
various concentrations of 7 for 24h, and the phosphorylation status of two protein substrates of 
CK2 was measured by Western Blot analysis of the cell extracts. GAPDH was probed as loading 
control. B. Western Blot quantification was performed using ImageJ and fitted to a sigmoid 
equation using SigmaPlot to determine the EC50s.  
 
3.1.9 The inhibition of CK2 activity by compound 7 is substrate–dependent 
It was intriguing that compound 7 exhibited a small but reproducible difference in the 
potency to inhibit the substrate phosphorylations of α-catenin (IC50: 6 µM) vs. Akt1 (IC50: 16 µM), a 
feature which was not seen in the case of CX-4945. Hence we aimed at corroborating this 
observation by analyzing the phosphorylation of further known CK2 protein substrates, using 
defined cell-free conditions (Figure 7A). Compound 7 inhibited Six1 phosphorylation and CK2β 
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autophosphorylation with the same efficacy as the canonical peptide substrate used in the 
previous dose–response assay (IC50: 3.4 µM). However, a striking 10-fold difference was observed 
for the phosphorylation of nucleolin (IC50: 42 µM). In contrast, CX-4945 inhibited the 
phosphorylation of nucleolin with about the same potency as that of other protein substrates 
and the peptide substrate (IC50: 5 nM). This result suggested that the efficacy of compound 7 to 
inhibit CK2 activity depends on the protein substrate. 
Nucleolin is an abundant nucleolar protein known to bind to CK2 with very high 
affinity.225 Due to this complex formation, a significant portion of CK2 in growing cells is usually 
concentrated in the nucleoli 226. CK2 phosphorylates the bipartite nuclear localization signal near 
the N-terminus of nucleolin, thus promoting its nuclear translocation.227 In consequence, the 
phosphorylation status of the CK2 phospho-acceptor site in nucleolin is expected to determine 
the subcellular localization of the high-affinity complex, which can be monitored by a 
fluorescent label. Using an EGFP-CK2 construct, we analyzed whether compound 7 and CX-
4945 differently influence the subcellular localization of CK2 in 786-O renal cancer cells. Indeed, 
we found that CX-4945 induced a significant translocation of EGFP-CK2 from the nucleoli to the 
nuclear matrix and the cytoplasm compartments (Figure 7B), whereas compound 7 was without 
visible effect. These results were consistent with the observed potency differences of compound 
7 and CX-4945 with respect to the inhibition of nucleolin phosphorylation. Thus, the alternative 
mode of action of 7, that rendered its potency substrate–dependent, further translated to a 
different impact on the subcellular localization pattern of high affinity CK2/substrate complexes 
when compared with the ATP-competitive inhibitor CX-4945.   
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Figure 7. Cellular consequences of the stabilization of the CK2 inactive conformation. A. Protein 
substrates phophosphorylation (  nucleolin,  Six1,  CK2β auto-phosphorylation) by CK22β2 in 
presence of various concentration of compound 7 (upper panel) or the ATP-competitive 
inhibitor, CX-4945 (under panel). Graphs represent the average of two measurements. B. 786-O 
pEGFP-CK2 cell imaging showing the subcellular localization of CK2 after 12h treatment with 
DMSO, compound 7 (40 µM) or CX-4945 (8 µM). Nuclei were stained with Hoechst-33342 and 
merged images as well as GFP single channel were depicted for clarity. 
 
3.1.10 Conclusion 
CK2 is of main interest in cancer treatment because of its implication in promoting 
cancer development,66 in drug resistances70 and in epithelial plasticity.228 However, only one CK2 
inhibitor, CX-4945, entered clinical trials up to now.92 The vast majority of CK2 inhibitors developed 
so far was directed against the ATP binding site, entailing insufficient selectivity and cellular 
activity in many cases.103,229 Even with CX-4945, selectivity issues arise99. To date, very few studies 
described alternative strategies for the pharmacological inhibition of CK2, and none of them 
presented drug-like small molecules.150–152,230 Herein, we have provided first evidence for the 
existence of an alternative binding pocket, distinct from the conserved ATP-site, which can 
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accommodate small drug-like molecules. We have also proven that binding affinities sufficient to 
impart efficient CK2 inhibition can be achieved. Based on single mutation scanning and STD-
NMR experiments, also supported by in silico studies, the small molecules described in this paper 
were predicted to bind to an allosteric pocket localized at the interface between the glycine-
rich loop and the αC-helix. Notably, the position of the allosteric pocket described here partially 
superimposes with that of the previously discovered alternative binding pocket in the MAP 
kinases MEK1 and -2 (data not shown)143. However, an αC-helix displacement was clearly 
observed upon allosteric inhibitor binding in the MEK pocket whereas the rigidity of this helix in 
CK2α prevents a significant displacement. In the case of CK2α, it is more likely that the glycine-
rich loop is the mobile part during pocket opening. Nevertheless, based on structural similarities, 
the identification of this allosteric pocket on the constitutively active CK2α supports the possible 
existence of a comparable pocket in other related kinases.148,231 
Our STD-NMR experiments revealed that binding of the ATP analog AMP-PNP was 
prevented in the presence of the 2-aminothiazole derivative 5. This might be explained by a 
partial direct competition of AMP-PNP – and analogously of ATP as well – with the small ligand. 
The docking result depicted in Figure 5F demonstrates that compound 5 would come rather 
close to the terminal phosphate moiety of theoretically bound ATP. Alternatively, the available 
crystal structures 3JUH and 3FWQ support the idea that upon binding of the 2-aminothiazole 
derivatives, the glycine-rich loop might switch to a conformation not compatible with binding of 
the terminal ATP phosphate moiety.149,218 The resulting allosteric down-regulation of ATP binding is 
also in keeping with the data from the STD-NMR and, importantly, also from the enzyme kinetics 
analysis. The latter showed a mixed-type of inhibition toward ATP with an increase in Km and a 
decrease in Vmax, suggesting that the inhibitors stabilize a less productive conformation, thus 
causing a decrease in the apparent affinity for ATP. In consequence, a truly allosteric 
mechanism of inhibition is more likely to be the prevailing mechanism of action of our 
compounds (Figure S5). This view also supported by the cellular experiments, which revealed for 
compound 7 only a low drop of potency in cells (EC50 (α-catenin phosphorylation): 6 µM) 
compared with the cell-free assay (IC50: 3.4 µM). Considering the high intracellular levels of ATP in 
the mM range, the noticeable retention of activity of 7 suggests that at least in cells, (partial) ATP 
competitive mechanisms cannot play a major role. It is noteworthy that a similar outcome had 
been observed with CI-1040, a highly selective and non-ATP competitive inhibitor of MEK1/2, that 
showed a ratio of about 5 to 6-fold between enzymatic potency (IC50 = 17 nM) and cellular 
efficacy (EC50 = 100 nM).141,232 For classical ATP-competitive inhibitors, the commonly observed 
ratio is much higher (in the 100-fold range), depending on the Km of the respective kinase for 
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ATP.11 Hence, the alternate mechanism of inhibition may provide an advantage for in vivo 
applications of future optimized derivatives of 7. 
Proteins and among them protein kinases are regulated through various conformational 
changes. In solution, an equilibrium between various conformations is observed and some of 
them could be stabilized by ligand binding, leading to a conformational selection.233,234 CK2α 
was considered as a constitutively active protein kinase since decades.30 Given that more than 
300 proteins were identified as potential substrates of this kinase, it is fair to ask how the catalytic 
activity towards these numerous substrates is regulated.27 Although CK2β was found to modulate 
substrate specificity of the catalytic subunit upon complex formation,77 it is unlikely that this is the 
only physiological mechanism of controlling the CK2 activity.212 Raaf et al. (2009) solved by X-ray 
crystallography an inactive conformation of CK2α, which displayed a putative allosteric pocket 
in the region we mapped as the interaction site; however, no evidence could be provided that 
such an inactive state exists in vivo.149 Altogether, the results presented herein provide evidence 
that CK2α does not exclusively exist in a “switch on” state but can adopt an inactive 
conformation, which can be stabilized by binding of our compounds, and which may resemble 
the inactive state of CK2α observed in the mentioned crystal structure. Furthermore, our results 
obtained both in cell-free and cellular assays demonstrated that the inhibitory efficacy of our 
allosteric modulators was substrate-dependent, suggesting that some substrates may affect - by 
physical interaction with CK2α - the compound´s ability to stabilize a catalytically inactive 
conformation. Therefore, the compounds described herein could be considered as the first 
substrate-selective modulators of cellular CK2 activity, clearly differing from the common total 
CK2 inhibitors. Nevertheless, compound 7 effected growth inhibition of tumor cells in vitro, even 
though - in contrast to CX-4945 - its potency to suppress specific phosphorylations may vary 
depending on the protein substrate. 
  In conclusion, our compounds are useful as probes to investigate how the modulation of 
CK2 conformational states may contribute to the regulation of the kinase´s activity in specific 
contexts. Also supported by the results from such experiments, our inhibitors may be further 
developed into drugs targeting pathogenic signaling pathways in specific tumor entities. 
  
109 
 
Supplementary Figures, Tables and Scheme 
 
Figure S1. A. Effects of increasing ATP concentrations on the inhibition of CK2α activity 
by compound 1. CK2α (20 ng) was incubated with or without 15 M of 1 after which its 
activity was assayed with 200 M of CK2β–independent peptide substrate in the 
presence of increasing ATP concentrations. B. Effects of increasing peptide substrate 
concentrations on the inhibition of CK2 activity by 1. CK2α (20 ng) was incubated with 
or without 15 M of 1 after which its activity was assayed with 100 M ATP in the 
presence of increasing concentrations of CK2β–independent peptide substrate. 
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Figure S2. STD NMR experiments for CK2α. 1D (black) and STD (red) NMR experiments of the 
compound 7-azaindole (500 µM), a small molecule known to target the ATP-binding site of 
kinases (STD signals with CK2α alone are displayed at the bottom), is displaced by the kinase 
inhibitor CX-4945 (100 µM) (STD spectrum at the top). 
 
 
 
Figure S3. 786-O cells viability in presence of various CX-4945 concentrations. EC50 was 
determined by linear interpolation after transformation to log[c] scale. 
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Figure S4. Inhibition of cellular CK2 activity by CX-4945. A. 786-O cells were plated and incubated 
for 24 h with various concentrations of CX-4945. The phosphorylation status of two protein 
substrates of CK2 was then measured by Western Blot analysis of the cell extracts. Anti-GAPDH 
was used as loading control. B. Western Blot quantification was performed using ImageJ and 
fitted to a sigmoid equation using SigmaPlot to determine the EC50s.  
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Figure S5. Proposed models of the mechanism of CK2α inhibition by compounds 5 and 7. On the 
left, compounds 5 and 7 bind to CK2α prior to or after ATP binding. Binding of the small ligands 
induces a decrease in the Vmax and an increase in the Km for ATP (cf. Lineweaver-Burk plot, 
Figure 2). Also considering the results from the STD-NMR experiments (cf. Figures 5), two 
alternative mechanisms are consistent with this mixed-type inhibition, as illustrated in the middle: 
(i) a direct, but limited steric clash between ATP and the new compounds, adding a minor 
competitive proportion to the non-ATP competitive mechanism (“non ATP-site inhibitor“); (ii) 
binding of new compounds stabilize a conformational deformation of the ATP-binding pocket, 
which involves a larger movement of the glycine-rich loop (in blue), inducing a decrease in 
affinity for ATP (indirect effect); this represents a truly allosteric mechanism. 
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Table S1. Residual kinase activity in the presence of compound 1 at 50 µM. 
Protein Kinase 
Residual 
activity 
(%) 
Protein Kinase 
Residual 
activity 
(%) 
Protein Kinase 
Residual 
activity 
(%) 
Protein Kinase 
Residual 
activity 
(%) 
CK2α(h) 0 HIPK2(h) 83 IR(h), activated 93 CaMK1(h) 101 
EGFR(h) 26 MAPK1(h) 84 CDK6/cyclinD3(h) 95 CDK2/cyclinE(h) 101 
EphA4(h) 45 LKB1(h) 85 cSRC(h) 97 Met(h) 102 
Pim-1(h) 46 PKBα(h) 85 FGFR1(h) 97 PAK2(h) 102 
MuSK(h) 62 CDK2/cyclinA(h) 86 Fyn(h) 97 IKKα(h) 103 
PDGFRα(h) 65 PKCα(h) 86 HIPK1(h) 97 MEK1(h) 103 
AMPKα1(h) 71 cKit(h) 87 HIPK3(h) 98 Abl (h) 104 
Aurora-B(h) 74 PKA(h) 87 CDK9/cyclinT1 99 CDK7/cyclinH(h) 104 
DYRK2(h) 78 CDK1/cyclinB(h) 89 Rsk1(h) 99 JAK2(h) 104 
Aurora-A(h) 79 CHK2(h) 89 ROCK-1(h) 100 Lyn(h) 104 
GSK3β(h) 79 c-RAF(h) 92 Yes(h) 100 mTOR(h) 104 
Results were obtained from kinase profiler service offered by Life Technologies with ATP 
concentration adjusted to the respective Km of each kinase. Duplicate values did not differ by 
more than 15 % in all assays. 
 
 
Table S2. Residual kinase activity in presence of compound 7 at 50 µM. 
Protein Kinase 
Residual 
activity 
(%) 
Protein Kinase 
Residual 
activity 
(%) 
Protein Kinase 
Residual 
activity 
(%) 
EphA4(h) 27 CLK2(h) 67 PKCα(h) 92 
GSK3β(h) 29 Abl(h) 69 MEK1(h) 95 
CK1γ1(h) 31 CHK2(h) 72 JAK2(h) 98 
ACVR1 (ALK2) 34 TBK1 75 MKNK1 (MNK1) 101 
CLK4(h) 39 CDK1/cyclinB(h) 78 PDGFRα(h) 102 
MLCK (MLCK2) 39 DYRK1a 79 DAPK3 104 
STK17A 
(DRAK1) 
48 CLK1(h) 80 EGFR(h) 106 
CK2a2 48 HIPK3 82 CDK2/cyclinE(h) 107 
GSG2 (HASPIN) 55 CLK3(h) 86 ROCK-1(h) 107 
Pim-1(h) 57 RIPK2 86 cKit(h) 116 
HIPK2 57 MuSK(h) 90 
  Results were obtained from kinase profiler service offered by Life Technologies with ATP 
concentration adjusted to the respective Km of each kinase. Duplicate values did not differ by 
more than 17 % in all assays. 
114 
 
 
 
Scheme S1. Synthesis of the aminothiazole 2-7 compounds. Reagents and conditions: a) CS2, 
Et3N in THF/H2O, RT, 24 h, then I2 in THF, 0 °C to RT, 3 h b) NH4OH 30 %, RT, 6 h c) EtOH, reflux, 3-12 h. 
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3.2 2-Aminothiazole derivatives as potent and selective allosteric 
modulators of the protein kinase CK2 
 
Protein kinase CK2 is an ubiquitous protein Ser/Thr kinase involved in cancer 
development. Based on the 4-(4-phenylthiazol-2-ylamino)benzoic acid scaffold, extensive 
Structure Activity Relationship studies were carried out and led to significant improvement of 
potency. The non-ATP competitive mechanism of action of the leading compound, 2-hydroxy-4-
((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (8e) was confirmed. In addition, cellular 
experiments have shown interesting effects for cellular CK2 inhibition and apoptosis induction, in 
comparison with CX-4945, a phase II clinical trial ATP-competitive CK2 inhibitor. Thus, targeting 
CK2 in a non-ATP competitive manner leads to in cellulo highly efficient compounds with 
interesting perspectives for further in vivo developments. 
 
3.2.1 Scientific rationale 
Tumor development could rely on deregulated oncogenes but also on deregulated non-
oncogenes.208 Indeed, several proteins sustain tumor development, even if they are not the 
primary cause of the cancer. In this context, CK2 plays a central role as several studies revealed 
its implication as a cancer driver.66 CK2 overexpression has been widely correlated with a poor 
prognosis for patient in prostate cancer54, breast carcinoma56, glioblastoma58, gastric 
carcinoma235 or renal cell carcinoma.60 Indeed, CK2 acts as a major support to prosurvival and 
antiapoptotic signals by interfering with NF-κB, Wnt and Akt pathways.66 Thus, CK2 overexpression 
supports a favorable environment for cancer development described as the “hallmarks of 
cancer”.4,5,236 
CK2 is a ubiquitous Ser/Thr protein kinase composed of a dimer of regulatory subunits (β) 
and two catalytic subunits, CK2 and/or CK2’.28 The catalytic subunit of CK2 is constitutively 
active, while the regulatory subunit modulates the selectivity toward a subset of substrate 
proteins.77 
CK2 inhibition has been proved to be a valuable strategy to fight cancer and several 
inhibitors have been developed, among which CX-4945 (5-(3-
chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, silmitasertib).209 This ATP-
competitive inhibitor of CK2 is the most promising molecule. Developed by Cylene 
Pharmaceuticals, this compound is a highly potent (IC50 = 14 nM) and selective (Gini coefficient98 
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= 0.67) inhibitor of CK2 with a good efficiency in cellular experiments. Besides, in mice 
xenografts models, tumor regression was observed upon CX-4945 treatment.92,97 Looking for 
splicing regulation through phosphorylation of serine/arginine rich (SR) proteins, Kim et al. 
revealed a special CK2-independent implication of CX-4945 in cellular regulation of SR protein 
phosphorylation.99 Indeed, this compound was found to be a strong inhibitor of Cdc2-like kinase-
2 (Clk-2) (IC50 = 4 nM), almost four-fold more potent than on CK2 (IC50 = 14 nM).99 Although the 
consequences in splicing regulation remain elusive, this off-target activity of silmitasertib 
underlines the need for potent and more selective CK2 inhibitors. 
Recently, 2-aminothiazole derivatives 1-3 (Figure 1) were identified as non-ATP 
competitive inhibitors of CK2α. A complete study allowed us to determine the allosteric 
mechanism of action of these molecules: (i) A simultaneous binding of compound 2 and of the 
ATP-competitive inhibitor CX-4945 was observed by STD-NMR experiments; (ii) The unfolding 
temperature of GST-CK2 monitored by CD spectrometry decreased upon compound 2 or 3 
binding whereas an increase was observed in the presence of CX-4945; (iii) Single mutation 
scanning coupled with extensive molecular modeling studies have led to the identification of an 
2-aminothiazole binding site, at the interface of the flexible glycine-rich loop, the C-helix, the 
third -strand of the N-terminal lobe and the activation loop. The allosteric pocket was defined 
by residues Tyr50, Leu70, Val73, Lys74, Lys77, Arg80 and Arg191. These findings emphasize the 
specificity of such mechanism of CK2 inhibition by this class of compounds. 
 
Cpd R IC50 (CK2α) in µM 
1 NO2 7 
2 H 9 
3 Br 3.4 
 
Figure 1. Chemical structures of three allosteric inhibitors previously described (S.D. < 20 %). 
(chapter 3.1) 
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3.2.2 Chemistry 
Aminothiazoles core were prepared according to Hantzsch-type syntheses from 2-
bromoacetophenones and thiourea intermediates (Scheme 1). Most of the 2-
bromoacetophenones 4 were commercially available or easily prepared (4a-c) from 
commercially available acetophenones through a bromination step, as described in the 
literature.237,238 Thioureas 5 were obtained after reaction of isothiocyanate intermediates with 
ammonia solution. The latter were synthesized after reaction of the primary amine of aniline 
derivatives with carbon disulfide, in presence of triethylamine, followed by iodine oxidation.239 
Hantzsch syntheses were carried out in ethanol and the resulting products were directly obtained 
as solids, after their precipitation with water. Semi-preparative HPLC, recrystallization, or washing 
procedures led to the final products with a LC-UV (254 nm) purity higher than 95%. In some cases, 
ethyl ester derivatives were obtained instead of the free carboxylic acids. Then, a saponification 
step with NaOH was carried out to obtain the desired products 6c and 7g. 
Compound 9 could not be obtained through Hantzsch-type synthesis, maybe due to the 
spatial proximity between the primary amine and the carboxylic acid of 2-aminobenzoic acid, 
which prevents the formation of the isothiocyanate intermediate. Consequently, a nucleophilic 
substitution between 2-bromo-4-(3-nitrophenyl)thiazole and 2-aminobenzoic acid in hydrochloric 
acid was performed to obtain the desired 2-((4-(3-nitrophenyl)thiazol-2-yl)amino)benzoic acid (9) 
albeit in a low 2% yield (Scheme 2). 
Several modifications were considered on the carboxylic acid function (Scheme 3). 
Methyl ester derivative 10 was easily obtained through a classical acidic esterification step. 
Sulfonamide derivatives 11a-b were obtained according to amino-acid coupling procedures 
whereas acetoxymethyl prodrugs 12a-c were accessed from carboxylic acid derivatives (1 or 7i-
j) and bromomethyl acetate through a previously described method.240 
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Scheme 1.Hantzsch-type synthesis. Reagents and conditions: a) Br2, CHCl3, 40°C, 5 min or Br2, HBr 
32% in AcOH, MeOH, 60°C, 4h.b) CS2, Et3N in THF/H2O 1/1, RT, 24h, then I2 in THF, 0°C to RT, 3h. c) 
NH4OH 30%, RT, 6h. d) EtOH, reflux, 3-12h. 
 
 
Scheme 2. Preparation of compound 9 through aromatic nucleophilic substitution. Reagents and 
conditions: a) HCl(aq) 37%, 1,4-dioxane, 90°C, 48h. 
 
 
Scheme 3. Syntheses of esters and amides 10-12. Reagents and conditions: a) H2SO4 95% 3 drops, 
MeOH, reflux, 2h. b) 11a: HATU, DIPEA, dry DMF, 30 min; NaH, RSO2NH2, dry THF, RT, 30 min; then 
RT, 4h. 11b: EDC, HCl, DMAP, RSO2NH2, CH2Cl2, RT, 36h. c) Bromomethyl acetate, Et3N, dry DMF, 
RT, 12h. 
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3.2.3 Structure-Activity Relationships 
The preliminary Structure-Activity Relationships (SAR) revealed the importance of key 
features of our diaryl aminothiazole derivatives for CK2 inhibition (chapter 3.1). Indeed, 
attempts to remove or to hide (as a methyl ester) the acid function led to totally inactive 
compounds (Table 1; compounds 6a and 10, respectively), underlying the importance of such 
functional group on the aromatic ring. Consequently, we envisaged the evaluation of several 
analogs sharing the 3-nitrophenyl moiety but with variations of the carboxylic acid part (Table 1). 
Compound 6b having this group at position 3 was 4-fold less potent than its para regioisomer 1. 
However, when the carboxylic acid functional group was displaced in position 2 (derivative 9) 
we observed a similar range of efficiency than the parent compound 1. Compound 6c with two 
carboxylic acid functions in meta positions was also prepared but its very low solubility prevented 
any biological evaluation. Compound 6d with a phenyl acetic acid moiety was, by far, less 
efficient on CK2α than compound 1, underlining the fact that benzoic acid in position 4 is the 
best moiety for protein inhibition. 
We tried thereafter various modulations on the second aromatic ring while conserving the 
4-benzoic acid group for the first one (Table 2). Starting from compound 1 with a 3-nitro 
substitution on the phenyl moiety, we modulated the electron density of this ring using various 
substitutions: 3-bromo 3, 3-methoxy 7a, 4-methoxy 7b, 2,4-methoxy 7c, 2,4-hydroxy 7d, 2-hydroxy-
4-bromo 7e, pyridin-2-yl 7f and without any substitution 2. In these cases, no significant 
improvement of IC50 was observed, even though hydrophobic substituent such as a bromine 
atom at position 3 or 4 improved CK2α inhibition, with IC50 values of 3.4 µM and 5 µM (3 and 7e, 
respectively). 
The small differences in IC50 values of compounds 1-3 and 7a-f with these various 
substitutions prompted us for more drastic structural modifications of the phenyl moiety. Removal 
of the phenyl ring (7g) or its replacement by a non-aromatic bulky tert-butyl moiety 7h resulted in 
a strong decrease of CK2α inhibition. On the other hand, replacement of the phenyl ring by a 3-
thiophene 7i improved twice the inhibition of CK2α (IC50= 5 µM for 7i). Moreover, we have 
observed that a naphthyl ring substitution resulted in a better protein inhibition, with an IC50 value 
of 3 µM for compound 7j. This latter finding is consistent with the requirement of a hydrophobic 
moiety in this part of the inhibitors, as already noticed with compound 3. 
In consequence, several benzoheterocyclic derivatives 7k-m were synthesized and 
evaluated. Compound 7k with a chromene instead of the naphthyl group and compound 7l 
containing a 2-benzofuran moiety were less potent than compound 7j. The promising result 
obtained with a thiophene substitution (7i) suggested us to introduce a 5-benzothiophene 
substituent, but in this case, no significant improvement of the inhibition of CK2α was noticed. 
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Preliminary docking experiments conducted on compounds 1 and 7j suggested that the 
size of the naphthyl moiety induces a more constraint binding mode in the allosteric pocket than 
for compound 1. In consequence, it seems promising to have a new look on the carboxylic acid 
substitution on a 4-naphthalen-2-yl-thiazol-2-yl-arylamines. Several derivatives 8a-e were 
synthesized (Table 3) and evaluated for their CK2α inhibitory properties. Compounds 8a without 
acid function and 8b with a 4-cyano substitution definitely lacked for CK2α inhibition. However, 
with the naphthyl substitution in R1, the carboxylic acid function appears to better increase the 
potency in position 3 (8c) than in position 4 (7j). The opposite result was observed in the presence 
of the 3-nitrophenyl group for R1 (Table 1; compounds 1 and 6b). The 6-methoxy-3-benzoic acid 
analog 8d exhibited a potency on CK2α similar than the parent compound 8c. So, results from 
the SAR studies underlined the need of an acid group in position 3/4 of the phenyl ring and 
docking results suggested that more interactions between the basic residues (Lys74, Lys77, Arg80 
and Arg191) of CK2α and this acidic function could be possible. To increase these interactions, 
we tried to add on this ring another functional group and a salicylic acid derivative 8e was 
considered. This structural modification provided a very good result as the inhibitory properties 
was five-fold higher (compound 8e compared to7j), as shown by the sub-micromolar IC50 value 
(IC50 = 0.6 µM for compound 8e, see Table 3). 
 
Carboxylic acid derivatives could sometimes be a source of troubles for in vivo 
experiments with cell permability issues. To continue the structural exploration, we considered 
bioisosteric modifications and a prodrug approach. Several compounds were synthesized, 
deriving from 1, 7i,j (Table 4) and compared with para-substituted acids 7j and 8e. These 
derivatives might not exhibit better in vitro potency but better physicochemical properties, 
suitable with cellular experiments. Thereby, cell viability experiments were considered as the 
easiest way to evaluate compound efficiency as CK2 inhibitors induce a decrease in cell 
viability.92,101 Acylsulfonamide derivatives are well known carboxylic acid bioisosteres as they 
preserve the acidic properties (pKa ≈ 4-5) but with improved bioavailability.241 In our case, two 
acylsulfonamide derivatives were synthesized and evaluated: methylsulfonamide 11a and 4-
methylbenzenesulfonamide 11b both exhibited similar in vitro potency with a respective 41% and 
54% inhibition of CK2α at 10 µM. However, looking at their ability to reduce cell viability, 
compound 11b (87% decrease at 25 µM) was by far better than compound 11a (23% decrease 
at 25 µM). Moreover, tosyl derivative 11b was more efficient than the parent compound 7j (43% 
decrease in cell viability at 25 µM) and as efficient as the best compound of this series (8e, 87% 
decrease at 25 µM). In order to discriminate these compounds, the Percentage Efficiency Index 
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(PEI), which render ligand efficiency as a function of molecular weight,242 was calculated for 
each molecule (Table 4).This index underlined the predominance of compound 8e (PEI = 2.6) in 
comparison with compound 11b (PEI = 1.1). For two structures having the same cellular 
efficiency, the one with the lowest molecular weight (8e) was considered as the best candidate 
for further developments. A prodrug strategy using acetoxymethyl ester groups was 
considered.240 Among the three evaluated derivatives 12a-c, none of them led to improvement 
in cellular efficiency (Table 4). Further experiments evaluating the stability of these prodrugs have 
to be carried out before envisaging new derivatives. 
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Table 1. Importance of the benzoic acids function on R2. 
 
Cpd R2 
IC50a 
(µM) 
1 
 
7 
6a 
 
>25 
10 
 
>25 
6b 
 
30 
9 
 
8 
6c 
 
b 
6d 
 
>50 
aIC50 values are the mean of ≥2 experiments with errors within 40% of the mean. bSolubility 
troubles prevent IC50 determination. 
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Table 2. SAR studies on hydrophobic ring R1. 
 
Cpd R1 IC50a 
(µM) 
1 
 
 7 
2 
 
9 
3 
 
3.4 
7a 
 
12 
7b 
 
6 
7c 
 
13 
7d 
 
7 
7e 
 
5 
7f 
 
14 
7g 
 
>50 
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7h 
 
>50 
7i 
 
5 
7j 
 
3 
7k 
 
8 
7l 
 
14 
7m 
 
4 
aIC50 values are the mean of ≥2 experiments with errors within 40% of the mean. 
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Table 3. Pharmacomodulation studies on 4-naphthalen-2-yl-thiazol-2-yl-arylamine derivatives. 
 
Cpd R2 
IC50a 
(µM) 
7j 
 
3 
8a 
 
>50 
8b 
 
>50 
8c 
 
2 
8d 
 
8 
8e 
 
0.6 
aIC50 values are the mean of ≥2 experiments with errors within 40% of the mean. 
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Table 4. In vitro and cellular effects of selected carboxylic acid bioisosteres and prodrugs. 
 
Cpd R1 R2 
CK2α 
inhibition 
(%) at 10 
µMa 
(IC50b) 
PEIc 
Cell 
toxicity 
(% from 
DMSO) 
at 25 
µMd 
7j 
  
67 (3) 1.9 43 
8e 
  
96 (0.6) 2.6 87 
11a 
 
 
41 1 23 
11b 
 
 
54 1.1 87 
12a 
 
 
41 1 45 
12b 
 
 
7 0.2 42 
12c 
 
 
37 1 48 
aRecombinant CK2α inhibition percentage in presence of 10 µM of corresponding compound. 
bIC50 values are the mean of ≥2 experiments with errors within 40% of the mean. cPEI = (% 
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inhibition as fraction (0 – 1.0) in presence of 10 µM of corresponding compound) / (molecular 
weight, kDa).242 d786-O cell toxicity, 24h, 25 µM of respective compound. 
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3.2.4 Enzymatic characterization of compound 8e effects on CK2  
With this efficient CK2 inhibitor 8e in hand, we then wanted to know if its mechanism of 
action was similar to that of initial compounds described in Figure 1, ie through binding to an 
allosteric site. 
So, to evaluate if this compound exhibits non-ATP competitive behaviors in enzymatic 
assays, we have performed a Lineweaver-burk plot analysis of CK2 inhibition by compound 8e. 
As illustrated in Figure 2A, a non-ATP competitive mechanism of action, similar to compounds 1-3, 
was observed, with a Ki value of 0.18 µM. Then, the effect of compound 8e was evaluated on 
CK2 and on the holoenzyme CK222, with a β-independent peptide substrate (peptide 29) 
and a β-dependent peptide substrate (peptide M) as well. These three experimental conditions 
displayed similar results, as the potency of 8e remained constant (Figure 2B): this thereby 
underlines the ability of 8e to inhibit CK2 and the holoenzyme complex with the same potency.  
 
Figure 2. Enzymatic characterization of compound 8e. A. Lineweaver-Burk inhibition plot of 
human recombinant CK2α by compound 8e at various concentrations: 0, 0.5, 1, 1.5, 2.5 µM. Ki 
was determined by plotting the slopes at varying inhibitor concentration from three independent 
experiments. B. CK2α and CK2α2β2 activity with various peptide substrates in presence of 
increasing concentration of compound 8e.  
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3.2.5 Compound 8e binds to an allosteric pocket of CK2  
Compound 8e was screened on a panel of 13 GST-CK2 mutants, mainly located in the 
area of the putative binding site described in chapter 3.1. Three mutants were significantly less 
sensitive toward inhibition by 8e: Val73Ala, Lys77Ala and His160Ala (Figure 3) and therefore 
selected for dose response experiments. Compound 8e IC50 was strongly increased in 
comparison with the wild-type GST-CK2 (IC50 = 0.6 µM), a 2.8-fold increase for Val73Ala (1.7 µM) 
was observed, a 4.3-fold increase for Lys77Ala (2.6 µM) and a 1.7-fold increase for His160Ala (1 
µM). 
 
Figure 3. Percentage of inhibition of GST-CK2 (WT or single alanine mutant) in presence of 
compound 8e (1 µM).  
 
3.2.6 Compound 8e is a selective inhibitor of CK2 
Selectivity among human kinome is an important feature for kinase inhibitors to avoid side 
effects.102,243 Using the Gini coefficient as a reporter of the overall selectivity, it is clear that 
allosteric inhibitors such as PD184352 (MAPKK1 optimized inhibitor), is more selective (Gini 
coefficient = 0.91)98 than quinalizarin, an optimized ATP-competitive inhibitor of CK2 (Gini 
coefficient = 0.61).101 Targeting the less conserved allosteric binding site of kinases could be a 
solution to have a higher selectivity. For our study, compound 8e was evaluated against a 
selected panel of 53 kinases (Supplementary Table S1) and only four other kinases, in addition to 
CK2, were inhibited by more than 50%: ErbB2 (70%), Aurora-B (62%), Pim-1 (60%) and PI3K (53%). 
It was noteworthy that the main off-target of the CX-4945, Clk2, was not inhibited by 8e and, 
among the four isoforms of cdc2-like kinases, only Clk4 (23%) was weakly inhibited. Moreover, 
compound 8e overall selectivity (Gini coefficient = 0.78) was higher than for CX-4945 (Gini 
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coefficient = 0.67) and than for other CK2 inhibitors described in the literature.97,103 
 
3.2.7 Inhibition of CK2 cellular activity and apoptosis induction by 8e 
CK2 inhibitors are known to decrease the cell viability92,101 and, consequently, the most 
active compound 8e was selected for a cell viability screening on nine cell lines, originated from 
various tissues (Table 5). Among cancer cells, aminothiazole 8e exhibited GI50 values from 5 µM in 
clear cell renal cell carcinoma (ccRCC) cell line 786-O to 20 µM in prostate cancer cell (DU145). 
Interestingly, compound 8e is by far less toxic in non-cancerous (benign) kidney cells (RPTEC) with 
a GI50 5-fold higher (27 µM) than in kidney cancer cells (786-O). This latter result is consistent with 
the dependence of cancer cells to a high level of CK2α expression for their development, as 
already described.66 Of note, CX-4945, the canonical ATP-competitive inhibitor of CK2α exhibited 
a GI50 of 6 µM in 786-O cells (Supplementary Figure S1), so in the same range than 8e. 
 
786-O cells are known to be resistant to classical chemotherapy.244 Moreover, the 
potential of CK2α as a relevant target to treat 786-O cells has been already described.60 
Therefore, the 786-O cell line was selected as a cellular model for further evaluation of 
compound 8e efficiency, by using Western Blot analysis. 
First, inhibition of CK2 activity within living cells was evaluated. Two protein substrates, Akt 
and α-catenin, known to be phosphorylated by CK2 on residue Ser129224 and Ser641223, 
respectively, were used as reporter of CK2 cellular activity. A strong decrease in phosphorylation 
of Akt (Ser129) and α-catenin (Ser641) was observed after a 24h treatment with compound 8e 
(Figure 5A). We can conclude that compound 8e inhibited CK2 cellular activity and decreased 
cell viability, also observed macroscopic observations during cell viability experiments (presence 
of numerous dead cells). 
Then, we were interested in apoptosis markers. Two of them, the apparition of cleaved 
PARP and the decrease in survivin protein level, were investigated by Western Blot. Both 
apoptosis markers appeared simultaneously after 24h treatment by compound 8e (Figure 5B). 
The concentration of 8e needed for apoptosis induction (about 6 µM) is consistent with the GI50 
(about 5 µM) and the cellular inhibition of CK2 activity (about 5 µM) supporting that CK2 
inhibition is responsible for cell death.  
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Table 1. Effect of compound 8e on various cell lines. 
 
Cells were grown as described in the experimental part and GI50 values were determined 
by linear interpolation after transformation to log[c] scale. Standard deviations from minimum 
two independent experiments are depicted between brackets. 
 
Figure 5. Cellular effect of compound 8e. A. Cellular inhibition of CK2 by compound 8e. 786-O 
cells were plated and incubated 24h in the presence of various concentrations of 8e. 
Phosphorylation statuses of two protein substrates of CK2 were measured by Western Blot analysis 
Tissue Cell name Cmpd 8e GI50 in µM
Kidney
786-O 5 ( 2)
RPTEC 27 ( 5)
Breast
MCF7 10 ( 2)
MCF10A 10 ( 3)
Lung
H1299 9 ( 4)
A549 12 ( 3)
Prostate
PC3 7 ( 2)
DU145 20 ( 6)
Glioblastoma U138 13 ( 3)
GAPDH
P-α-catenin
(S641)
P-Akt
(S129)
0.50.25
Akt
α-catenin
0 1 2 4 6 8 10 12
1 0.98 0.74 0.60 0.61 0.53 0.44 0.37 0.30 0.25
1 1.33 1.10 0.99 0.88 0.79 0.55 0.52 0.62 0.54
Compound 8e (µM)
GAPDH
PARP
0.5
Compound 8e (µM)
0.25
Survivin
0 1 2 4 6 8 10 12
A
B
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of cell extracts. Band intensities were quantified using ImageJ and Anti-GAPDH was used as 
loading control. B. Apoptosis induction upon compound 8e treatment. 786-O cells were plated 
and incubated 24h in the presence of various concentrations of 8e. Apparition of cleaved PARP 
and decrease of survivin was observed by Western Blot analysis of cell extracts. Anti-GAPDH was 
used as loading control. 
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3.2.8 Conclusion 
From the allosteric inhibitor of CK2α described in chapter 3.1, compound 3, we 
investigated new pharmacomodulation studies based on the 2-aminothiazole scaffold. SAR 
studies have led to potent and selective allosteric inhibitors of CK2α. The SAR demonstrated 
clearly that a hydrophobic and aromatic substitution in position 2 of the 2-aminothiazole core 
had a positive effect on CK2α inhibition; as well as an acid function at the opposite side, on the 
aromatic linked to the amino group of the thiazole. The binding site of the optimized compound 
8e was confirmed in the allosteric pocket by single mutation scanning and docking studies. The 
allosteric binding pocket of 8e is located at the interface delimited by the flexible glycine-rich 
loop, the αC-helix, the 3rd β-strand of the N-terminal lobe and the activation loop. A good 
selectivity was achieved with a Gini coefficient of 0.78 against a panel of 53 selected kinases. In 
comparison, the clinical phase II inhibitor, CX-4945 exhibited a Gini coefficient of 0.67. Moreover, 
Clk2, the main off-target of CX-4945 was not inhibited by 8e, neither the other kinase of the Clk 
family. In addition of an interesting selectivity, the mechanism of action of compound 8e may be 
responsible for the advantageous efficiency in cellular-based assay. Indeed, 8e exhibited an 
very good potency to inhibit CK2α cellular activity, in the same ranges than the clinical phase II 
inhibitor, CX-4945. This latter result has to be linked with the important difference of potency on 
recombinant CK2α (0.6 µM for 8e and 0.014 µM for CX-4945). As a potent CK2α inhibitor, 8e 
induced apoptosis after 24h treatment at a concentration of 6 µM and lead various cancer cell 
lines to death. In summary, the optimized allosteric inhibitor of CK2, 8e, exhibited a cell efficiency 
comparable with the clinical phase II inhibitor, CX-4945 and it is a promising molecule for further 
in vivo studies. 
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3.3 Identification of the first cellular efficient modulator of the 
protein kinase CK2 subunit interaction 
 
CK2 is a tetrameric protein kinase composed of two catalytic subunits ( and/or ’) and 
a dimer of regulatory subunit (β). CK2β interaction changes the substrate selection of the 
catalytic moiety. Previous studies demonstrated that a deregulation of the dynamic interaction 
between CK2 and CK2β induced major alterations in cell signaling leading to phenotype 
modifications. However, cellular efficient CK2β-competitive inhibitors are required to understand 
this complex mechanism. In the present study, a cellular efficient inhibitor of the CK2 subunit 
interaction was obtained through biomolecular engineering of a small cyclic peptide previously 
described as a CK2 antagonist. This fusion peptide exhibited a micromolar potency to interfere 
with the CK2/β interaction in cell-based assay leading to striking modifications of the CK2 
subunits subcellular localization as well as to a significant modification in p21 phosphorylation, 
coupled with EGFR down-regulation. In addition of its potential to investigate the dynamic 
regulation of the CK2/β interaction in living-cell, the remarkable decrease in cell viability 
observed upon disruption of /β interaction makes it as a valuable cell death-inducing tool.  
3.3.1 Scientific rationale 
CK2 exhibits  an heterotetrameric quaternary structure in which a central dimer of 
regulatory subunits (CK2β) bridges two catalytic subunits, CK2 and/or CK2’.28 The plethora of 
CK2 substrates27 that are involved in the promotion of cell survival, proliferation and 
differentiation213 shows the complexity of the CK2 cellular signaling network and supports the 
view that this enzyme participates to the regulation of many of the same cellular responses that 
characterize the ‘‘hallmarks of cancer’’ originally described by Hanahan and Weinberg4,5. Thus 
the crucial role of CK2 in tumorigenesis makes it an attractive pharmacological target in cancer 
therapy, and CK2 inhibition proved to be an effective method to induce tumor regression.92 Most 
of chemically diverse CK2 inhibitors bind to the ATP pocket91 such as, for example, CX-4945 (5-(3 
chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, silmitasertib, IC50 = 14 nM) 
which is currently in phase II clinical trials.209  
Both the isolated CK2 subunits and the holoenzyme are endowed with constitutive 
activity. However, the regulatory subunit modulates the substrates preference of the catalytic 
subunit.77 Previous studies demonstrated that the CK2 subunits interactions are dynamic and that 
each subunit could be independently found in different subcellular compartment.203,245 It is 
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assumed that a dynamic rather than a static interaction of the CK2 subunits may help adjust the 
kinase specificity to ensure that the relevant form of the catalytic subunit is present at each of 
these locations. Moreover, several studies75,228 revealed the role of the regulatory subunit in the 
control of the epithelial to mesenchymal transition (EMT). Indeed, CK2β down-regulation in 
epithelial breast cells is sufficient to promote EMT through Snail1 upregulation.76 However, despite 
the great importance of the /β interaction in the regulation of cell polarity and cell morphology, 
the cellular effectors responsible of its fine control remain unknown. Furthermore, perturbating the 
prominent CK2α/CK2β interaction with artificial compounds might suppress specific CK2 
holoenzyme functions. 
Very few potential inhibitors of this interaction have been published50,51,206,207. Using a 
structure-based design approach50 and a random screening strategy,206 we previously identified  
a  CK2β-competitive lead compound: Pc, a cyclic peptide that could actually counteract the 
holoenzyme formation in cell-free assays.50 In the CK2 holoenzyme structure, a segment located 
in the N-terminal region of CK2β (L187-H193) forms a β-hairpin loop which inserts deep into a 
remote hydrophobic groove present in the β4/β5 sheets of CK2.28 Two residues, Tyr188 and 
Phe190 were characterized as the hot-spots and therefore, the peptide Pc was designed from 
the structure of the CK2β-tail encompassing these two hot-spots. Thus, Pc represents a unique 
CK2β-based small molecule fully capable of interacting with CK2 and to disrupt the /β 
interaction in cell-free assays at 3 µM concentration. Moreover, Pc was shown to disturb the CK2-
holoenzyme-catalyzed phosphorylation of CK2β-dependent CK2-substrate proteins.50 The hot-
spots mutations (Tyr5Ala, Phe7Ala; equivalent to Tyr188 and Phe190 in CK2β structure) were 
sufficient to impair the in vitro efficiency of Pc.50 Later on, both X-ray crystallography data and 
thermodynamic signatures demonstrated that Pc and CK2β binding to CK2 are similar.51 Thus, 
Pc represents the first effective CK2β–competitive compound derived from the C-terminal CK2β 
segment. However, this peptide antagonist lacks cellular efficiency and its optimization through 
structural modifications, such as attachment to cell-permeable adducts was required. 
In the present study, we described biomolecular engineering of the Pc peptide to 
promote its cellular activity. Using this peptidic tool, we provide the first evidence of the 
consequences of a specific disruption of CK2/CK2β interaction in living cells.  
3.3.2 Design of a cell permeable chimeric TAT-Pc 
We synthesized a chimeric Pc analogue termed TAT-Pc composed of both active Pc in 
which the disulfide bond used for cyclization have been replaced by an amide linking the side 
chain of K1 and to the C-term of G13 (KGGRLYGFKIHGG) and a 13-mer peptide 
(GRKKRRQRRRPPQ) derived from TAT protein of the human immunodeficiency virus 1.246,247 This 
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TAT sequence is a cell-penetrating peptide which can carry element such as drugs, small 
peptide or nucleic acid into the cells.248 Thus, the covalently linked TAT-Pc chimeric construct in 
which the TAT sequence is placed at the N-terminal side of Pc was expected to be cell-
permeable (Figure 1). In order to assess the cell penetration, a TAMRA fluorescent probe was 
added to the construct which could then be located by fluorescence microscopy. The TAT 
sequence enabled a remarkable uptake of the TAMRA-TAT-Pc construct into the cells as the 
majority of the peptide was located into the cells in less than 4h (data not shown). We also 
synthesized a cyclic peptide (TAT-Pc-rand) in which the Pc residues were in a random position 
was obtained as well as a cyclic peptide (TAT-Pc-mut) with the two Pc hot spots residues (Tyr5 
and Phe7) mutated to alanine (Figure 1).  
 
Figure 1: Sequences of the Pc, TAT-Pc, TAT-Pc-rand, TAT-Pc-mut, TAMRA-TAT-Pc. The two spots, Y5 
and F7 (corresponding to Y188 and F190 in CK2β sequence) or mutated residues are depicted in 
bold for clarity.  
 
3.3.3 TAT-Pc suppresses the CK2/CK2β interaction in living cells 
  Previous studies have demonstrated that Pc peptide is an efficient CK2β-competitor in 
cell-free assay.50,51 Consequently, we were interested in the cellular observation of the 
CK2/CK2β interaction upon treatment with the cell-permeable TAT-Pc. Proximity ligation assay is 
a method of choice to evaluate a protein-protein interaction in living cells as it enables the 
direct observation of proteins interactions in unmodified cells.249 Thus, we applied this 
methodology in HeLa cells. In untreated cells, CK22β2 complexes were observable as dots with 
an average 5.5 interactions per cell (Figure 2). Confirming literature data,245 the CK22β2 
TAT sequence = GRKKRRQRRRPPQ-
TAMRA = 5-Carboxytetramethylrhodamine
PcGCRLYGFKIHGCG
TAT-PcKGGRLYGFKIHGGTAT
TAT-Pc-randG-----------------CGTAT
TAT-Pc-mutGCRLAGAKIHGCGTAT
TAMRA-TAT-PcGCRLYGFKIHGCGTAMRA TAT
137 
 
complexes were transient as only few sporadic complexes were detected  and as they did not 
overlap with the large CK2 and CK2β expression observed by immunostaining experiments 
(data not shown). In TAT-Pc treated cells, a striking decrease of the overall number of complex 
formation was observed with an average number of interactions lower than 2 per cell for a 
concentration of TAT-Pc equal or greater than 40 µM (Figure 2). These observations suggest that 
TAT-Pc translocates through cell membranes and behaves as a cell-efficient inhibitor of the 
CK2/CK2β interaction.  
 
Figure 2: Inhibition of the CK2 subunit interaction in HeLa cells. (a) PLA images of HeLa cells 
treated for 6h with 0, 20, 40 or 60 µM of TAT-Pc. Red blobs represents CK2/CK2β interaction. 
Nuclei were stained with Hoechst-33342. (b) Quantification of the average blobs per cell using 
BlobFinder.250 More than 150 Cells were analyzed for each condition. Error bars represent S.E.M. 
 
3.3.4 CK2 subunits subcellular localization is altered by TAT-Pc 
  Previous studies demonstrated that CK2 subunits have the capacity to translocate 
independently from the nucleus to the cytoplasm.245 We hypothesized that the inhibition of the 
CK2/CK2β interaction might affect/disturb the CK2 subunits localization. Indeed, we observed a 
strinking translocation of CK2 and CK2’ from the nucleus to the cytoplasm upon TAT-Pc 
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treatment (Figure 3), whereas the catalytic subunits remained mostly nuclear in presence of 
DMSO or in the presence of the ATP-competitive CX-4945 inhibitor. In contrast, CK2β was mainly 
located in the cytoplasm in controls as well as in the presence of TAT-Pc. These observations are 
in agreement with the independent and dynamic regulation of CK2 subunit subcellular 
localization and highlight the influence of the holoenzyme formation on CK2 subunit 
translocations. 
 
Figure 3: Subcellular localization of CK2 subunits in 786-O renal carcinoma cells. Cells were 
treated with DMSO as control, TAT-Pc (30 µM) or CX-4945 (12 µM) for 12h before fixation.  
  
3.3.5 Epidermal growth factor receptor (EGFR) down-regulation upon TAT-Pc treatment 
  Upon stimulation, the EGFR can initiate several downstream signaling cascades leading 
to cell proliferation.251 Autophagosome-mediated EGFR down-regulation induced by CK2 
inhibition has been documented.252 As we observed a decrease in cell proliferation after TAT-Pc 
treatment, we investigated the EGFR status in presence of TAT-Pc or CX-4945. Using 
immunostaining methods, we observed a striking translocation from the cell membrane to the 
cytoplasm associated with a down-regulation of EGFR after TAT-Pc or CX-4945 treatments in 
mammary epithelial cells (MCF10A) (Figure 4). Moreover, these observations were correlated 
with an increase of endosomal activity attested by the LAMP1 marker. Interestingly, stable 
silencing of CK2β expression in these epithelial cells (MCF10A-Δβ) led to a similar translocation of 
CK2α’Merge
DMSO
CX-4945
TAT-Pc 
CK2α CK2β Merge
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EGFR from the cell membrane to the cytoplasm (Figure 4). Thus, the previously described 
implication of CK2 in EGFR regulation252 is dependent on the CK2α/CK2β interaction and its 
perturbation could lead to a decrease in cell proliferation. This finding may provide a new 
strategy to target the EGFR signaling pathways and to overcome resistance to EGFR inhibitors.253  
 
Figure 4: EGFR degradation through lysosomal activity upon TAT-Pc treatment. MCF10A cells 
were treated for 12h with DMSO as control, TAT-Pc (30 µM) or CX-4945 (12 µM). MCF10A-Δβ cells 
were used as additional reference. Cells were immunostained with anti-EGFR (red), anti-LAMP1 
(green), chemically stained with DAPI (blue), and then analyzed by confocal microscopy.  
 
3.3.6 p21 phosphorylation is increased by TAT-Pc 
  p21CIP1/WAF1 is an universal inhibitor of cyclin-dependent kinases such as CDK1, CDK2 and 
CDK4/6 playing a key role in cell cycle regulation.254,255 It has been reported that p21 is 
phosphorylated by CK22β2 and interacts with the CK2β N-terminal end in vitro.256 A decrease of 
p21 (T145) phosphorylation was systematically observed upon treatment with ATP-competitive 
inhibitors of CK2,92,257 suggesting that status of p21 phosphorylation could be used as a reporter 
of CK2 activity. However, in contrast of these previously described results, we did not observe the 
phosphorylation of recombinant p21 protein by CK22β2 in our in vitro assay (data not shown). 
Nevertheless, as p21 phosphorylation seems to be related to CK2 activity in cellular-based assays, 
DMSO
CX-4945 
TAT-Pc 
EGFR LAMP1
MCF10A
MCF10A-ΔβDMSO
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we evaluated this feature by Western Blot analysis of cell extracts. Indeed, a striking dose-
dependent increase of p21 (T145) phosphorylation was observed upon treatment with TAT-Pc 
(Figure 5a-b). Additionally, this effect was not observed upon treatment with the cell-permeable 
but inactive versions of Pc (TAT-Pc-rand and TAT-Pc-mut) (Figure 5a-b). In contrast, the ATP-
competitive inhibitor, CX-4945, promoted a decrease of p21 (T145) phosphorylation (Figure 5a). 
The TAT-Pc dependent increase of p21 phosphorylation was, of note, a general effect as it was 
observed in several cell lines (786-O, MCF10 and HeLA).  
  Interestingly, previous studies showed that the C-terminal segment of p21 (p21(145-164)) 
could adopt different secondary conformations regulating proteins PCNA, CaM and SET 
binding258 and the phosphorylation of p21 on the residue T145 prevents PCNA binding.259 Since 
the nuclear localization signal of p21 (RKR(140-142)) is located near T145,260 we hypothesized that 
phosphorylation on T145 could impact the C-terminal structure leading to significant modification 
of protein binding and of the subcellular localization of p21. Indeed, TAT-Pc treatment triggered 
a striking nuclear localization of p21 whereas a homogeneous localization in the cytoplasm and 
in the nucleus was observed in DMSO controls or upon treatment with the ATP-competitive 
inhibitor, CX-4945 (Figure 5c-d).  
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Figure 5: Effect on p21. (a) Phosphorylation status of p21 in 786-O renal carcinoma cells. Cells 
were treated for 48h with TAT-Pc (various concentrations, see upper panel), DMSO, TAT-Pc-rand 
(40 µM) or CX-4945 (6 µM) (see lower panel). (b) Phosphorylation status of p21 in MCF10A cells. 
Cells were treated for 48h with TAT-Pc (various concentration, upper panel), DMSO, TAT-Pc (40 
µM), TAT-Pc-rand (40 µM) or TAT-Pc-mut (40 µM) in the lower panel. (c) Subcellular localization of 
p21 in 786-O renal carcinoma cells treated for 12h with DMSO as control, TAT-Pc (30 µM) or CX-
4945 (12 µM). (d) Subcellular localization of p21 in MCF10A cells treated for 12h with DMSO as 
control, TAT-Pc (30 µM) or CX-4945 (12 µM).  
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3.3.7 Differential effects of CK2/CK2β interaction inhibition and CK2β knockdown 
  Previous studies demonstrated that CK2β has a key role in epithelial plasticity and that 
shRNA-mediated silencing of CK2β expression in epithelial MCF10A led to Epithelial-to-
Mesenchymal Transition (EMT) through upregulation of SNAIL1.76 Therefore, we investigated the 
effect of TAT-Pc on SNAIL1 expression as well as on two CK2 activity reporters (-catenin-phospo-
S641 and Akt1-phopho-S129). Surprisingly, no changes in Snail1 expression or in reporter 
phosphorylation level were observed whereas p21 phophorylation was strongly increased upon 
TAT-Pc treatment (Figure 6). The latter support the concept that, in contrast to CK2β silencing, 
inhibition of CK2/CK2 interaction alters CK2 functions in a different manner that conveys in 
different cell phenotypes. Indeed, both approaches induced th e degradation of EGFR (Figure 4) 
whereas EMT induction was only observable in the case of CK2β silencing. 
 
Figure 6: Western Blot analysis of TAT-Pc effects on CK2 activity markers (P--catenin, P-Akt), on 
EMT (Snail1 expression) and on p21 phosphorylation. 786-O renal carcinoma cells were treated 
with TAT-Pc for 48h prior to Western Blot analysis. 
 
3.3.8 TAT-Pc decreases cancer cell viability 
  The observation that TAT-Pc induced the EGFR down-regulation and p21 translocation 
into the nucleus suggested that these two events could respectively lead to a decrease of cell 
viability and to cell cycle inhibition. Indeed, we observed a significant decrease of HeLa cell 
viability upon TAT-Pc treatment whereas the inactive TAT-Pc-rand did not exhibit any effect 
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(Figure 7). Therefore, this effect on cell viability as well as other cellular consequences triggered 
by TAT-Pc treatment are likely to be related to its ability to inhibit the CK2α/CK2β interaction. 
 
Figure 7: TAT-Pc decreased cell viability. HeLa cells were treated with TAT-Pc or TAT-Pc-rand for 
48h before evaluation of cell viability in comparison with DMSO treatment.  
 
3.3.9 Conclusion 
Molecules that selectively inhibit the CK2 subunit interaction would be useful in 
determining the importance of CK2β in the control of the many cellular processes that are 
governed by this multifunctional kinase. In particular, such inhibitors would provide more rapid 
and reversible tools than siRNA or overexpression methods for correctly identifying relevant CK2β-
dependent substrates. They will also serve as leads for the rational design of function-specific 
chemical drugs that disrupt some actions of CK2, but leave others intact, allowing the 
deregulation of specific intracellular pathways. Furthermore, selective disruption of the CK2α–
CK2β interaction could find important applications to test pharmacologically the importance of 
this interaction in tumor cell growth. 
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3.4 Structure-Based discovery of a small chemical scaffold 
targeting the CK2 Subunits interface 
The small cyclic peptide described in the chapter 3.3 demonstrated the therapeutic 
interest of the CK2/CK2β interaction inhibition. However peptides are more difficult to transform 
into therapeutics than small molecules. Therefore, a virtual ligand screening was considered to 
identify small molecules able to bind in the /β interaction pocket.  
3.4.1 Virtual Screening and hit validation 
A Virtual Ligand Screening directed on fumigated pocket at the interface of CK2/CK2β 
subunit was realized by Irina Kufareva and Ruben Abagyan (Skaggs School of Pharmacy, La 
Jolla, USA). The hundred top scoring compounds were selected and their ability to inhibit the 
phoshorylation of CK2-dependent substrate in vitro was evaluated. After hit validation and 
removal of the promiscuous binders, one compound remained, the hit compound 1 (Figure 1). A 
parent compound (2) was commercially available and thus, was purchased. 
 
Figure 1. Chemical structures of the hit compound (1) from the in silico-screening and the parent 
inactive compound 2. 
Interestingly, compound 1 was able to inhibit the phosphorylation of CK2β-dependent 
peptide substrate whereas compound 2 was not efficient (Figure 2a). CK2β-independent 
peptide substrate phosphorylation was only slightly impacted by 1 and independently of CK2β 
concentration (Figure 2b) whereas the inhibition of the CK2β-dependent peptide substrate 
depends on CK2β. 
 
1 2
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Figure 2. (a) Compound 1 inhibits phosphorylation of a CK2-dependent substrate (eIF2-derived 
peptide) by the CK2 holoenzyme in a dose-dependent manner. Under the same conditions, 
compound 2 has no effect; (b) Compound 1 affects CK2-independent peptide 
phosphorylation to a smaller degree than CK2-dependent peptide phosphorylation. CK2 (40 
nM) was incubated without or with 100 µM compound 1, in the presence of increasing 
concentrations of CK2 and assayed for phosphorylation of CK2-independent and CK2-
dependent peptide substrates (133 and 600 µM, respectively) and 100 M ATP.  
  In addition, inhibition of CK2β-dependent phosphorylation by compound 1 can be 
antagonized by increasing CK2β concentrations (Figure 3a). This result indicates that 1 and CK2β 
are likely to bind to CK2α in a mutually exclusive mode. Steady-state kinetic analysis of 
compound 1 was performed by incubation of CK2α with increasing concentrations of CK2β in 
the presence of different concentrations of the compound (Figure 3b). This experiment suggests 
a mixed competitive inhibition towards CK2β: Ki was estimated to 66 µM. 
 
Figure 3. Inhibition of CK2-dependent phosphorylation by compound 1 is reversed by CK2. (a) 
CK2 (50 nM) was incubated in the presence of 200 M compound 1, saturating concentrations 
compound 1
compound 2
- compound 1
+ compound 1
CK2β-dependent peptide
CK2β-independent peptide
- compound 1
+ compound 1
compound 1 compound 1
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of the CK2β-dependent peptide substrate (600 M) and ATP (100 M), and increasing 
concentrations of CK2; (b) Steady-state kinetic analysis of CK2 complexation showed a Ki of 66 
µM. The data represent the average of three experiments performed in duplicate.  
 
Docking of compound 1 in the β-interaction pocket (Figure 4) is consistent with the 
preliminary results obtained. Moreover, the reason of the inactivity of compound 2 is easy to 
understand as the N-methyl substitution on the indole will prevent the hydrogen bond between 
the amino function and the backbone of Tyr39. Furthermore, we can postulate that the size of 
the methyl prevents the entry of the indole core into the hydrophobic pocket. 
 
Figure 4. Compound binding mode predicted by ICM virtual docking: (a) Overall 
architecture and compound/CK2 binding site; (b) Predicted pose of compound 1.  
 
The two compounds described above exhibited interesting in vitro properties to inhibit the 
CK2/CK2β interaction and they demonstrated the druggability of the CK2/β interaction 
pocket. Therefore, we considered the development of a small library of compound 1 analogs to 
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improve their potency and study the structure-activity relationships. A small selection of 
compounds and their syntheses are presented in the next paragraphs. 
 
3.4.2 Chemical synthesis 
3.4.2.1 Linear synthetic approach for the grafting of the lateral chain 
A linear synthetic approach was first investigated by Dr. Mohamed Ettaoussi (EA 4446 
B2C): three intermediates were required for this strategy. 
First of all, the acid function had to be introduced on the C3 indole position. Several 
methods have been tried and the most effective one had a global yield up to 80 % on 5-nitro-1H-
indole, with an easy work up and no additional purification was needed (Scheme 1).261,262  
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             3a-c 4a-c                    5a-c 
Scheme 1. Acid functionalization in position 3 of the indole. Reagents and conditions: a) TFAA 
(2.25 eq), anhydrous DMF, 0°C to 150°C, 12h; b) NaOH (10 eq), H2O, 100°C, 2 h. 
Compound 8 was also required and was obtained as described in Scheme 2 from the 
commercially available ethyl isonipecotate 6 in two steps. First, the amino function was 
protected with a benzyl group. The ester function was then reduced into an alcohol using lithium 
aluminum hydride to give compound 8 with an excellent yield over the two steps (Scheme 2). 
NH
O
OEt
N
O
OEt
N
OH
a b
 
6 7 8 
Scheme 2. Synthesis of (1-benzyl-piperidin-4-yl)methanol. Reagents and conditions: a) BnCl, 
K2CO3, EtOH, RT, 48h; b) LiAlH4, THF, 0°C then reflux, 3h. 
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Chloro derivatives were used to graft the sulfonamide part of the target molecules. 
Compounds 10 (Scheme 3) were obtained by reaction between chloroethylamine 9 and 
methyl- or phenyl-sulfonylchloride, in the presence of triethylamine.  
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9  10a,b 
Scheme 3. Synthesis of N-(2-Chloroethyl)-methane/phenyl-sulfonylamide derivatives. Reagents 
and conditions: a) NEt3, THF, 5-10°C then RT. 
The linear synthesis consists of 3 steps. From 3-carboxylic-1H-indole acid, an esterification 
reaction was carried out throught acyl chloride intermediate to obtain compound 11 (Scheme 
4). The second step was the deprotection of the amino function: the benzyl group was cleaved 
using a catalytic hydrogenation to give compound 12. The last step was the amino alkylation 
with chloro derivatives 10. The expected compounds were obtained and were isolated among a 
complex mixture of polysubstitued indoles. The purification of this crude mixture was very difficult 
to carry out (Scheme 4). 
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Scheme 4. Synthesis of N-(2-Chloroethyl)-methane/phenyl-sulfonylamide derivatives. Reagents 
and conditions: a) (COCl)2, THF, RT, 24h; b) (1-Benzyl-piperidin-4-yl)methanol (8), CHCl3, 0°C then 
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reflux for 24 h; c) H2, Pd/C, MeOH, RT; d) N-(2-Chloroethyl)-methane or phenyl-sulfonylamide (10) 
K2CO3, acetone, reflux for 24 h. 
Two main solutions were considered to circumvent this problem: 
- The N1 indole protection with a benzenesulfonyl group, for example. 
- A new and more convergent synthesis pathway, with the esterification at last step. 
The second solution seemed to be the most reliable one because it was well described on similar 
structures.263 
 
3.4.2.2 Convergent synthetic approach 
 To circumvent the poly alkylation problem at the last step, a new synthetic pathway was 
applied. The key step was the esterification between an indole 3-carboxylic acid and a 
functionalized piperidinyl (Scheme 5). Furthermore, these two acid and alcohol precursors were 
easily obtained in large amounts. 
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Scheme 5. Retrosynthetic convergent synthetic pathway. 
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a) Acid intermediates 
Acid building blocks 5b-c were obtained by the TFAA method (Scheme 1) or, in the case 
of 3-carboxylic-1H-indole acid 5a, from the 1H-indole-3-carbonitrile intermediate. With these two 
methods, six compounds were obtained in good yields (Table 1). 
Table 1: Acid derivatives. 
Structure/Name Yield 
N
H
OH
O
 
69 % 
From 1H-indole-3-carbonitrile 
 
3-carboxylic-1H-indole acid - 5a  
N
H
OH
O
O
2
N
 
91 % 
5-nitro-1H-indole-3-carboxylic acid – 5b  
N
H
OH
O
F
 
90 % 
5-fluoro-1H-indole-3-carboxylic acid – 5c  
 
b) Alcohol intermediates 
Alcohol derivatives were obtained in two steps by a different method than in the linear 
pathway (Scheme 6).263–265 The difference in yields between the two analogues 14a and 14b 
(Table 2) could be explained by the products’ solubility: precipitation in the last step of the 
sulfonamide with a phenyl group occurred, whereas it was not observed with the methyl 
sulfonamide. This precipitation facilitates the isolation of intermediate 14b. The extraction of the 
methyl derivative (R8 = Me) was more difficult leading to a lower yield (30%).  
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6 13 14a,b  
Scheme 6. Synthesis of alcohol intermediates. Reagents and conditions: a) LiAlH4, anhydrous THF, 
0°C to RT, 20h; b) N-(2-Chloroethyl)phenylsulfonylamide, DIPEA, MeCN, reflux, 2h; or N-(2-
Chloroethyl)methylsulfonylamide, MeCN, RT, 12h. 
Table 2: Alcohol intermediates. 
 
  
Structure/Name Yield 
N
OH
NHSO
2
CH
3
 
30 % 
N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]methanesulphonamide - 14a 
N
OH
NHSO
2
Ph
 
82 % 
N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]phenylsulphonamide - 14b 
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c) Coupling step 
The esterification step described in Scheme 7 is exactly the same for all derivatives, which 
allowed the use of a Radleys© parallel reaction device.  
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  15a-e  
Scheme 7. Coupling step through an esterification reaction. Reagents and conditions: a) SOCl2, 
CH2Cl2, reflux, 24h; b) CH2Cl2, reflux, 24h. 
With this method, the small library of compounds 15a-e was synthesized within few steps 
and with easily accessible building blocks. 
 
d) Substitution in position 2 of the indole 
The insertion of the methoxy in position 2 was also a key reaction because it allowed an 
additional functionalization on the indole core at the last step. 
The method described in Scheme 8 consists of a two-step reaction: first a chlorination with 
N-chlorosuccinimide in dichloromethane followed by addition of the reaction mixture over an 
acidic methanol solution. This protocol was successfully adapted from litterature263,266 for the 
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preparation of all ester derivatives, except with the 5-nitroindole core as LC/MS analyses showed 
that the reaction did not occur at all. 
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Scheme 8. Methoxy substitution at position 2 of the indole ring. Reagents and conditions: a) NBS, 
CH2Cl2, 0°C, 10 min and then MeSO3H, MeOH, 0°C to RT, 2h. 
  
3.4.3 Cell-free biological evaluation 
Compounds were evaluated in kinase activity assays and in SPR dose-response 
experiments to measure the affinity for CK2α.  
Two different peptide substrates were used in these assays: 
 peptide 29, phosphorylated either by CK2α or by the holoenzyme (β-independent), 
 peptide M, only phosphorylated by the holoenzyme (β-dependent). 
This assay was reliable and reproducible but it measured the kinase activity and not only 
the direct impact on the α/β interaction. It was performed in three different experimental 
conditions to evaluate the effect on the α/β interaction as well as the effects on α inhibition 
(Table 3): 
 (a) with peptide 29 (β independent) and a 10 µM ATP concentration, 
 (b) with peptide M (β dependent) and a 10 µM ATP concentration, 
 (c) with peptide M and 100 µM ATP concentration. 
 
Results obtained from Surface Plasmon Resonance (SPR) and enzymatic experiments 
were consistent, though the CK2 inhibition was observed in every conditions (a, b and c) of the 
enzymatic assays. The latter was in opposite of our expectations for a strong inhibition, only in the 
presence of the β-dependent peptide substrate and independently of the ATP concentration. 
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A possible explanation relies on the close proximity of the CK2/CK2β interaction with the 
ATP pocket. Indeed, the Tyr39 residue separates the ATP pocket to the bottom of the 
hydrophobic pocket, in which the indole core is binding. Therefore, binding of other compounds 
could partially impair the ATP binding according to an allosteric model. This hypothesis was 
supported by the mixed-type of inhibition observed toward ATP with compound 1. 
Table 3: Evaluation of CK2 affinity and of CK2 inhibition in presence of 50 µM of the 
corresponding inhibitor.  
 
The percentage inhibition is the average of duplicate experiments, performed in the 
presence of the respective inhibitor at 50 µM and (a) peptide 29 (β-independent) (100 
Compound Structures
CK2 inhibition 
(%) in condition 
SPR
(a) (b) (c) Kd (µM)
1 37 55 29 100 (20)
2 nd nd 15 nd
15a 29 49 13 87 (8)
15b 9 29 25 100 (20)
15c 53 67 44 61 (2)
16 68 80 52 37 (1)
15d 72 79 41 14 (1)
15e 45 49 57 33 (5)
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µM), ATP (10 µM); or (b) peptide M (β-dependent) (100 µM), ATP (10 µM); or (c) peptide M 
(100 µM), ATP (100 µM). Kd values represent the affinity for CK2 and were determined 
from dose-response curve from SPR experiments. The error in affinity determination is 
represented between brackets. nd: not determined. 
 
3.4.4 Structure-Activity Relationship Studies 
The preliminary SAR study with compound 1 and 2 revealed the importance of the free 
nitrogen atom on the indole core: this structural motif was thus conserved in all the compounds. 
The suppression of the methoxy group at position 2 of the indole (compound 15a) did not impact 
the affinity for CK2α, the latter is consistent with the docking of compound 1, in which the 
methoxy group was exposed to the solvent (Fig 4, b) and did not exhibit specific interaction with 
CK2α. Next, we studied the influence of the fluoro substitution at position 5 of the indole: our 
attempt to remove it (15b) demonstrated significant effect of this substituent. 
At this point, all the compounds (1, 15a,b) exhibited more or less the same affinity for 
CK2α. Consequently, we hypothesized that this absence of significant effects could be due to 
the too weak affinities of our compounds for CK2α, which could prevent a good ranking among 
them. Looking for substantial modifications that could improve the activity of our compound, we 
envisaged the addition of a phenyl group on the sulfonamide part. Indeed, preliminary docking 
studies suggested that the phenyl could make a π-cation interaction with the Lys71 and 
therefore be an asset for CK2α affinity. Indeed, compound 15c exhibited a better inhibition of 
CK2 than the parent compound 15a. Consequently, we studied further the effect of the methoxy 
group at position 2 of the indole as well as the substitution at position 5, while maintaining the 
phenylsulfonamide moiety. Interestingly, in this case, the methoxy group at position 2 (16) 
increased CK2α affinity as well as the substitution of the indole in position 5 with a nitro function 
(15d). The fluoro substitution at position 5 (15c) was, of note, negative for the activity in 
comparison with an unsubstituted compound (15e). 
 
3.4.5 Biological evaluation in living cells 
In the chapter 3.3, CK2α/CK2β interaction inhibition by TAT-Pc led to a decrease in cell 
viability. Consequently, we considered to begin our evaluation by a cell viability screening of our 
small set of compounds in MCF10A cells (Figure 5). In accordance with the in vitro evaluation, 
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compound 1, 15a,b did not exhibited a good efficiency. However, almost all the cells were dead 
after a 48h treatment with compounds 15c,d and 16. As a remark, precipitation occurred with 
compound 15d at a concentration inferior to its cell efficiency concentration, thus preventing 
further evaluation of this derivative. 
 
Figure 5. MC10A cell viability after 48h treatment with compounds 1, 15a-e and 16. 
In the chapter 3.3, p21 phosphorylation was proved to be a cellular marker of CK2/CKβ 
interaction inhibition. Indeed, p21 phosphorylation was increased in a dose-dependent manner 
and correlated with the cell free potency of various TAT-Pc constructs. Therefore, after 48h cell 
treatment with compound 15b,e and 16, cell extracts were analyzed by western blot to evaluate 
the phosphorylation of p21 (Figure 6). The less potent compound 15b exhibited a weak impact 
on p21 phosphorylation. Indeed, a concentration of 100 µM was necessary to increase p21 
phosphorylation. No effect was observed in the presence of 50 µM of compound 15b, the latter 
is consistent with the 80 % of living cell observed in the cell viability experiment at 50 µM (Figure 5) 
and the 25 % of CK2 inhibition at 50 µM measured in the enzymatic assay (Tab 3).  
Whereas compound 15e increased in a dose-dependent manner p21 phosphorylation in 
the same range than TAT-Pc, compound 16 exhibited a striking better efficiency than TAT-Pc to 
increase p21 phosphorylation. Indeed, a 20 µM concentration of 16 is enough to reach the 
maximum level of p21 phosphorylation. 
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Figure 6. Phosphorylation status of p21 in MC10A after 48h treatment with compounds 15b, 15e 
and 16. 
 
3.4.6 Conclusion 
In this chapter, we identified a small chemical scaffold which targets the CK2/CK2β 
interaction after a virtual ligand screening. The effect of the hit compound 1 was in vitro 
characterized in several biochemical assays and demonstrated its ability to inhibit CK2β-
dependent substrate phosphorylation and to bind to CK2 in a mutual exclusive mode with 
CK2β. Then, a small set of compounds was synthesized using a convergent synthesis pathway 
and led to a first SAR study. Consequently, three compounds were evaluated in a cell-based 
assay and their ability to inhibit the CK2α/CKβ interaction was assessed through the western blot 
analysis of a marker of this inhibition. The best compound 16 exhibited a better efficiency than 
the reference TAT-Pc and could therefore be used as a relevant starting point for the 
development of new structures aiming to disturb the CK2α/CK2β interaction. 
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4. Final discussion 
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Identifying new mechanisms of protein regulation is of great interest as it opens the door 
to innovative strategies and new targets in therapeutic area. Two hit compounds with atypical 
mechanisms of action on protein kinase CK2 were identified during in silico screening 
campaigns. Thus, the aim of the present study was to develop these two classes of compounds 
and to characterize their effects in biochemical as well as in cellular-based assay. Therefore, their 
novel mechanism of CK2 regulation could be described accurately and the relevance of such 
approaches to target CK2 could be evaluated. The two classes of compounds could be defined 
as: 
(i) allosteric modulators of CK2 (4.1) 
(ii) CK2/CK2β interaction inhibitors (4.2) 
 
4.1 Allosteric modulator of CK2 
A weak hit was identified in a screening process for CK2 inhibitors and further 
characterization revealed its non-ATP competitive mechanism of action. Therefore, we 
developed a library of small molecules and obtained several compounds with good overall 
properties, as described in chapters 3.1 and 3.2. 
4.1.1 CK2 specificities and allosteric inhibitors 
The discovery of allosteric modulator of CK2 is challenging as CK2 was always observed in 
an active state.30 Indeed, in previous studies, only few small molecules were proposed to inhibit 
CK2 with a non-ATP competitive and non-β competitive mechanism (see Introduction of 
chapter 1.4.4).230 Derivatives of the azonaphthalen class of dyes were described to modulate the 
CK2 activity in a non-ATP competitive manner. However, the precise binding site of these 
compounds was not characterized. Nevertheless, the use of CK2 mutants and SAXS 
experiments allowed to approximately localize the binding site near the αC-helix and the 
activation segment.150 Unfortunately, these molecules could not be considered as drug-like and 
their development had to be stopped. 
Besides small organic molecules, inorganic PolyOxoMetalates (POMs) have been 
described as potent allosteric inhibitors of CK2 and one of them, [P2Mo18O62]6-, exhibited a 
nanomolar IC50 and a great selectivity in a panel of 29 kinases.151 POMs are anionic complexes of 
early-transition metal ions and oxo ligands that lack cellular activity. Thus, there is few 
perspectives to develop them further into in vivo active agents. Biochemical analyses revealed 
that the mode of inhibition was mixed-type with respect to ATP and non-competitive toward the 
For the sake of clarity, all compounds that are referred to in chapter 4 are characterized by a numeral to identify 
the chapter in which they are described followed by a second numeral that is identical with the corresponding 
compound number of the particular chapter (e.g., 3.1-1 is compound 1 from chapter 3.1) 
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peptide substrate. Partial proteolysis by trypsin followed by amino acid sequencing showed that 
two distinct fragments were protected from degradation by POM binding. One comprised of the 
N-terminal domain and three β strands (β1, β2 and β3) encompassing the glycine-rich loop, 
whereas the other one consisted of the activation segment and the αF and αG-helices.151 
Hence, the putative binding sites of the negatively charged azonaphthalenes and POMs 
molecules show an overlap in the region encompassed by C-helix, glycine-rich loop and 
activation segment. This region plays a crucial role in kinase regulation, and several allosteric 
kinase inhibitors were demonstrated to act through C-helix displacement.129 The constitutive 
activity of Protein kinase CK2 is mainly due to the unique interaction between the N-terminal 
segment and the activation loop abolishing the necessity of any activating phosphorylation. In 
consequence, the activation loop is locked in the open-active conformation, and this region is 
one of the less flexible in CK2 crystal structures, suggesting that any displacement by small 
molecules might be a tricky challenge.30 On the other hand, the glycine-rich loop is one of the 
most flexible regions of CK2, which might facilitate a potential induced movement of this loop 
by small molecules.31 In most of the CK2α crystal structures, the conformation of the glycine-rich 
loop is maintained by two hydrogen bonds linking the Tyr50 of the glycine-rich loop and two 
lysine residues (Lys74, Lys77) of the basic cluster. However, two crystal structures (PDB ID: 3FWQ149, 
4UB7218) make exception by the lack of these key hydrogen-bonds and the collapse of Tyr50 in 
the ATP binding site. No explanations such as small molecule presence or crystallographic 
conditions were proposed as probable reason of the inactive conformation observed in 3FWQ.149 
However, in the case of 4UB7, they proposed that a specific halogen bond between an ATP-
competitive inhibitor and the Tyr50 in presence of high salt concentration could be responsible of 
the glycine-rich loop displacement.218 All the hints from the literature described above let us 
believe that CK2 could harbor an allosteric pocket in the region encompassing the activation 
segment, the glycine-rich loop (P-loop) and the C-helix (Fig 42a). Therefore, preliminary docking 
experiments as well as single-alanine mutagenesis experiments were focused on this area and 
led to the determination of the precise interactions between our compounds and CK2 (Fig 42b). 
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4.1.2 X-ray structures 
Co-crystallization experiments in collaboration with Jean-Baptiste Reiser (Institut de 
Biologie Structurale, Grenoble) were envisaged to identify the binding site of our compounds. 
After several campaigns, suitable co-crystallization conditions were identified (based on 
PEG3350, pH 5.5, ammonium sulfate), and after a scale-up, diffracting crystals of CK2 in the 
presence of several 2-aminothiazole derivatives were obtained (Table 4). Of note, the resolution 
obtained with the compound 3.1-3 was too low (superior to 3 Å) to lead to precise structure: its 
refinement was therefore not pursued. In addition, crystals obtained in the presence of 
compound D3,35 (Table 4) were found without any ligand. However, electron density 
modification, representing compounds 3.2-7j, 3.2-7e and 3.2-8e were identified: those 
compounds were located into the ATP pocket. The main interaction of our compounds with CK2 
was between the carboxylic acid and the K68/D81 residues, with the cooperation of a water 
molecule (Fig 43). Of note, the same type of interaction is visible in CX-4945/CK2 co-crystal 
structures (PDB ID: 3NGA and 3PE1).97,214 Moreover, the overall structure of CK2 in the presence 
of our inhibitors is similar to those obtained in the presence of ATP-competitive inhibitors or 
a
b
αC-helix
P-loop
Activation segment
Fig 42: Key features of the structure of CK2 and of its allosteric pocket. (a) Key features of the 
structure of CK2 (based on 2PVR110). (b) Allosteric pocket of CK2 with 3.2-8e docked inside 
(based on PDB ID: 3JUH33).   
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AMPPNP (PDB ID: 2PVR, 3MB6, 3MB7, 3NSZ).110,267 Therefore, based only on X-ray results, our class 
of compounds should exibit an ATP-competitive mechanism of action. Consequently, we tried to 
answer to the key question: “How can we link the X-ray diffraction results with the whole set of 
our data?” 
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Table 4: Main parameters of the CK2 X-ray structures obtained in the presence of various 
compounds. 
Compound Structure Resolution 
Electron density of 
the inhibitor 
3.1-3 
 
> 3 Å - 
3.2-7j 
 
2.65 Å Yes 
D3,35 
 
2.85 Å No 
3.2-7e 
 
2.85 Å Yes (partial) 
3.2-8c 
 
2.40 Å partial 
3.2-8e 
 
2.20 Å Yes 
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3.2-7j 3.2-7e 
  
3.2-8c 3.2-8e 
Fig 43: Representation of the ATP-binding pocket with several of our inhibitors, obtained from the 
X-ray structures. 
The incompatibility of the results obtained from X-ray structures and the ones obtained 
from enzymatic kinetics, TdCD, STD-NMR and mutagenesis experiments (chapter 3.1) needed to 
be explained. Indeed, no information in the X-ray structures is in accordance with the mixed-type 
of inhibition, neither the lower thermal stability, nor the effects of V73A and K77A mutants. In 
addition, STD-NMR experiments clearly showed that 2-aminothiazole derivatives and CX-4945 
could simultaneously bind to CK2. The latter is obviously impossible if 2-aminothiazole derivatives 
would bind into the same pocket than CX-4945, ie the ATP-site. 
Crystal packing or crystallization conditions could be the source of the obtained 
incoherent structures. Indeed, co-crystals were obtained under special salt and pH conditions 
(pH = 5.5) in which CK2 does not show any catalytic activity. In addition, X-ray structures are by 
definition obtained from a solid state which could block a specific conformation of the protein.  
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Due to their chemical structures, our compounds could certainly bind to the ATP-pocket, 
as seen in the X-ray structures. However, based on strong evidences, we have demonstrated 
that they could also bind to an allosteric pocket. Furthermore, the high cellular efficiency 
exhibited by compound 3.2-8e, in comparison with ATP-competitive inhibitors, suggested that 
the cellular effects of our compounds relied on the allosteric mechanism of action. 
Therefore, further co-crystallization campaigns are required to find the proper conditions 
to obtain new X-Ray structures consistent with the rest of our data. Additional attempts of co-
crystallization, in presence of both CX-4945 and one of our inhibitor, will be considered. 
4.1.3 Similarities and differences with others allosteric inhibitors 
C-helix displacement is a common method for allosteric inhibition of protein kinases129 
and several small molecules were described to bind near the αC-helix.128,140,148,268 Interestingly, as 
in the case of our allosteric inhibitors of CK2, the allosteric inhibitor of MEK1, PD318088,143 and the 
allosteric inhibitor of ERK2, SCH772984148 (Fig 44), bind at the interface of the αC-helix and of the 
glycine-rich loop, also called P-loop (Fig 45a).  
 
Fig 44: Chemical structures of PD318088 and SCH772984 
 
The inactivation of MEK1 occurs through a small displacement (0.9 Å) of the C-helix as 
well as a larger movement (2 Å) of the short helix present in the activation segment.269 The 
allosteric inhibitors of MEK1 (eg PD318088) stabilize this inactive conformation143 and, interestingly, 
they bind to the protein in the presence of an ATP molecule or an ATP analog, with a synergistic 
effect.144 Structure superimposition showed that the binding site of the allosteric MEK1 inhibitors 
(PD318088) and the allosteric CK2 inhibitor 3.2-8e are in close proximity and share some 
similarities (Fig 45a,b). Nevertheless, the presence of the small helix in the activation segment of 
MEK1, and its flexibility combined with the one of the C-helix, enable a deeper binding of the 
PD318088 (MEK1/2 inhibitor) SCH772984 (ERK1/2 inhibitor)
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allosteric MEK1 inhibitors in comparison with CK2 inhibitor 3.2-8e. Moreover, the basic cluster of 
residues located in the αC-helix and in the activation segment of CK2, and necessary for 3.2-8e 
binding, is absent in MEK1. Additionally, allosteric CK2 inhibitors and the ATP-competitive inhibitor, 
CX-4945, could bind together to CK2 (see chapter 3.1) but they could not bind in the presence 
of ATP or ATP analogs whereas MEK1 inhibitor can. Therefore, despite some similarities in their 
binding site, allosteric CK2 inhibitors and allosteric MEK1 inhibitors are very different and 3.1-7 and 
3.2-8e did not inhibit MEK1 (see the kinase panel, chapter 3.1 and 3.2). 
SCH772984 is a potent and selective ERK inhibitor,147 which acts through a simultaneous 
binding in the ATP-site and in the P-loop pocket.148 The piperazine-phenyl-pyrimidine moiety of 
SCH772984 binds into the P-loop pocket near the C-helix, with the P-loop Tyr36 shifted to the “in” 
position (Fig 45). The latter is similar to the binding of the naphthyl moiety of 3.2-8e which also 
requires the switch to the “equivalent of Tyr36” in the CK2 structure, ie Tyr50. Interestingly, CK2 
and CK2’ are strongly inhibited by SCH772984 but their mechanism of inhibition is not 
described.148 However, SCH772984 also inhibits the kinase Haspin but in an ATP-competitive 
manner and the same mechanism could be suspected for CK2 as the residue Tyr64 of ERK1 
necessary for SCH772984 binding is replaced by a lysine in the case of CK2. 
Despite strong differences which enable to design highly selective inhibitors, the 
similarities in the binding pocket of these three compounds open the possibility to have similar 
pockets in other related kinases. 
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Fig 45: Allosteric binding site in CK2, MEK1 and ERK2. Structure from molecular modeling of CK2 
(blue, based on PDB ID: 3JUH33) and X-ray structures of MEK1 (magenta, PDB ID: 1S9J143) and ERK2 
(green, PDB ID: 4QTA148) were superimposed. Respective allosteric inhibitors for each kinase, 3.2-
8e for CK2, PD318088 for MEK1 and SCH772984 for ERK2 were depicted in dark blue, pink and 
bright green. (a) Overview of the kinase structures. (b) Overview of the allosteric pocket located 
between the αC-helix and the glycine-rich loop. (c) For clarity, only CK2/3.2-8e and 
ERK2/SCH772984 were conserved. The ATP-competitive inhibitor of CK2, CX-4945 (black), was 
docked in the ATP-pocket. 
 
4.1.4 Indirect effect in the single-alanine mutagenesis experiments 
In the single-alanine mutagenesis described in the chapter 3.1 and 3.2, we noticed an 
impact of the His160Ala mutation: a 2.2-fold increase of the IC50 was observed with 3.1-7, and 
1.7-fold for 3.2-8e. Nonetheless, the His160 was not in direct interaction with our compounds in 
Glycine-rich loop
(P-Loop)
αC-helix
ATP-site
Allosteric site
a
b
c
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the 3D structure models. Interestingly, an hydrogen bonding between Tyr50 and His160 was 
observed in the inactive structure (4UB7) described by Guerra, B. et al. (Fig 46)218 Thus, we could 
hypothesize that the His160 residue is necessary to stabilize Tyr50 in the inactive conformation, 
and so for the efficient binding of our compounds. 
 
Fig 46: Glycine-rich loop displacement (from Guerra, B. et al.218). 
 
4.2 CK2α/CK2β interaction inhibitors 
Different effects than with “classical” CK2 inhibitors were expected, as the regulatory 
subunit modulates the selectivity of CK2 toward a subset of substrate proteins.77  
Previously, a cyclic peptide (Pc) was identified as a potent in vitro modulator of CK2 but 
it was ineffective in cellular based assay.50 Therefore, this peptide was conjugated to a viral TAT 
sequence and the resulting compound TAT-Pc was used in cellular-based assay. At the same 
time, a Virtual Ligand Screening (VLS) campaign was performed and several small molecules 
inhibitors of the /β interaction were identified. After hit validation, one molecule  3.4-1 was 
selected as a true α/β interaction inhibitor. A small library of analogs was synthesized and then 
evaluated in biochemical assays and in cellular assays. 
4.2.1 Structurale similarities with other related compound 
Previously, 5,6-Dichlorobenzimidazole-1-β-D-ribofuranoside (DRB) was suggested to bind 
to two different sites: the ATP pocket and the “remote cavity” in the /β interaction, although 
only CK2 inhibition through the interaction with the ATP pocket was proven.207 However, 
171 
 
interestingly structural similarities could be observed between DRB and our class of compounds 
3.4-1 (Fig 47). Indeed, both compounds share hydrophobic moiety (benzimidazole or indole) 
which could deeply bind into the hydrophobic pocket, occupied by the Phe190 of CK2β. In 
addition, the more polar moiety (ribofuranoside or ester/methoxy functions) are more exposed 
on the surface of CK2. Of note, active compounds from our library have an additional side 
chain composed of a piperidine linked to a methyl- or phenyl-sulfonamide. The latter function is 
responsible of the strict binding into the /β interaction pocket, thus leading to a better observed 
affinity for CK2. 
 
Fig 47: Schematic representation of the DRB (based on PDB ID: 3H30207) and compound 4.2-1 
(based on docking experiments) in the /β interaction pocket (blue line).  
 
4.2.2 Effects in cell signaling 
Both small molecules and the TAT-Pc construction induced different cellular effects than 
the ATP-competitive inhibitors or the allosteric inhibitors described in chapters 3.1 and 3.2. As 
described in Fig 48, CK2/CK2β inhibitors led to degradation of EGFR which could block the 
MAPK, Akt and JNK pathways, therefore leading to a decrease of cell proliferation.270 An 
increase of p21 phosphorylation correlated with its translocation to the nucleus was also 
observed, the latter is likely to induce cell cycle arrest.260,271 In consequence, CK2/CK2β 
interaction inhibitors seem to have a great potential in cancer therapy. 
DRB 3.4-1
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Fig 48: Schematic representation of the cellular consequences of the CK2α/CK2β interaction 
inhibition. “Normal” state represents the cell in absence of α/β interaction inhibitor and the dash 
line is the separation with the cell in presence of α/β interaction inhibitors. 
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4.3 Perspectives of further drug development 
The two classes of compound described herein are of potential therapeutic interest. 
Therefore, the question of their further development into in vivo candidates emerged. 
Compound 3.2-8e for the allosteric inhibitor and compound 3.4-16 for the protein-protein 
interaction inhibitor are the respective lead compound of each class (Fig 49).  
 
Fig 49: Overview of the lead compounds of each class. 
 
4.3.1 Allosteric modulator of CK2α 
Compound 3.2-8e demonstrated acceptable cell efficiency despite a strong binding to 
bovine serum albumin. Indeed, decrease of the serum concentration in the cell culture medium 
led to significant improvement of its cellular efficiency. This feature is in accordance with the 
chemical structure of 3.2-8e whose acid function attached to a strong hydrophobic naphthyl 
part  is the good pharmacophore for albumin binding.272 The structural optimization of this 
compound in order to decrease the albumin binding is tempting, especially to modify the 
naphthyl ring, which is not really drug-like. And this appear to be feasible, thanks to the low 
molecular weight (362.4 g.mol-1) of compound 3.2-8e. However, literature reviewing 
demonstrated that 24% of the recently approved drugs have a plasma protein binging higher 
than 99% and that the low intrinsic clearance is the most important parameter to reach an 
acceptable in vivo unbound level of drug.273 Therefore, 3.2-8e does not have to be optimized 
before further in vivo development in reason of its binding to albumin. Nevertheless, the sharp 
3.4-163.2-8e
Allosteric modulator of CK2α
Protein-protein interaction inhibitor (PP2I) 
targeting the CK2α/CK2β interaction
362.4 g.mol-1 489.6 g.mol-1 (free base)
EC50: 3-6 µM (CK2 activity inhibition) EC50~ 15 µM (p21 phosphorylation) 
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SAR and the recent identification of the binding site could enable a quick optimization of 
compound 3.2-8e in regard to potency and drug-like properties. 
 
4.3.2 CK2/CK2β interaction inhibitors 
On the other hand, the optimized compound, 3.4-16, belonging to the CK2/CK2β 
interaction inhibitors is still in the preliminary development. Indeed, the SAR sample size appears 
to be relatively limited and further studies could lead to significant improvement of it affinity. 
Compound 3.4-16 demonstrated the feasibility of the CK2/CK2β interaction inhibition and its 
therapeutic interest. Thus, the novelty of this class of compounds is remarkable. However, protein-
protein interaction inhibition is highly challenging and requirement large and long studies.178,187,188 
Consequently, further STD-NMR, X-ray crystallography, SAR studies and cellular evaluations are 
necessary prior to consider in vivo development of this class of compounds. 
 
4.4 Outlook 
In conclusion, the present study aimed to describe two novel approaches to target CK2 (Fig 50): 
 CK2 modulators which are able to block CK2α into an inactive state, through a 
binding in an allosteric pocket located at the interface of the C-helix and the P-
loop. 
 CK2/CK2β interaction inhibitors which are able to counteract the formation of the 
holoenzyme through binding in the β interaction pocket in the N-terminal lob of CK2. 
We believe that the two new strategies described herein are of main interest because 
they could lead to more selective inhibitors with better in vivo efficiency. Moreover, a fine 
substrate-dependent modulation of CK2 activity instead of a complete inhibition could be 
achieve through both strategy, thus they could decrease the side effect inherent to cancer 
treatment. A precise mapping of the in vivo consequences of CK2 modulation with the inhibitors 
described herein will be required to understand completely their implications in cell signaling 
modulation. 
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Fig 50: Schematic representation of the two novel strategies targeting CK2 presented in this work. 
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5. Experimental section 
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6.1 Chemistry 
 
6.1.1  Synthesis of compounds of chapter 3.1 
 
4-((4-(3-Nitrophenyl)thiazol-2-yl)amino)benzoic acid (1) was purchased from Sigma-Aldrich. All 
commercially available chemicals (phenylthiourea, 2-bromo-3’-nitro-acetophenone, 1,2-
dichloro-1-ethoxyethane, 2-bromoacetophenone, 2-bromo-4’-methoxyacetophenone, 2-bromo-
1-(3-bromophenyl)ethanone) and solvents were purchased from Sigma-Aldrich, Acros Organics, 
Fischer scientific or Alfa Aesar and were used without further purification. Reactions were 
monitored by Thin Layer Chromatography (TLC Silica gel 60 F254) purchased from Merck and 
observed under UV light (254 nM). Purification by semi-preparative HPLC was carried out on an 
Agilent 1200 series HPLC system (Agilent Technologies) using an Agilent C18 column (30 x 100 
mm/10 µm) as stationary phase and a gradient of water and acetonitrile as eluent. 1H and 13C 
NMR spectra were obtained in dimethylsulphoxide-d6 on a Bruker DRX-500 instrument, operating 
at 500 MHz for the 1H and at 125 MHz for the 13C at 300 K, using residual signal of deuterated NMR 
solvent as internal reference 274. Chemical shifts are reported in parts per million (ppm), 
multiplicity of the signals are indicated by lower-case letters (singlet s, doublet d, triplet t, 
quadruplet q, multiplet m, broad singlet br s, or combination of letters). DEPT 135 was used to 
determine carbon valence. Analytical HPLC was performed using a SpectraSYSTEMTM 
(ThermoFisher) with a Macherey-Nagel C18 column (3 x 125 mm/5 µm). HPLC purities were 
determined by UV absorption at 254 nm. ElectroSpray Ionisation (ESI) mass spectra were 
measured on a Finnigan Surveyor MSQ Plus mass spectrometer (ThermoFisher). Melting points 
(mp) of the solids were determined by SMP3 Melting Point Apparatus from Bibby Sterling.  
4-Thioureidobenzoic acid (i). 4-Thioureidobenzoic acid was prepared according to the 
procedure already described 239. Carbon disulfide (22 mmol, 1.32 mL) was slowly added to a 
mixture of 4-aminobenzoic acid (7.3 mmol, 1 g), THF (5 mL), H2O (5 mL) and Et3N (18 mmol, 1.82 
mL). The resulting mixture was stirred at RT for 24 h. Then iodine (7.7 mmol, 1.94 g) in THF (5 mL) 
was added dropwise at 0 °C and mixture was stirred for 3h. A 1 M HCl aqueous solution (7.5 mL) 
and Na2SO3 (1.46 mmol, 184 mg) were added and stirring was pursued for 15 min. The aqueous 
layer was extracted with EtOAc (3 x 50 mL). Combined organic layers were washed twice with 
brine, dried on Na2SO4, filtered and concentrated to give the isothiocyanate intermediate as a 
slightly yellow solid, which was converted to the thiourea derivatives by stirring it at RT in NH4OH 
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(30 %) for 6 h. After removal of the insolubles by filtration on a sintered-glass funnel, filtrate was 
concentrated to afford the title product as an off-white solid (7.3 mmol, 1.43 g). Yield = 
quantitative. LC-UV purity = 80 %. The compound was not ionized by ESI. 1H-NMR (500 MHz, 
DMSO-d6): δ (ppm) 7.56 – 7.58 (m, 2H), 7.80 – 7.82 (m, 2H). 13C-NMR (125.7 MHz, DMSO-d6): δ 
(ppm) 116.9, 120.9, 129.3, 130.6, 169.2, 181.0. mp = 189-191 °C (in accordance with literature: 194 
°C) 275.  
Methyl 4-((4-(3-nitrophenyl)thiazol-2-yl)amino)benzoate (2). Three drops of 95 % H2SO4 were 
added to a mixture of 4-((4-(3-nitrophenyl)thiazol-2-yl)amino)benzoic acid (0.14 mmol, 46 mg) in 
MeOH (5 mL) and the mixture was then heated at reflux for 2 h. Na2CO3 1 M was added until pH 
= 10-11 and MeOH was removed under vacuo. The obtained solid was filtrated and washed with 
water (2 x 5 mL) to afford the title product as a yellow solid (0.14 mmol, 49 mg). Yield = 
quantitative. LC-UV purity = 97 %. LCMS (ESI+) m/z = 356.01 for [M+H]+. 1H-NMR (500 MHz, DMSO-
d6): δ (ppm) 3.82 (s, 3H), 7.79 (m, 4H), 7.96 (s, 2H), 8.17 (s, 1H), 8.40 (s, 1H), 8.71 (s, 1H), 10.84 (s, 1H). 
13C-NMR (125.7 MHz, DMSO-d6): δ (ppm) 51.7 (CH3), 107.0 (CH), 116.1 (2 x CH), 119.9 (CH), 121.8 
(C), 122.1 (CH), 130.3 (CH), 130.6 (2 x CH), 131.9 (CH), 135.7 (C), 144.9 (C), 147.8 (C), 148.3 (C), 
162.6 (C), 165.8 (C). mp = 242-244 °C. 
General procedure for the preparation of 2-aminothiazole analogs. An ethanolic solution of 2’-
bromo-acetophenone derivative and aryl thiourea derivative at equimolar ratio adjusted with 
respect to LC-UV purity was heated at 80 °C for 3-12 h (reaction monitoring by TLC). The mixture 
was then cooled down to RT and water (twice more than EtOH v/v) was added. Mixture was 
stirred for 30 min and then filtrated. The obtained solid was washed twice with water to afford the 
product as a solid. When necessary, purification was performed (i) by recrystallization or washing 
with boiling MeCN (ii) by recrystallization or washing in H2O/MeOH (iii) by HPLC preparative to 
obtain the product with LC-UV purity higher than 95 %. 
4-(3-Nitrophenyl)-N-phenylthiazol-2-amine (3). The reaction was carried out according to the 
general procedure. Scale: 2-bromo-3’-nitro-acetophenone (0.66 mmol, 161 mg), phenylthiourea 
(0.66 mmol, 100 mg), absolute EtOH (5 mL). After removal of the solvents, water (10 mL) and 
MeOH (2 mL) were added. The pH of the solution was adjusted to 9 with solid Na2CO3 and then 
stirred for 1 h. After filtration and washing of the residual solid with water (3 x 5 mL), the product 
was obtained as a yellow solid (0.66 mmol, 196 mg). Yield = quantitative. LC-UV purity = 99 %. 
LCMS (ESI+) m/z = 298.06 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 6.99 (t, J = 6.9 Hz, 1H), 
7.36 (t, J = 6.6 Hz, 2H), 7.65 (s, 1H), 7.71 (m, 3H), 8.14 (d, J = 7.3 Hz, 1H), 8.35 (d, J = 6.9 Hz, 1H), 8.69 
(s, 1H), 10.39 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ (ppm) 105.6 (CH), 116.9 (2 x CH), 119.8 
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(CH), 121.4 (CH), 121.9 (CH), 129.0 (2 x CH), 130.1 (CH), 131.7 (CH), 135.9 (C), 140.9 (C), 147.6 (C), 
148.2 (C), 163.5 (C). mp = 136-138 °C. (in accordance with literature: 122-124 °C)276.  
 
4-(Thiazol-2-ylamino)benzoic acid (4). The reaction was carried out according to the general 
procedure. Scale: 1,2-dichloro-1-ethoxyethane (0.41 mmol, 50 µL), 4-thioureidobenzoic acid (0.41 
mmol, 80 mg), absolute EtOH (5 mL). Purification by semi-preparative HPLC (H2O/MeCN/TFA: 
from 79/20/1 to 0/99/1 in 40 min) to afford ethyl 4-(thiazol-2-ylamino)benzoate as a white solid 
(0.09 mmol, 23 mg). Yield = 23 %. LC-UV purity = 96 %. LCMS (ESI+) m/z = 249.01 for [M+H]+. The 
ethyl 4-(thiazol-2-ylamino)benzoate (0.085 mmol, 21 mg) obtained was directly hydrolyzed in a 
mixture of THF (2 mL) and aqueous 0.5 M NaOH (1.15 mmol, 2.3 mL) at reflux for 4 h. Aqueous 1 M 
HCl was added until pH = 1 and then solvents were removed in vacuo. Crude product was 
purified by semi-preparative HPLC (H2O/MeCN + 0.1 % TFA: from 90/10 to 10/90 in 40 min) to 
afford the title product as a white solid (0.07 mmol, 16 mg). Yield = 86 %. LC-UV purity > 99 %. 
LCMS (ESI+) m/z = 220.78 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 7.02 (d, J = 3.8 Hz, 1H), 
7.33 (d, J = 3.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 2H), 7.88 (d, J = 8.8 Hz, 2H), 10.59 (s, 1H). 13C-NMR (127 
MHz, DMSO-d6): δ (ppm) 109.7 (CH), 115.7 (2 x CH), 122.5 (C), 130.7 (2 x CH), 138.8 (CH), 144.9 (C), 
162.9 (C), 166.9 (C). mp = 270-272 °C (commercially available).277  
4-((4-Phenylthiazol-2-yl)amino)benzoic acid (5). The reaction was carried out according to the 
general procedure. Scale: 2-bromo-acetophenone (0.51 mmol, 102 mg), 4-thioureidobenzoic 
acid (0.51 mmol, 100 mg), absolute EtOH (5 mL). Purification was performed by washing with 
boiling MeCN (5 mL) and hot filtration to afford the title product as a grey solid (0.24 mmol, 70 
mg). Yield = 58 %. LC-UV purity = 95 %. The compound was not ionized by ESI. 1H-NMR (500 MHz, 
DMSO-d6): δ (ppm) 7.33 (t, J = 6.9 Hz, 1H), 7.44 (t, J = 6.9 Hz, 3H), 7.84 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 
7.9 Hz, 4H), 10.70 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ (ppm) 104.1 (CH), 115.9 (2 x CH), 
122.8 (C), 125.7 (2 x CH), 127.7 (CH), 128.6 (2 x CH), 130.8 (2 x CH), 134.3 (C), 144.9 (C), 150.2 (C), 
162.2 (C), 167.0 (C). mp = 256-258 °C (in accordance with literature: 252 °C).278   
4-((4-(4-Methoxyphenyl)thiazol-2-yl)amino)benzoic acid (6). The reaction was carried out 
according to the general procedure. Scale: 2-bromo-4’-methoxy-acetophenone (0.71 mmol, 163 
mg), 4-thioureidobenzoic acid (0.51 mmol, 100 mg), absolute EtOH (10 mL). Purification was 
performed by washing with boiling MeCN (5 mL) and hot filtration to afford the title product as a 
grey solid (0.15 mmol, 49 mg). Yield = 29 %. LC-UV purity = 96 %. LCMS (ESI+) m/z = 327.09 for 
[M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ (ppm) 3.80 (s, 3H), 7.00 (d, J = 7.3 Hz, 2H), 7.29 (s, 1H), 7.81 
(d, J = 7.9 Hz, 2H), 7.87 (d, J = 7.9 Hz, 2H), 7.93 (d, J = 7.9 Hz, 2H),10.65 (s, 1H), 12.54 (br s, 1H, O-H). 
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13C-NMR (125.7 MHz, DMSO-d6): δ (ppm) 55.1 (CH3), 101.9 (CH), 114.0 (2 x CH), 115.9 (2 x CH), 
122.7 (C), 127.1 (2 x CH), 127.2 (C), 130.8 (2 x CH), 145.0 (C), 150.1 (C), 158.9 (C), 162.1 (C), 167.0 
(C). mp = 266-268 °C (commercially available). 
4-((4-(3-Bromophenyl)thiazol-2-yl)amino)benzoic acid (7). The reaction was carried out 
according to the general procedure. Scale: 2-bromo-1-(3-bromophenyl)ethanone (0.36 mmol, 
100 mg), 4-thioureidobenzoic acid (0.54 mmol, 106 mg), absolute EtOH (5 mL). Purification was 
performed by recrystallization in MeCN (5 mL) to afford the title product as a yellow solid (0.20 
mmol, 75 mg). Yield = 56 %. LC-UV purity = 95 %. LCMS (ESI+) m/z = 374.62/376.65 for [M+H]+. 1H-
NMR (500 MHz, DMSO-d6): δ (ppm) 7.40 (t, J = 7.9 Hz, 1H), 7.51 (ddd, J = 7.9, 1.9, 0.9 Hz, 1H), 7.59 (s, 
1H), 7.80 (d, J = 8.8 Hz, 2H), 7.94 – 7.97 (m, 3H), 8.11 (t, J = 1.9 Hz, 1H), 10.72 (s, 1H), 12.60 (br s, 1H). 
13C-NMR (125.7 MHz, DMSO-d6): δ (ppm) 105.7 (CH), 115.9 (2 x CH), 122.1 (C), 122.9 (C), 124.7 
(CH), 128.0 (CH), 130.3 (CH), 130.8 (2 x CH), 130.9 (CH), 136.5 (C), 144.7 (C), 148.4 (C), 162.4 (C), 
166.9 (C). mp = 281-283°C. 
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6.1.2 Synthesis of compounds of chapter 3.2 
4-((4-(3-Nitrophenyl)thiazol-2-yl)amino)benzoic acid (1) and 3-((4-(3-nitrophenyl)thiazol-2-
yl)amino)benzoic acid (6b) was purchased from Sigma-Aldrich. All commercially available 
chemicals,2-bromo-1-(3-nitrophenyl)ethanone (4d), 2-bromo-1-phenylethanone (4e), 2-bromo-1-
(3-bromophenyl)ethanone (4f), 2-bromo-1-(2,4-dimethoxyphenyl)ethanone (4g), 2-bromo-1-(2,4-
dihydroxyphenyl)ethanone (4h), 2-bromo-1-(4-bromo-2-hydroxyphenyl)ethanone (4i), 1-bromo-
3,3-dimethylbutan-2-one (4j), 2-bromo-1-(thiophen-3-yl)ethanone (4k), 2-bromo-1-(naphthalen-2-
yl)ethanone (4l), 3-(2-bromoacetyl)-2H-chromen-2-one (4m), 1-(benzofuran-2-yl)-2-
bromoethanone (4n), 1-(benzo[b]thiophen-5-yl)-2-bromoethanone (4o), other starting materials 
and solvents were purchased from Sigma-Aldrich, Acros Organics, Fischer scientific or Alfa Aesar 
and were used without further purification. Reactions were monitored by Thin Layer 
Chromatography (TLC Silica gel 60 F254) purchased from Merck and observed under UV light 
(254 nm). Purification by semi-preparative HPLC was carried out on an Agilent 1200 series HPLC 
system (Agilent Technologies) using an Agilent C18 column (30 x 100 mm/10 µm) as stationary 
phase and a gradient of water and acetonitrile as eluent. 1H and 13C NMR spectra were 
obtained in dimethylsulphoxide-d6, acetone-d6 or CDCl3 on a Bruker DRX-500 instrument, 
operating at 500 MHz for the 1H and at 125 MHz for the 13C at 300K, using residual signal of 
deuterated NMR solvent as internal reference.279 Chemical shifts are reported in parts per million 
(ppm), multiplicity of the signals are indicated by lower-case letters (singlet s, doublet d, triplet t, 
quadruplet q, multiplet m, broad singlet br s, or combination of letters). DEPT 135 was used to 
determine carbon multiplicity. Analytical HPLC was performed using a SpectraSYSTEMTM 
(ThermoFisher) with a Macherey-Nagel C18 column (3 x 125 mm/5 µm). HPLC purities were 
determined by UV absorption at 254 nm. ElectroSpray Ionisation (ESI) mass spectra were 
measured on a Finnigan Surveyor MSQ Plus mass spectrometer (ThermoFisher). Melting points 
(mp) of solids were determined by SMP3 melting point apparatus from Bibby Sterling.  
General procedure 1 for the preparation of 2’-bromo-acetophenone analogs from 
acetophenones (method A):237 
Bromine (1 eq) was added dropwise over 5 min to a stirred and warmed (40°C) solution of 
acetophenone derivative (1 eq) in CHCl3. At the end of the addition, the mixture was cooled 
down at RT; Et2O was then added, followed by a saturated aqueous solution of NaHCO3 and the 
resulting mixture was then stirred for 30 min. The organic layer was separated, washed with a 
saturated aqueous solution of NaHCO3, dried with Na2SO4 and filtered. The volatiles were 
removed under reduced pressure to afford the product as a solid, which was used in the next 
step without further purification. 
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General procedure 2 for the preparation of 2’-bromo-acetophenone analogs from 
acetophenones (method B):238 
Bromine (1 eq) was added dropwise to a solution of acetophenone derivative (1 eq) in a mixture 
of MeOH and HBr 32 % (2 eq) in AcOH. The mixture was then heated at 60°C for 4h. After removal 
of the volatiles in vacuo, the solid residue was washed 5 times with Et2O and filtered to afford the 
product as a solid, which was used in the next step without further purification. 
2’-bromo-3-methoxy-acetophenone (4a)  
The reaction was carried out according to general procedure 1, scale: 3-
methoxyacetophenone (3.33 mmol, 459 µL), bromine (3.33 mmol, 172 µL), CHCl3 (10 mL), Et2O 
(100 mL), to afford the title product as a yellow solid (3.33 mmol, 762 mg). Yield = quantitative. 
LC-UV purity = 75%. The compound was not ionized by ESI+. 1H-NMR (500 MHz, CDCl3) δ = 3.70 (s, 
3H, CH3-O), 4.3 (s, 2H, CH2-Br), 6.99 (ddd, J = 1.0; 2.5; 8.2 Hz, 1H), 7.24 (t, J = 8.2 Hz, 1H), 7.34 (dd, J 
= 1.6, 2.5 Hz, 1H), 7.39 (ddd, J = 1.0, 1.6, 7.6 Hz, 1H). mp = 52-54°C, spectral data and melting 
point are in accordance with lit. data (61-62°C).280 
2’-bromo-4-methoxy-acetophenone (4b)  
The reaction was carried out according to general procedure 1, scale: 4-
methoxyacetophenone (3.33 mmol, 500 mg), bromine (3.33 mmol, 172 µL), CHCl3 (10 mL), Et2O 
(100 mL), to afford the title product as a grey solid (3.33 mmol, 765 mg). Yield = quantitative. LC-
UV purity = 78%. LC-MS (ESI+) m/z = 229.31 for [M+H]+. 1H-NMR (500 MHz, CDCl3) δ = 3.89 (s, 3H, 
CH3-O), 4.40 (s, 2H, CH2-Br), 6.95 – 6.97 (m, 2H), 7.96 – 7.98 (m, 2H). mp = 49-51°C, spectral data is 
in accordance with lit. data281,282 
2-bromo-1-(pyridin-2-yl)ethanone hydrogen bromide (4c) 
The reaction was carried out according to general procedure 2, scale: 2-acetylpyridine (8.2 
mmol, 930 µL), bromine (8.2 mmol, 430 µL), HBr 32 % in AcOH (16.5 mmol, 2.98 mL), MeOH (1 mL), 
to afford the title product as a slightly yellow solid (8.2 mmol, 2.3 g). Yield = quantitative. LC-UV 
purity = 85%. LC-MS (ESI+) m/z = 200.05/202.08 for [M+H]+. 1H-NMR (500 MHz, CDCl3) δ = 4.95 (s, 2H, 
CH2-Br), 7.70 – 7.73 (m, 1H), 7.99 (td, J = 1.3, 7.9 Hz, 1H), 8.04 – 8.07 (m, 1H), 8.62 (br s, NH+), 8.70 – 
8.71 (m, 1H). mp = 206-208°C, spectral data and melting point are in accordance with lit. data 
(200-205°C).283 
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General procedure 3 for the preparation of thiourea analogs from amines:  
Carbon disulfide (3 eq) was slowly added to a mixture of aminobenzoic acid derivative (1 eq) in 
a 1/1 THF/H2O (0.7 mol.L-1) solvent mixture and Et3N (2.5 eq). The resulting mixture was stirred at RT 
for 24h. Then iodine (1.05 eq) in THF (5 mL) was added dropwise at 0°C and the mixture was 
stirred for 3h. A 1M HCl aqueous solution (7.5 mL) and Na2SO3 (0.2 eq) were added and the 
stirring was continued for 15 min. The aqueous layer was extracted with EtOAc (3 x 50 mL). The 
combined organic layers were washed twice with brine (25 mL) and dried on Na2SO4. After 
filtration, the volatiles were removed under reduced pressure to give the isothiocyanate 
intermediate as a slightly yellow solid, which was converted to the thiourea derivative by stirring 
at RT in NH4OH (100 mL) for 6h. NH4OH refers to a 35% w/w ammonia solution in water. After 
removal of the solids by filtration on a sintered-glass funnel, the filtrate was concentrated to 
afford the thiourea product, which was used in the next step without further purification. 
4-thioureidobenzoic acid (5a)  
The reaction was carried out according to the general procedure 3, scale: 4-aminobenzoic acid 
(7.3 mmol, 1 g), to afford the title product as an off-white solid (7.3 mmol, 1.43 g). Yield = 
quantitative. LC-UV purity = 80%. The compound was not ionized by ESI+. 1H-NMR (500 MHz, 
DMSO-d6): δ = 7.56 – 7.58 (m, 2H), 7.80 – 7.82 (m, 2H). mp = 189-191°C, spectral data and melting 
point are in accordance with lit. data (194°C).275 
3-thioureidobenzoic acid (5b)  
The reaction was carried out according to the general procedure 3, scale: 3-aminobenzoic acid 
(7.3 mmol, 1 g), to afford the title product as an off-white solid (7.3 mmol, 1.43 g). Yield = 
quantitative. LC-UV purity = 96%. The compound was not ionized by ESI+. 1H-NMR (500 MHz, 
DMSO-d6): δ = 7.28 (t, J = 7.8 Hz, 1H), 7.57 – 7.59 (m, 2H), 8.04 (d, J = 6.5 Hz, 1H), 8.92 (br s, 1H), 
10.96 (br s, 1H). mp = 183-185°C, melting point is in accordance with lit. data (163°C).284 
2-(4-thioureidophenyl)acetic acid (5d) 
The reaction was carried out according to the general procedure 3, scale: 2-(4-
aminophenyl)acetic acid (3.31 mmol, 500 mg), to afford the title product as an off-white solid 
(3.1 mmol, 651 mg). Yield = 93 %. LC-UV purity = 97%. LC-MS (ESI+) m/z = 211.05 for [M+H]+. 1H-NMR 
(500 MHz, DMSO-d6): δ = 3.34 (s, 2H), 5.00 (br s, 3H), 7.15 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.2 Hz, 2H), 
7.58 (br s, 1H), 10.2 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 43.0, 122.7, 129.2, 133.4, 137.2, 
173.9, 181.0. mp = 139-141°C (partially described).285 
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5-thioureidoisophthalic acid (5e)  
The reaction was carried out according to the general procedure 3, scale: 5-aminoisophthalic 
acid (7.3 mmol, 1.32 g), to afford the title product as an off-white solid (7.3 mmol, 1.75 g). Yield = 
quantitative. LC-UV purity = 82%. The compound was not ionized by ESI+. 1H-NMR (500 MHz, 
DMSO-d6): δ = 7.53 (s, 1H), 8.09 – 8.18 (m, 3H), 9.18 (br s, 1H), 11.20 (br s, 1H). 13C-NMR (125.7 MHz, 
DMSO-d6): δ = 124.8, 125.5, 137.3, 139.4, 170.4, 181.6. mp = 246-248°C. 
2-hydroxy-4-thioureidobenzoic acid (5f) 
The reaction was carried out according to the general procedure 3, scale: 4-aminosalicylic acid 
(7.3 mmol, 1.12 g) to afford the title product as an off-white solid (7.3 mmol, 1.55 g). Yield = 
quantitative. LC-UV purity = 70%. The compound was not ionized by ESI+. 1H-NMR (500 MHz, 
DMSO-d6): δ = 6.73 (dd, J = 2.2, 8.2 Hz, 1H), 6.96 (s, 1H), 7.30 – 7.50 (br s, labile H), 7.60 (d, J = 8.2 
Hz, 1H), 7.56 – 7.70 (br s, labile H), 10.00 (s, 1H). mp = 185-187°C, melting point is in accordance 
with lit. data (179-180°C).286 
4-methoxy-3-thioureidobenzoic acid (5g) 
The reaction was carried out according to the general procedure 3, scale: 3-amino-4-
methoxybenzoic acid (7.3 mmol, 1.22 g) to afford the title product as an off-white solid (7.3 
mmol, 1.65 g). Yield = quant. LC-UV purity = 97%. LC-MS (ESI+) m/z = 226.79 for [M+H]+. 1H-NMR 
(500 MHz, DMSO-d6): δ = 3.80 (s, 3H), 5.33 (br s, labile H), 6.97 (d, J = 8.8 Hz, 1H), 7.52 (br s, 1H), 7.70 
(dd, J = 1.9, 8.5 Hz, 1H), 8.10 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 55.7, 110.4, 126.5, 127.5, 
127.7, 129.6, 154.2, 169.3, 181.6. mp = 241-243°C.  
Phenylthiourea (5i)  
Phenylisothiocyanate (8.37 mmol, 1 mL) was added to a solution of NH4OH(aq) (40 mL) and stirred 
at RT for 12h. After removal of volatile in vacuo, the white residue was triturated in water and 
filtered to obtain the title product as a white solid (8.15 mmol, 1.24 g). Yield = 97%. LC-UV purity > 
99%. LC-MS (ESI+) m/z = 153.1 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.12 (t, J = 7.3 Hz, 1H), 
7.32 (t, J = 7.3 Hz, 2H), 7.40 (d, J = 7.6 Hz, 2H), 9.70 (s, 1H). mp = 153-155°C, spectral data and 
melting point are in accordance with lit. data (153-154°C).287 
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1-(4-cyanophenyl)thiourea (5j)  
A solution of 4-cyanophenyl isothiocyanate (6.24 mmol, 1 g) in NH4OH(aq) (80 mL) was stirred at RT 
for 12h. After cooling at 0°C, the mixture was filtrated to afford the title product as an off-white 
solid (4.85 mmol, 860 mg). Yield = 78%. LC-UV purity > 99%. The compound was not ionized by 
ESI+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.75 (m, 4H), 10.07 (s, 1H). mp = 204-206°C, spectral data 
and melting point are in accordance with lit. data (239°C).283,288 
General procedure 4 for the preparation of 2-aminothiazole analogs: 
An ethanolic solution of 2’-bromo-acetophenone derivative and aryl thiourea derivative at 
eqimolar ratio, corrected with respect to LC-UV purity, was heated at 80°C for 3-12h (reaction 
monitoring by TLC). The mixture was then cooled down to RT and water (twice more than EtOH 
v/v) was added. The mixture was stirred for 30 min and then filtrated. The obtained solid was 
washed twice with water to afford the product as a solid. When necessary, purification was 
performed (i) by recrystallization or washing with boiling MeCN (ii) by recrystallization or washing 
in H2O/MeOH (iii) by HPLC preparative to obtain the product with LC-UV purity higher than 95%. 
4-((4-phenylthiazol-2-yl)amino)benzoic acid (2)  
The reaction was carried out according to general procedure 4, scale: 2-bromo-acetophenone 
(0.51 mmol, 102 mg), 4-thioureidobenzoic acid (0.51 mmol, 100 mg), absolute EtOH (5 mL). 
Purification was performed by washing with boiling MeCN (5 mL) and hot filtration to afford the 
title product as a grey solid (0.24 mmol, 70 mg). Yield = 58%. LC-UV purity = 95%. The compound 
was not ionized by ESI+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.33 (t, J = 6.9 Hz, 1H), 7.44 (t, J = 6.9 Hz, 
3H), 7.84 (d, J = 8.5 Hz, 2H), 7.95 (d, J = 7.9 Hz, 4H), 10.70 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): 
δ = 104.1 (CH), 115.9 (2 x CH), 122.8 (C), 125.7 (2 x CH), 127.7 (CH), 128.6 (2 x CH), 130.8 (2 x CH), 
134.3 (C), 144.9 (C), 150.2 (C), 162.2 (C), 167.0 (C). mp = 256-258 °C (in accordance with 
literature: 252 °C).278  
4-((4-(3-bromophenyl)thiazol-2-yl)amino)benzoic acid (3)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-(3-
bromophenyl)ethanone (0.36 mmol, 100 mg), 4-thioureidobenzoic acid (0.54 mmol, 106 mg), 
absolute EtOH (5 mL). Purification was performed by recrystallization in MeCN (5 mL) to afford the 
title product as a yellow solid (0.20 mmol, 75 mg). Yield = 56%. LC-UV purity = 95%. LC-MS (ESI+) 
m/z = 374.62/376.65 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.42 (t, J = 7.9 Hz, 1H), 7.52 (d, J = 
7.1 Hz, 1H), 7.62 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.93 – 7.98 (m, 3H), 8.11 (t, J = 1.6 Hz, 1H), 10.73 (s, 
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1H), 12.60 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 105.7 (CH), 115.9 (2 x CH), 122.1 (C), 122.9 
(C), 124.7 (CH), 128.0 (CH), 130.3 (CH), 130.8 (2 x CH), 130.9 (CH), 136.5 (C), 144.7 (C), 148.4 (C), 
162.4 (C), 166.9 (C). mp = 281-283°C. 
4-(3-nitrophenyl)-N-phenylthiazol-2-amine (6a)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-3’-nitro-
acetophenone (0.66 mmol, 161 mg), phenylthiourea (0.66 mmol, 100 mg), absolute EtOH (5 mL). 
After removal of the solvents under reduced pressure, water (10 mL) and MeOH (2 mL) were 
added. The pH of the solution was adjusted to 9 with solid Na2CO3 and then stirred for 1h. After 
filtration and washing of the residual solid with water (3 x 5 mL), the product was obtained as a 
yellow solid (0.66 mmol, 196 mg). Yield = quantitative. LC-UV purity = 99%. LC-MS (ESI+) m/z = 
298.06 for [M+H]+.1H-NMR (500 MHz, DMSO-d6): δ = 6.99 (t, J = 6.9 Hz, 1H), 7.36 (t, J = 6.6 Hz, 2H), 
7.65 – 7.71 (m, 4H), 8.14 (d, J = 7.3 Hz, 1H), 8.35 (d, J = 6.9 Hz, 1H), 8.69 (s, 1H), 10.39 (s, 1H). 13C-
NMR (125.7 MHz, DMSO-d6): δ = 105.6 (CH), 116.9 (2 x CH), 119.8 (CH), 121.4 (CH), 121.9 (CH), 
129.0 (2 x CH), 130.1 (CH), 131.7 (CH), 135.9 (C), 140.9 (C), 147.6 (C), 148.2 (C), 163.5 (C). mp = 
136-138 °C (in accordance with literature: 122-124 °C)276. 
5-((4-(3-nitrophenyl)thiazol-2-yl)amino)isophthalic acid (6c) 
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-(3-
nitrophenyl)ethanone (0.42 mmol, 102 mg), 5-thioureidoisophthalic acid (0.63 mmol, 151 mg), 
EtOH absolute (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot 
filtration to afford a yellow solid (0.36 mmol, 140 mg). Yield = 87%. LC-UV purity = 97%. LC-MS (ESI+) 
m/z = 385.59 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.71 (t, J = 7.6 Hz, 1H), 7.77 (s, 1H), 8.10 
(s, 1H), 8.17 (d, J = 6.9 Hz, 1H), 8.38 (d, J = 6.3 Hz, 1H), 8.63 (s, 2H), 8.77 (s, 1H), 10.79 (s, 1H), 13.27 
(br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 106.6 (CH), 120.0 (CH), 121.1 (2 x CH), 122.2 (CH), 
122.6 (CH), 130.1 (CH), 131.6 (CH), 132.1 (2 x C), 135.8 (C), 141.3 (C), 147.6 (C), 148.4 (C), 162.9 
(C), 166.6 (2 x C). mp > 410°C.  
2-(4-((4-(3- amino)phenyl) nitrophenyl)thiazol-2-yl) acetic acid (6d) 
The reaction was carried out according to the general procedure 4, scale: 2-bromo-3’-nitro-
acetophenone (0.48 mmol, 117 mg), 2-(4-thioureidophenyl)acetic acid (0.48 mmol, 100 mg), 
EtOH (5 mL) to afford ethyl 2-(4-((4-(3-nitrophenyl)thiazol-2-yl)amino)phenyl) (0.41 mmol, 158 mg). 
Then, a mixture of ethyl 2-(4-((4-(3-nitrophenyl)thiazol-2-yl)amino)phenyl)acetate in THF (5 mL) 
and NaOH 0.5 M (1.3 mmol, 2.6 mL) was heated at 80°C for 4h. After removal of THF under 
reduced pressure, HCl 1Mwas added until pH = 1. The product was obtained after filtration as a 
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black solid (0.22 mmol, 78 mg). Yield = 73%. LC-UV purity = 96%. LC-MS (ESI+) m/z = 355.74 for 
[M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ =  3.53 (s, 2H), 7.24 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 8.2 Hz, 
2H), 7.69 (s, 1H), 7.73 (t, J = 7.9 Hz, 1H), 8.16 (d, J = 7.9 Hz, 1H), 8.37 (d, J = 7.9 Hz, 1H), 8.70 (s, 1H), 
10.43 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 39.7 (CH2), 105.5 (CH), 116.9 (CH), 119.8 (CH), 
122.0 (CH), 128.0 (C), 129.0 (CH), 130.2 (CH), 131.7 (CH), 135.9 (C), 139.5 (C), 147.6 (C), 148.2 (C), 
163.6 (C), 172.8 (C). mp = 205-207 °C. 
4-((4-(3-methoxyphenyl)thiazol-2-yl)amino)benzoic acid (7a)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-3’-methoxy-
acetophenone (0.66 mmol, 152 mg), 4-thioureidobenzoic acid (0.51 mmol, 100 mg), EtOH (10 
mL). Purification was performed by washing the residue with boiling MeCN (5 mL) and hot 
filtration to give a crude solid which was then purified by flash chromatography 
(cyclohexane/Acetone 50/50) to afford the title product as a yellow solid (0.09 mmol, 29 mg). 
Yield = 17%. LC-UV purity = 96%. LC-MS (ESI+) m/z = 327.10 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): 
δ = 3.83 (s, 3H), 6.91 (dd, J = 8.2, 2.2 Hz, 1H), 7.36 (t, J = 8.2 Hz, 1H), 7.48 (s, 2H), 7.53 (d, J = 7.9 Hz, 
1H), 7.81 (d, J = 8.8 Hz, 2H), 7.94 (d, J = 8.8 Hz, 2H), 10.69 (s, 1H), 12.56 (br s, 1H).13C-NMR (125.7 
MHz, DMSO-d6): δ = 55.0 (CH3), 104.5 (CH), 111.1 (CH), 113.2 (CH), 115.8 (CH), 118.1 (CH), 122.8 
(C), 129.7 (CH), 130.8 (CH), 135.6 (C), 144.8 (C), 150.0 (C), 159.5 (C), 162.1 (C), 167.0 (C). mp = 
246-248°C. 
4-((4-(4-methoxyphenyl)thiazol-2-yl)amino)benzoic acid (7b)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-4’-methoxy-
acetophenone (0.71 mmol, 163 mg), 4-thioureidobenzoic acid (0.51 mmol, 100 mg), absolute 
EtOH (10 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot filtration 
to afford the title product as a grey solid (0.15 mmol, 49 mg). Yield = 29%. LC-UV purity = 96%. LC-
MS (ESI+) m/z = 327.09 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 3.80 (s, 3H), 7.00 (d, J = 7.3 Hz, 
2H), 7.29 (s, 1H), 7.81 (d, J = 7.9 Hz, 2H), 7.87 (d, J = 7.9 Hz, 2H), 7.93 (d, J = 7.9 Hz, 2H), 10.65 (s, 1H), 
12.54 (br s, 1H, O-H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 55.1 (CH3), 101.9 (CH), 114.0 (2 x CH), 
115.9 (2 x CH), 122.7 (C), 127.1 (2 x CH), 127.2 (C), 130.8 (2 x CH), 145.0 (C), 150.1 (C), 158.9 (C), 
162.1 (C), 167.0 (C). mp = 266-268 °C (commercially available). 
4-((4-(2,4-dimethoxyphenyl)thiazol-2-yl)amino)benzoic acid (7c)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-(2,4-
dimethoxyphenyl)ethanone (0.38 mmol, 100 mg), 4-thioureidobenzoic acid (0.58 mmol, 114 mg), 
EtOH (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot filtration to 
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afford an off-white solid (0.25 mmol, 89 mg). Yield = 66%. LC-UV purity = 97%. LC-MS (ESI+) m/z 
= 356.78 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6)  δ = 3.81 (s, 3H), 3.91 (s, 3H), 6.65 – 6.67 (m, 2H), 
7.31 (s, 1H), 7.81 (td, J = 2.2, 9.1 Hz, 2H), 7.93 (td, J = 2.2 Hz, 8.83 Hz, 2H), 8.08 – 8.10 (m, 1H), 10.58 
(s, 1H), 12.56 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 55.2 (CH3), 55.5 (CH3), 98.5 (CH), 105.2 
(CH), 105.5 (CH), 115.7 (CH), 115.8 (C), 122.5 (C), 130.2 (CH), 130.7 (CH), 145.0 (C), 146.2 (C), 
157.7(C), 159.8 (C), 160.3 (C), 167.0 (C). mp = 271-273°C. 
4-((4-(2,4-dihydroxyphenyl)thiazol-2-yl)amino)benzoic acid (7d) 
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-(2,4-
dihydroxyphenyl)ethanone (0.43 mmol, 100 mg), 4-thioureidobenzoic acid (0.65 mmol, 127 mg), 
absolute EtOH (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot 
filtration to afford the title product as yellow solid (0.38 mmol, 125 mg). Yield = 89%. LC-UV purity = 
95% LC-MS (ESI+) m/z = 328.84 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 6.34 (dd, J = 8.4, 2.4 Hz, 
1H), 6.36 (d, J = 2.3 Hz, 1H), 7.26 (s, 1H), 7.67 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 
8.8 Hz, 2H), 9.48 (br s, 1H), 10.67 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 102.2 (CH), 102.8 (CH), 
107.1 (CH), 111.6 (C), 116.0 (CH), 122.9 (C), 129.0 (CH), 130.8 (CH), 144.7 (C), 147.6 (C), 156.2(C), 
158.1 (C), 161.2 (C), 166.9 (C). mp = 367-369°C. 
4-((4-(5-bromo-2-hydroxyphenyl)thiazol-2-yl)amino)benzoic acid (7e)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-(5-bromo-
2-hydroxyphenyl)ethanone (0.34 mmol, 100 mg), 4-thioureidobenzoic acid (0.51 mmol, 100 mg), 
absolute EtOH (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot 
filtration to afford a yellow solid (0.31 mmol, 120 mg). Yield = 90%. LC-UV purity = 98%. LC-MS (ESI+) 
m/z = 390.65/392.62 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6)  δ = 6.91 (d, J = 8.5 Hz, 1H), 7.31 (dd, J 
= 2.5, 8.5 Hz, 1H), 7.64 (s, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.94 (d, J = 9.1 Hz, 2H), 8.12 (d, J = 2.5 Hz, 1H), 
10.74 (s, 1H), 10.84 (s, 1H), 12.60 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 107.7 (CH), 110.3 
(C), 116.0 (CH), 118.4 (CH), 122.1 (C), 123.1 (C), 130.3 (CH), 130.8 (CH), 130.9 (CH), 144.6 (C), 145.4 
(C), 154.2 (C), 161.4 (C), 166.9 (C). mp = 312-314°C. 
4-((4-(pyridin-2-yl)thiazol-2-yl)amino)benzoic acid (7f) 
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-(pyridin-2-
yl)ethanone hydrogen bromide (0.61 mmol, 171 mg), 4-thioureidobenzoic acid (0.51 mmol, 100 
mg), absolute EtOH (10 mL). After water (5 mL) addition to the mixture, NH4OH (30%) was added 
until complete dissolution. The pH of the solution was then adjusted to 2-3 by addition of aqueous 
HCl (1M) and the mixture was stirred for 30 min. The obtained solid was then filtrated and washed 
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with water (3 x 5 mL) to afford the title product as a yellow solid (0.28 mmol, 85 mg). Yield = 56%. 
LC-UV purity = 97%. LC-MS (ESI+) m/z = 298.07 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.83 (t, J 
= 5.5 Hz, 1H), 7.95 (m, 4H), 8.35, (br s, 1H), 8.50 (m, 2H), 8.79 (d, J = 5.4 Hz, 1H), 11.24 (br s, 1H).  13C-
NMR (125.7 MHz, DMSO-d6): δ = 114.8 (CH), 116.6 (2 x CH), 123.3 (CH), 124.7 (CH), 130.7 (2 x CH), 
143.1 (CH), 144.2 (C), 144.6 (CH), 146.0 (C), 163.5 (C), 167.0 (C). mp = 274-276°C. 
4-(thiazol-2-ylamino)benzoic acid (7g) 
The reaction was carried out according to the general procedure 4, scale: 1,2-dichloro-1-
ethoxyethane (0.41 mmol, 50 µL), 4-thioureidobenzoic acid (0.41 mmol, 80 mg), absolute EtOH (5 
mL). Purification by semi-preparative HPLC (H2O/MeCN/TFA: from 79/20/1 to 0/99/1 in 40 min) to 
afford ethyl 4-(thiazol-2-ylamino)benzoate as a white solid (0.09 mmol, 23 mg). Yield = 23%. LC-UV 
purity = 96%. LC-MS (ESI+) m/z = 249.01 for [M+H]+.The ethyl 4-(thiazol-2-ylamino)benzoate (0.085 
mmol, 21 mg) obtained was directly hydrolyzed in a mixture of THF (2 mL) and aqueous 0.5 M 
NaOH (1.15 mmol, 2.3 mL) at reflux for 4h. Aqueous 1 M HCl was added until pH = 1 and then 
solvents were removed in vacuo. Crude product was purified by semi-preparative HPLC 
(H2O/MeCN + 0.1% TFA: from 90/10 to 10/90 in 40 min) to afford the title product as a white solid 
(0.07 mmol, 16 mg). Yield = 86%. LC-UV purity > 99%. LC-MS (ESI+) m/z = 220.78 for [M+H]+. 1H-NMR 
(500 MHz, DMSO-d6): δ = 7.02 (d, J = 3.8 Hz, 1H), 7.33 (d, J = 3.8 Hz, 1H), 7.72 (d, J = 8.5 Hz, 2H), 7.88 
(d, J = 8.8 Hz, 2H), 10.59 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 109.7 (CH), 115.7 (2 x CH), 
122.5 (C), 130.7 (2 x CH), 138.8 (CH), 144.9 (C), 162.9 (C), 166.9 (C). mp = 270-272 °C 
(commercially available).277  
4-((4-(tert-butyl)thiazol-2-yl)amino)benzoic acid (7h) 
The reaction was carried out according to the general procedure 4, scale: 1-bromo-3,3-
dimethylbutan-2-one (0.45 mmol, 60 µL), 4-thioureidobenzoic acid (0.41 mmol, 80 mg), absolute 
EtOH(5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot filtration to 
afford the title product as a white solid (0.10 mmol, 28 mg). Yield = 25%. LC-UV purity = 96%. LC-
MS (ESI+) m/z = 277.04 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 1.28 (s, 9H), 6.53 (s, 1H), 7.70 (d, 
J = 8.5 Hz, 2H), 7.88 (d, J = 8.5 Hz, 2H), 10.48 (s, 1H), 12.49 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): 
δ = 29.5 (CH3), 34.3 (C), 100.5 (CH), 115.5 (CH), 122.3 (C), 130.6 (CH), 145.1 (C), 161.5 (C), 161.6 
(C), 166.9 (C). mp = 280-282 °C. 
4-((4-(thiophen-3-yl)thiazol-2-yl)amino)benzoic acid (7i) 
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-(thiophen-
3-yl)ethanone (0.41 mmol, 84 mg), 4-thioureidobenzoic acid (0.41 mmol, 80 mg), absolute EtOH 
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(5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot filtration by hot 
filtration to afford the title product as a brown solid (0.20 mmol, 59 mg). Yield = 48%. LC-UV purity 
= 96%.LC-MS (ESI+) m/z = 302.86 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.27 (s, 1H), 7.59 (m, 
2H), 7.82 (m, 2H), 7.91 (m, 3H), 10.65 (s, 1H), 12.56 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 
103.4 (CH), 115.9 (2 x CH), 121.8 (CH), 122.7 (C), 125.9 (CH), 126.8 (CH), 130.7 (2 x CH), 136.6 (C), 
144.8 (C), 146.6 (C), 162.1 (C), 166.9 (C).  mp = 278-280 °C. 
4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (7j) 
The reaction was carried out according to the general procedure 4,scale: 2-bromo-1-
(naphthalen-2-yl)ethanone (0.41 mmol, 102 mg), 4-thioureidobenzoic acid (0.41 mmol, 80 mg), 
absolute EtOH (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot 
filtration to afford the title product as a brown solid (0.17 mmol, 59 mg). Yield = 42%. LC-UV purity 
= 95%. LC-MS (ESI+) m/z = 346.57 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.53 (m, 2H), 7.60 (s, 
1H), 7.89 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 7.9 Hz, 2H), 7.98 (m, 3H), 8.04 (d, J = 8.5 Hz, 1H), 8.08 (dd, J 
= 8.5, 1.9 Hz, 1H), 8.50 (s, 1H), 10.73 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 104.8 (CH), 116.0 (2 
x CH), 122.8 (C), 123.9 (CH), 124.3 (CH), 126.0 (CH), 126.3 (CH), 127.5 (CH), 128.1 (CH),128.2 (CH), 
130.8 (2 x CH), 131.7 (C), 132.4 (C), 133.1 (C), 144.8 (C), 150.1 (C), 162.3 (C), 167.0 (C). mp = 294-
296 °C. 
4-((4-(2-oxo-2H-chromen-3-yl)thiazol-2-yl)amino)benzoic acid (7k)  
The reaction was carried out according to the general procedure 4, scale: 3-
(bromoacetyl)coumarin (0.45 mmol, 120 mg), 4-thioureidobenzoic acid (0.54 mmol, 106 mg), 
EtOH absolute (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot 
filtration to afford the title product as a yellow solid (0.33 mmol, 120 mg). Yield = 73%. LC-UV purity 
= 96%. LC-MS (ESI+) m/z = 364.86 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ =  7.42 (t, J =  8.2 Hz, 
1H), 7.46 (d, J = 8.5 Hz, 2H), 7.64 (t, J = 8.2 Hz, 1H), 7.88 (m, 3H), 7.99 (d, J = 8.8 Hz, 2H), 8.02 (d, J = 
7.9 Hz, 1H), 8.75 (s, 1H), 10.75 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 110.8 (CH), 115.8 (CH), 
116.2 (CH), 119.2 (C), 120.1 (C), 122.9 (C), 124.6 (CH), 129.0 (CH), 130.9 (CH), 131.7 (CH), 138.9 
(CH), 143.6 (C), 144.6 (C), 152.3 (C), 158.7 (C), 161.7 (C), 167.0 (C). mp = 343-345 °C. 
4-((4-(benzofuran-2-yl)thiazol-2-yl)amino)benzoic acid (7l)  
The reaction was carried out according to the general procedure 4, scale: 1-(benzofuran-2-yl)-2-
bromoethanone (0.42 mmol, 100 mg), 4-thioureidobenzoic acid (0.50 mmol, 99 mg), absolute 
EtOH (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot filtration to 
afford a brown solid which was further purified by semi-preparative HPLC (H2O/MeCN + 0.1% TFA: 
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from 70/30 to 0/100 in 45 min) to afford the title product as a yellow solid (0.19 mmol, 63 mg). 
Yield = 45%. LC-UV purity = 99%. LC-MS (ESI+) m/z = 336.96 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): 
δ =  7.28 (m, 2H), 7.34 (dd, J = 8.2, 1.3 Hz, 1H), 7.45 (s, 1H), 7.62 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.3 , 
1H), 7.84 (d, J = 8.8 Hz, 2H), 7.95 (d, J = 8.8 Hz, 2H), 10.83 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ 
= 103.0 (CH), 106.4 (CH), 110.9 (CH), 116.1 (CH), 121.4 (CH), 123.0 (CH), 123.2 (C), 124.7 (CH), 
128.4 (C), 130.7 (CH), 141.4 (C), 144.6 (C), 151.6 (C), 154.1 (C), 163.0 (C), 166.9 (C). mp = 296-
298°C. 
4-((4-(benzo[b]thiophen-5-yl)thiazol-2-yl)amino)benzoic acid (7m) 
The reaction was carried out according to the general procedure 4, scale: 1-(1-benzothiophen-
5-yl)-2-bromo-1-ethanone (0.39 mmol, 100 mg), 4-thioureidobenzoic acid (0.59 mmol, 115 mg), 
absolute EtOH (5 mL). The obtained solid was stirred in boiling MeCN (20 mL) and filtrated. The 
filtrate layer was concentrated and the remaining solid was then dissolved in hot MeOH (10 mL). 
After cooling at RT, water (10 mL) was added and the obtained solid was filtrated and washed 
with water (2 x 5 mL) to obtain the title product as a yellow solid (0.15 mmol, 51 mg). Yield = 38%. 
LC-UV purity = 95%. LC-MS (ESI+) m/z = 352.76 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.48 (s, 
1H), 7.56 (d, J = 5.4 Hz, 1H), 7.79 (d, J = 5.4 Hz, 1H), 7.88 (d, J = 8.8 Hz, 2H), 7.94 – 7.99 (m, 3H), 8.04 
(d, J = 8.5 Hz, 1H), 8.48 (d, J = 1.6 Hz, 1H), 10.70 (s, 1H), 12.52 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-
d6): δ = 103.7 (CH), 115.9 (2 x CH), 120.7 (CH), 122.3 (CH), 122.7 (CH), 122.8 (C), 124.3 (CH), 128.0 
(CH), 130.8 (3 x CH), 138.4 (C), 139.9 (C), 144.9 (C), 150.3 (C), 162.2 (C), 167.0 (C). mp = 353-
355°C. 
4-(naphthalen-2-yl)-N-phenylthiazol-2-amine (8a) 
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-
(naphthalen-2-yl)ethanone (0.66 mmol, 164 mg), phenylthiourea (0.66 mmol, 100 mg), absolute 
EtOH (15 mL). After water (25 mL) addition, the pH was adjusted to 9 with aqueous Na2CO3 (1M). 
The resulting mixture was cooled at 0°C and the precipitate was filtrated to afford the title 
product as a white solid (0.65 mmol, 195 mg). Yield = 98%. LC-UV purity> 99%.LC-MS (ESI+) m/z 
= 302.85 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.00 (t, J = 7.3 Hz, 1H), 7.39 (t, J = 8.2 Hz, 2H), 
7.48 (s, 1H), 7.52 (qi, J = 8.2 Hz, 2H), 7.79 (d, J = 7.6 Hz, 2H), 7.91 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 8.8 
Hz, 1H), 8.00 (d, J = 7.9 Hz, 1H), 8.07 (dd, J = 8.5, 1.5 Hz, 1H), 10.32 (s, 1H). 13C-NMR (125.7 MHz, 
DMSO-d6): δ = 103.6 (CH), 116.8 (CH), 121.2 (CH), 124.0 (CH), 124.1 (CH), 125.9 (CH), 126.3 (CH), 
127.5 (CH), 128.0 (CH), 128.1 (CH), 129.0 (CH), 131.9 (C), 132.4 (C), 133.1 (C), 141.1 (C), 150.0 (C), 
163.1 (C). mp = 148-150°C. 
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4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzonitrile (8b) 
The reaction was carried out according to the general procedure 4, scale: 2-bromo-
2’acetonaphtone (1.41 mmol, 351 mg), 1-(4-cyanophenyl)thiourea (1.41 mmol, 250 mg), EtOH 
absolute (5 mL). The resulting mixture was cooled at RT and aqueous Na2CO3 (1M) was added 
dropwise until pH = 8.After cooling at 0°C,the precipitate was filtrated and washed with H2O (2 x 
5 mL) to afford the title product as a slightly yellow solid (462 mg, 1.41 mmol). Yield = quantitative. 
LC-UV purity = 99%. LC-MS (ESI+) m/z = 327.94 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ =  7.51 
(dt, J = 6.9, 1.3 Hz, 1H), 7.55 (dt, J = 6.9, 1.6 Hz, 1H), 7.61 (s, 1H), 7.81 (d, J = 8.8 Hz, 2H), 7.92 (d, J = 
8.2 Hz, 1H), 7.96 (m, 3H), 8.01 (d, J = 7.9 Hz, 1H), 8.08 (dd, J = 8.5, 1.3 Hz, 1H). 13C-NMR (125.7 MHz, 
DMSO-d6): δ = 101.8 (C), 105.2 (CH), 116.8 (CH), 119.6 (C), 123.9 (CH), 124.3 (CH), 126.0 (CH), 
126.4 (CH), 127.5 (CH), 128.1 (CH), 131.6 (C), 132.4 (C), 133.1 (C), 133.5 (2 x CH), 145.2 (C), 150.2 
(C), 162.4 (C). mp = 228-230°C. 
3-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (8c)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-
(naphthalen-2-yl)ethanone (0.40 mmol, 100 mg), 3-thioureidobenzoic acid (0.52 mmol, 102 mg), 
EtOH absolute (5 mL). The title product was obtained pure after filtration as a yellow solid (0.34 
mmol, 118 mg). Yield = 86%. LC-UV purity = 98%. LC-MS (ESI+) m/z = 346.80 for [M+H]+. 1H-NMR (500 
MHz, DMSO-d6): δ = 7.49 – 7.56 (m, 4H), 7.59 (d, J = 7.6 Hz, 1H), 7.90 – 7.98 (m, 4H), 8.08 (dd, J = 1.9, 
8.5 Hz, 1H), 8.55 (s, 1H), 8.77 (s, 1H), 10.56 (s, 1H), 13.01 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ 
= 104.1 (CH), 117.7 (CH), 120.8 (CH), 121.9 (CH), 123.8 (CH), 124.5 (CH), 126.0 (CH), 126.4 (CH), 
127.5 (CH), 128.0 (CH), 128.1 (CH), 129.2 (CH), 131.5 (C), 131.8 (C), 132.4 (C), 133.2 (C), 141.3 (C), 
149.8 (C), 162.7 (C), 167.4 (C). mp = 275-277°C. 
4-methoxy-3-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (8d)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-
(naphthalen-2-yl)ethanone (1 mmol, 250 mg), 3-methoxy-4-thioureidobenzoic acid (1.3 mmol, 
294 mg), EtOH absolute (25 mL). Product was obtained pure after filtration as a yellow solid (0.94 
mmol, 353 mg). Yield = 94%. LC-UV purity = 97%. LC-MS (ESI+) m/z = 376.82 for [M+H]+. 1H-NMR (500 
MHz, DMSO-d6)  δ = 3.97 (s, 3H), 7.14 (d, J = 8.5 Hz, 1H), 7.49 – 7.55 (m, 3H), 7.64 (dd, J = 2.2, 8.2 Hz, 
1H), 7.91 – 7.96 (m, 3H), 8.07 (dd, J = 1.9, 8.5 Hz, 1H), 8.60 (d, J = 0.6 Hz, 1H), 9.70 (d, J = 2.2 Hz, 1H), 
9.90 (s, 1H), 12.71 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 55.9 (CH3), 104.7 (CH), 110.0 (CH), 
118.8 (CH), 122.9 (C), 123.5 (CH), 123.6 (CH), 124.5 (CH), 125.9 (CH), 126.3 (CH), 127.5 (CH), 127.9 
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(CH), 128.0 (CH), 129.9 (C), 131.8 (C), 132.3 (C), 133.2 (C), 149.1 (C), 150.8 (C), 162.7 (C), 167.5 
(C). mp = 256-258°C. 
2-hydroxy-4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (8e)  
The reaction was carried out according to the general procedure 4, scale: 2-bromo-1-
(naphthalen-2-yl)ethanone (0.50 mmol, 124 mg), 2-hydroxy-4-thioureidobenzoic acid (0.70 mmol, 
149 mg), EtOH (5 mL). Purification was performed by washing with boiling MeCN (5 mL) and hot 
filtration to afford a yellow solid (0.37 mmol, 133 mg). Yield = 73%. LC-UV purity = 96%. LC-MS (ESI+) 
m/z = 362.84 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 7.19 (dd, J = 1.9, 8.8 Hz, 1H), 7.49 – 7.57 
(m, 3H), 7.61 (s, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.98 (d, J = 8.2 Hz, 2H), 8.07 (d, J 
= 8.5 Hz, 1H), 8.46 (s, 1H), 10.75 (s, 1H), 11.8 (br s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 103.0 
(CH), 105.2 (CH), 105.6 (C), 108.4 (CH), 124.0 (CH), 124.2 (CH), 126.0 (CH), 126.5 (CH), 127.6 (CH), 
128.1 (CH), 128.2 (CH), 131.3 (CH), 131.7 (C), 132.5 (C), 133.1 (C), 147.0 (C), 150.2 (C), 162.1 (C), 
162.6 (C), 171.7 (C). mp = 221-223°C. 
2-((4-(3-nitrophenyl)thiazol-2-yl)amino)benzoic acid (9) 
A solution of HCl 37% (1 mL) and 1,4-dioxane (5 mL) containing 2-bromo-4-phenylthiazole (2.08 
mmol, 500 mg) and 2-aminobenzoic acid (2.08 mmol, 286 mg) was heated at reflux for 60h. After 
solvents removal, the residual solid was washed with water (5 mL) and then with cold acetone (5 
mL) to obtain a white solid which was further purified by flash chromatography 
(cyclohexane/EtOAc, from 7/3 to 0/100) to obtain a second white solid containing 75% of 
product (by HPLC). After a second purification by preparative HPLC (H2O/MeCN - 1% formic 
acid, from 70/30 to 0/100), the pure title product was obtain as a white solid (0.04 mmol, 12 mg). 
Yield = 2%. LC-UV purity = 97%.LC-MS (ESI+) m/z = 297.08 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ 
=  7.07 (t, J = 7.9 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.45 (t, J = 7.6 Hz, 2H), 7.53 (s, 1H), 7.69 (td, J = 7.6, 
1.6 Hz, 1H), 7.94 (d, J = 6.9 Hz, 2H), 8.02 (dd, J = 7.9, 1.6 Hz, 1H), 8.62 (d, J = 8.5 Hz, 1H), 11.48 (s, 
1H).13C-NMR (125.7 MHz, DMSO-d6): δ = 104.6 (CH), 113.7 (C), 116.9 (CH), 120.4 (CH), 125.7 (CH), 
127.8 (CH), 128.6 (CH), 131.4 (CH), 134.1, 134.7 (CH), 142.9 (C), 150.3 (C), 161.8 (C), 170.0 (C). mp 
= 95-97 °C. 
Methyl 4-((4-(3-nitrophenyl)thiazol-2-yl)amino)benzoate (10)  
Three drops of 95% H2SO4 were added to a mixture of 4-((4-(3-nitrophenyl)thiazol-2-
yl)amino)benzoic acid (1) (0.14 mmol, 46 mg) in MeOH (5 mL) and the mixture was then heated 
at reflux for 2h. Na2CO3 1 M was then added until pH = 10-11 and MeOH was removed under 
vacuo. The obtained solid was filtrated and washed with water (2 x 5 mL) to afford the title 
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product as a yellow solid (0.14 mmol, 49 mg). Yield = quantitative. LC-UV purity = 97%. LC-MS 
(ESI+) m/z = 356.01 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 3.82 (s, 3H), 7.74 – 7.84 (m, 4H), 
7.96 (s, 2H), 8.17 (s, 1H), 8.40 (s, 1H), 8.71 (s, 1H), 10.83 (s, 1H). 13C-NMR (125.7 MHz, DMSO-d6): δ = 
51.7 (CH3), 107.0 (CH), 116.1 (2 x CH), 119.9 (CH), 121.8 (C), 122.1 (CH), 130.3 (CH), 130.6 (2 x CH), 
131.9 (CH), 135.7 (C), 144.9 (C), 147.8 (C), 148.3 (C), 162.6 (C), 165.8 (C). mp = 242-244 °C. 
N-(methylsulfonyl)-4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzamide (11a) 
A solution of 4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (7j) (0.23 mmol, 80 mg), HATU 
(0.28 mmol, 106 mg) and DIPEA (0.69 mmol, 120 µL) in dry DMF (2 mL) was stirred under N2 for 30 
min. And then added to a solution of NaH (0.92 mmol, 22 mg) and MeSO2NH2 (1.15 mmol, 110 
mg) in dry THF (2 mL) beforehand stirred at RT under N2 for 30 min. The resulting mixture was stirred 
at RT for 4h. After removal of solvents under vacuo, residue was purified by semi-preparative 
HPLC (H2O/MeCN + 0.1% TFA: from 40/60 to 0/100 in 50 min) followed by a second purification by 
semi-preparative HPLC (H2O/MeCN + 0.1% TFA: from 25/75 to 20/80 in 45 min) to obtain the title 
product as a white solid (0.026 mmol, 11 mg). Yield = 11%. LC-UV purity = 99%. LC-MS (ESI+) m/z 
= 423.73 for [M+H]+. 1H-NMR (500 MHz, acetone-d6) δ = 3.40 (s, 3H), 7.48 (s, 1H), 7.49 – 7.56 (m, 2H), 
7.92 (d, J = 7.9 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 8.01 – 8.04 (m, 2H), 8.08 - 8.12 
(m, 3H), 8.56 (s, 1H), 9.89 (brs, 1H), 10.49 (brs, 1H). 13C-NMR (125.7 MHz, acetone-d6) δ = 42.8 (CH3), 
106.2 (CH), 118.3 (CH), 126.0 (CH), 126.2 (C), 126.8 (CH), 128.0 (CH), 128.3 (CH), 129.5 (CH), 130.1 
(CH), 130.2 (CH), 131.8 (3 x CH), 134.0 (C), 135.1 (C), 135.7 (C), 153.1 (C), 167.1 (C). mp = 240-
242°C. 
 4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)-N-tosylbenzamide (11b) 
4-methylbenzenesulfonamide (0.23 mmol, 39.5 mg), N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (0.46 mmol, 88 mg) and 4-dimethylaminopyridine (0.46 mmol, 
56 mg) were added to a solution of 4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoic acid (7j) 
(0.23 mmol, 80 mg) inCH2Cl2 (10 mL). The resulting mixture was stirred at RT under N2 atmosphere 
for 36h. NH4Cl(aq) (10 mL) was added, and then H2O (10 mL). The aqueous layer was extracted 
with CH2Cl2 (2 x 20 mL). The combined organic layers were dried with Na2SO4, filtrated and 
concentrated to give a brown solid which was further purified by semi-preparative HPLC 
(H2O/MeCN + 0.1% TFA: from 30/70 to 0/100 in 45 min) to obtain the title product as a white solid 
(0.026 mmol, 13 mg). Yield = 11%. LC-UV purity = 97%. LC-MS (ESI+) m/z = 499.79 for [M+H]+. 1H-
NMR (500 MHz, aceton-d6) δ = 2.43 (s, 3H), 7.43 (dt, J = 7.9, 0.6 Hz, 2H), 7.52 (m, 2H), 7.91 (dd, J = 
7.9, 0.6 Hz, 1H), 7.94 (d, J = 9.1 Hz, 1H), 7.99 (m, 8H), 8.09 (dd, J = 8.5, 1.9 Hz, 1H), 8.54 (s, 1H). 13C-
NMR (125.7 MHz, Acetone-d6) δ = 22.5 (CH3), 118.2 (CH), 125.9 (CH), 126.1 (C), 126.8 (CH), 127.9 
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(CH), 128.3 (CH), 129.5 (CH), 130.1 (CH), 130.2 (CH), 130.2 (CH), 131.2 (CH), 131.7 (CH), 133.9 (C), 
135.0 (C), 135.6 (C), 139.2 (C), 146.3 (C), 147.3 (C), 152.8 (C), 164.2 (C), 165.9 (C). mp = 223-225°C. 
General procedure 5 for the preparation of acetoxymethyl prodrug: 
To a solution of the acid derivative (1 eq) in dry DMF (5 mL) under N2 flow was added 
triethylamine (5 eq) and bromo-methylacetate (3 eq). After stirring for 12h, water (10 mL) was 
added and a precipitate occurred. The solid obtained after filtration was washed three times 
with water (5 mL) and further purified by semi-preparative HPLC (H2O/MeCN: from 40/60 to 0/100 
in 50 min) to obtain the desired product.  
acetoxymethyl 4-((4-(naphthalen-2-yl)thiazol-2-yl)amino)benzoate (12a)  
The reaction was carried out according to the general procedure 5, scale: 4-((4-(naphthalen-2-
yl)thiazol-2-yl)amino)benzoic acid (7j) (0.14 mmol, 50 mg), Et3N (0.7 mmol, 98 µL), bromo-
methylacetate (0.43 mmol, 42 µL), DMF (5 mL), then H2O (10 mL). After purification by semi-
preparative HPLC, the product was obtained as an off-white solid (0.098 mmol, 41 mg). Yield = 
70%. LC-UV purity = 95%. LC-MS (ESI+) m/z = 418.61 for [M+H]+. 1H-NMR (500 MHz,aceton-d6) δ = 
2.11 (s, 3H), 5.98 (s, 2H), 7.47 (s, 1H), 7.49 – 7.55 (m, 2H), 7.91 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 8.8 Hz, 
1H), 8.03 – 8.06 (m, 5H), 8.12 (dd, J = 8.5, 1.9 Hz, 1H), 8.59 (s, 1H), 9.90 (s, 1H). 13C-NMR (125.7 MHz, 
aceton-d6) δ = 21.6 (CH3), 81.2 (CH2), 106.2 (CH), 118.3 (CH), 123.3 (C), 125.9 (CH), 126.8 (CH), 
127.9 (CH), 128.2 (CH), 129.5 (CH), 130.1 (CH), 130.3 (CH), 133.2 (CH), 134.04 (C), 135.1 (C), 135.7 
(C), 148.0 (C), 153.2 (C), 164.3 (C), 166.2 (C), 171.1 (C). mp = 148-150°C. 
acetoxymethyl 4-((4-(3-nitrophenyl)thiazol-2-yl)amino)benzoate  (12b) 
The reaction was carried out according to the general procedure 5, scale: 4-((4-(3-
nitrophenyl)thiazol-2-yl)amino)benzoic acid (1) (0.26 mmol, 90 mg), Et3N (1.3 mmol, 183 µL), 
bromo-methylacetate (0.79 mmol, 78 µL), DMF (5 mL), then H2O (10 mL). After purification by 
semi-preparative HPLC, the product was obtained as an orange solid (0.11 mmol, 46 mg). Yield = 
43%. LC-UV purity > 99%. LC-MS (ESI+) m/z = 413.60 for [M+H]+. 1H-NMR (500 MHz, DMSO-d6): δ = 
2.11 (s, 3H), 5.91 (s, 2H), 7.73 (t, J = 8.2 Hz, 1H), 7.80 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.97 (d, J = 8.8 
Hz, 2H), 8.16 (ddd, J = 8.2, 2.2, 1.0 Hz, 1H), 8.40 (dt, J = 8.2, 1.0 Hz, 1H), 8.70 (t, J = 1.9 Hz, 1H), 10.94 
(s, 1H).13C-NMR (125.7 MHz, DMSO-d6): δ = 20.5 (CH3), 79.4 (CH2), 107.2 (CH), 116.2 (CH), 119.9 
(CH), 120.4 (C), 122.1 (CH), 130.3 (CH), 131.1 (CH), 131.9 (CH), 135.7 (C), 145.6 (C), 147.8 (C), 148.3 
(C), 162.4 (C), 164.0 (C), 169.4 (C). mp = 169-171°C. 
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acetoxymethyl 4-((4-(thiophen-3-yl)thiazol-2-yl)amino)benzoate (12c) 
The reaction was carried out according to the general procedure 5, scale: 4-((4-(thiophen-3-
yl)thiazol-2-yl)amino)benzoic acid (7i) (0.25 mmol, 77 mg), Et3N (1.25 mmol, 176 µL), bromo-
methylacetate (0.76 mmol, 75 µL), DMF (5 mL), then H2O (10 mL). After purification by semi-
preparative HPLC, the product was obtained as an off-white solid (0.04 mmol, 14 mg). Yield = 
16%. LC-UV purity = 96%. LC-MS (ESI+) m/z = 374.66 for [M+H]+. 1H-NMR (500 MHz, aceton-d6) δ = 
2.10 (s, 3H), 5.96 (s, 2H), 7.15 (s, 1H), 7.51 (dd, J = 5.0, 3.2 Hz, 1H), 7.60 (dd, J = 5.0, 1.3 Hz, 1H), 7.93 
(dd, J = 3.2, 1.3 Hz, 1H), 7.98 (d, J = 9.0 Hz, 2H), 8.03 (d, J = 9.0 Hz, 2H), , 9.83 (s, 1H).13C-NMR (125.7 
MHz, acetone-d6) δ = 21.6 (CH3), 81.2 (CH2), 105.0 (CH), 118.3 (CH), 123.2 (C), 123.8 (CH), 127.7 
(CH), 128.1 (CH), 133.1 (CH), 139.0 (C), 148.0 (C), 149.5 (C), 164.2 (C), 166.2 (C), 171.7 (C). mp = 
136-138°C. 
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6.1.3 Synthesis of compounds of chapter 3.4 
All commercially available chemicals and solvents were purchased from Sigma-Aldrich, 
Acros Organics, Fischer scientific and Alfa Aesar. They were used without further purification, 
unless specified. 1H NMR spectra were obtained on a Bruker ALS300 and DRX300 (300 MHz), and 
a DRX400 Bruker (400 MHz) using residual signal of deuterated NMR solvent as internal 
reference.274 Chemical shifts are expressed in parts per million (ppm), multiplicity of the signals 
are indicated by lower-case letters (singlet s, doublet d, triplet t, quadruplet q, multiplet m, broad 
singlet br s, doublet of triplet dt, triplet of doublet td, triplet of triplet tt) coupling constants are 
expressed in Hz, and deuterated solvents are either dimethylsulphoxide-d6 or CDCl3. Analytical 
HPLC was performed on an Agilent Technology 1290 Infinity chromatographic system equipped 
with a 1260 Diode Array Detector and a single quadrupole 6120 Mass Spectrometer Detector 
(column: Zorbax Eclipse Plus C18, 2.1 x 50 mm, 1.8 µm; temperature: 40°C). Solvent system was 
water/acetonitrile, each containing 0.1% of formic acid with an isocratic 90/10 elution during 0.5 
min then a gradient till 10/90 over 5 min and kept during 1 min at 0.5 mL/min. Injection volume 
was typically 0.1 µL HPLC purities were measured at 254 nm. Electrospray ionization spectra (ESI) 
are obtained on an Agilent Technologies 6120 Quadrupole LC/MS. High Resolution Mass 
Spectrometry (HRMS) were performed on Bruker microTOF-Q II. Parallel syntheses were performed 
with a Radleys Tech system. Purifications are performed on silica gel 40-60 µm, 60A for normal 
phase. Thin Layer Chromatographies (TLC) (thickness: 200 µm, particle size: 25 µm) were 
purchased from Fluka Analytical. When specified, products were obtained in different batches 
according to their HPLC purity. In this case, analytical and biological data were obtained from 
the most pure batch. 
1H-Indole-3-carboxylic acid (5a) 
N
H
OH
O
 
To a solution of 1H-indole-3-carbonitrile (13.4 mmol, 1.9 g) in water (50 mL) was added a solution 
of NaOH (147 mmol, 5.9 g) in water (50 mL). The mixture was then heated at reflux under argon 
for 24h. This aqueous layer was washed with 3 x 20 mL of EtOAc and then acidified until pH = 1 
with HCl 1M. A white precipitate occured and it was filtered, washed with HCl 1M to give the title 
compound as a white solid (9.24 mmol, 1.49 g). Yield = 69 %. Chemical formula: C9H7NO2. 
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Molecular weight: 161.16 g.mol-1. LC/MS (ESI): 95 % pure, m/z [M + H]+: 162. 1H-NMR (300 MHz, 
DMSO-d6) δ = 7.09 – 7.23 (m, 2H), 7.41 – 7.50 (m, 1H), 7.96 – 8.04 (m, 2H), 11.80 (s, 1H).289 
5-Nitro-1H-indole-3-carboxylic acid (5c) 
N
H
OH
O
O
2
N
 
General procedure 1 for the preparation of indole-3-carboxylic acids 
TFAA (42 mmol, 5.9 mL) was added dropwise to a solution of 5-nitro-1H-indole (18.5 mmol, 3 g) in 
dry DMF (25 mL) at 0°C under argon. After the end of the addition, the mixture was heated at 
reflux for 12h. Solvent was removed under reduced pressure and crude was taken off with water 
(50 mL) and a solution of NaOH (250 mmol, 10 g) in water (100 mL) was added. The resulting 
mixture was then heated at reflux for 12h. The solution was washed with Et2O (4 x 50 mL) and then 
acidified with HCl 1M until pH = 2. The resulting solid was filtered and dried to afford the title 
compound (16.8 mmol, 3.46 g). Yield = 91 %. Chemical formula: C9H6N2O4. Molecular weight: 
206.158 g.mol-1. LC/MS (ESI): 97 % pure, m/z [M + H]+: 207.4. 1H-NMR (300 MHz, DMSO-d6) δ = 7.68 
(d, J = 9.0, 1H), 8.09 (dd, J = 2.4, 9.0, 1H), 8.27 (d, J = 2.9, 1H), 8.89 (d, J = 2.4, 1H), 12.52 – 12.58 (m, 
2H). mp: 244-245°C. Spectral data and melting point are in accordance with literature 
reference.290 
 
5-Fluoro-1H-indole-3-carboxylic acid (5b) 
N
H
OH
O
F
 
The reaction was carried out according to General procedure 1 with the corresponding scale: 5-
fluoro-1H-indole (22.2 mmol, 3 g), TFAA (50 mmol, 7.1 mL), DMF (22 mL) then NaOH (300 mmol, 12 
g), water (70 mL). The title compound (20.0 mmol, 3.59 g) was isolated as a grey solid. Yield = 90 
%. Chemical formula: C9H6FNO2. Molecular weight: 179.15 g.mol-1. LC/MS (ESI): 95 % pure, m/z [M 
+ H]+: 180. 1H-NMR (300 MHz, DMSO-d6) δ = 7.03 (td, J = 2.6, 9.2, 1H), 7.48 (dd, J = 4.6, 8.9, 1H), 7.64 
(dd, J = 2.7, 10.0, 1H), 8.05 (d, J = 3.0, 1H), 11.99 (s, 1H). mp > 410°C.291 
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N-(2-Chloroethyl)methanesulfonamide (10a) 
Cl
N
H
S
O O  
To a slurry of 2-chloroethylamine hydrochloride (70 mmol, 8.12 g) in MeCN (150 mL) at 5°C was 
added dropwise and simultaneously Et3N (140 mmol, 19.7 mL) and MeSO2Cl (70 mmol, 5.42 mL) 
were also added during 30 min. After 30 min at 5°C, the mixture was slowly allowed to warm at RT 
and the stirring was pursued during 3h. The mixture became slightly orange. After removal of 
solvent, residue was taken off with water, the resulting aqueous phase was saturated with NaCl 
and extracted with CH2Cl2 (6 x 50 mL). The combined organic layers were dried on Na2SO4, 
filtered and the solvent was removed under vacuum to give a brown oil (5.87 g) which was 
purified on a normal phase silica gel column (cyclohexane/EtOAc: 6/4) to afford the title 
compound as a yellow oil which crystallized at -18°C (19.9 mmol, 3.13 g). Yield = 28 %. Chemical 
formula: C3H8ClNO2S. Molecular weight: 157.62 g.mol-1. LC/MS (ESI): not UV visible, m/z [M + H]+: 
not ionizable. 1H-NMR (300 MHz, CDCl3) δ = 3.02 (s, 3H), 3.49 (td, J = 5.2, 6.2, 2H), 3.68 (dd, J = 5.17, 
6.1, 2H), 4.80 (s, 1H). 
 
N-(2-Chloroethyl)benzenesulfonamide (10b) 
Cl
N
H
S
OO  
To a mixture of 2-chloroethylamine hydrochloride (43.1 mmol, 5 g) solubilized in CH2Cl2 (100 mL) 
and H2O (50 mL) at 10°C was added K2CO3 (43.1 mmol, 5.7 g) followed by chlorosulfonylbenzene 
(43.1 mmol, 5.5 mL). The reaction was stirred during 3h, with a temperature kept at 10±3°C and 
the pH value was maintained around 7-8 with K2CO3. The mixture was then allowed to warm up 
at RT for 2h. Layers were partitioned and aqueous one was extracted with CH2Cl2 (2 x 100 mL). 
After recrystallization in iPr2O (50 mL, 70°C then RT), the title compound was obtained as a white 
solid (28.9 mmol, 6.36 g). Yield = 67 %. Chemical formula: C8H10ClNO2S. Molecular weight: 219.69 
g.mol-1. LC/MS (ESI): 86 % pure at 254 nm, m/z [M + H]+: not ionizable. 1H-NMR (CDCl3, 300 MHz): δ 
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= 3.32 (q, J = 6.0, 2H), 3.56 (t, J = 6.0, 2H), 4.97 (br s, 1H), 7.51 – 7.64 (m, 3H), 7.87 – 7.89 (m, 2H). mp: 
70-72°C. Melting point is in accordance with lit. data (70°C).292 
 
(Piperidin-4-yl)methanol (13) 
NH
OH
 
A solution of ethyl isonipecotate (77.9 mmol, 12.24 g) in anhydrous THF (80 mL) was added 
dropwise under argon to an ice-cooled suspension of LiAlH4 (97.3 mmol, 3.69 g) in anhydrous THF 
(250 mL). After 30 min, the mixture was allowed to warm at room temperature and stirred for 20h. 
After treatment with water (4.8 mL), NaOH(aq) 1M (4.8 mL), and water (9.6 mL) the solution was 
stirred with diethyl ether (200 mL) for 30 min. The slurry was then filtered and washed with diethyl 
ether (3 x 100 mL). Solvents were removed under vacuum to afford the title compound as a 
colorless oil (77.9 mmol, 8.97 g). Yield = 100 %. Chemical formula: C6H13NO. Molecular weight: 
115.17 g.mol-1. LC/MS (ESI): not UV visible, m/z [M + H]+: 116.2. 1H-NMR (300 MHz, CDCl3) δ = 1.06 – 
1.22 (m, 2H), 1.61 (s, 1H), 1.67 – 1.77 (m, 2H), 2.00 (s, 3H), 2.60 (td, J = 2.6, 12.2, 2H), 3.03 – 3.16 (m, 
2H), 3.44 – 3.47 (m, 2H). Spectral data are in accordance with lit. data.264 
 
N-[2-[4-(Hydroxymethyl)-1-piperidinyl]ethyl]methylsulphonamide (14a) 
N
OH
N
H
S
O O
 
To an ice-cooled solution of (piperidin-4-yl)methanol (67.7 mmol, 7.8 g) in MeCN (70 mL) was 
added dropwise a N-(2-chloroethyl)methanesulfonamide (54.1 mmol, 8.45 g) solution in MeCN 
(50 mL). After the end of the addition, the mixture was allowed to warm at RT and stirred over 2 
days. Then a 4 % aqueous solution of NaOH (200 mL) was added dropwise. The mixture was 
extracted with CH2Cl2 (6 x 100 mL) and the combined organic layers were dried on MgSO4 and 
then filtered. After solvent removal, a yellow oil was obtained and was further purified by normal 
phase silica gel column (CH2Cl2/EtOH: 5/5) to afford the title compound as a yellow oil (16.2 
mmol, 3.8 g). Yield = 30 %. Chemical formula: C9H20N2O3S. Molecular weight: 236.34 g.mol-1. 
LC/MS (ESI): not UV visible, m/z [M + H]+: not ionizable. 1H-NMR (300 MHz, CDCl3) δ = 1.20 (t, J = 7.0, 
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2H), 1.51 (s, 1H), 1.69 – 1.77 (m, 2H), 1.97 – 2.06 (m, 2H), 2.45 – 2.57 (m, 2H), 2.87 (d, J = 11.6, 2H), 
2.96 (s, 3H), 3.10 – 3.25 (m, 2H), 3.49 (d, J = 6.3, 2H). Spectral data are in accordance with lit. 
data.265 
 
N-[2-[4-(Hydroxymethyl)-1-piperidinyl]ethyl]phenylsulphonamide (14b) 
N
OH
N
H
S
O O
 
To a solution of piperidin-4-ylmethanol (17.4 mmol, 2 g) in MeCN (50 mL) were added DIPEA (35 
mmol, 6.1 mL) and N-(2-chloroethyl)benzenesulfonamide (17.4 mmol, 3.82 g). The mixture was 
heated at reflux under argon for 3h. The solvent was evaporated under reduced pressure to give 
a white solid which was washed with water (2 x 75 mL) to give the title compound as a white 
solid (13.2 mmol, 3.95 g). Yield = 76 %. Chemical formula: C14H22N2O3S. Molecular weight: 298.41 
g.mol-1. LC/MS (ESI): 95 %, m/z [M + H]+: 299.3. 1H-NMR (300 MHz, DMSO-d6) δ = 1.25 (d, J = 14.5, 
2H), 1.50 – 1.62 (m, 2H), 1.69 – 1.97 (m, 2H), 2.33 (s, 2H), 2.73 (d, J = 9.6, 2H), 2.86 (t, J = 6.9, 2H), 
3.19 (dd, J = 3.8, 6.2, 2H), 4.40 (d, J = 6.0, 1H), 7.61 (qdd, J = 1.9, 3.6, 8.8, 4H), 7.81 (dd, J = 1.7, 8.0, 
2H). 
(1-(2-(Methylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-1H-indole-3-carboxylate 
hydrochloride (15a) 
N
H
O
O
N
F
NHSO
2
Me
.HCl
 
General procedure 2 for the preparation of (1-(2-(Phenyl-/methyl-sulfonamido)ethyl)piperidin-4-
yl)methyl 1H-indole-3-carboxylate 
Thionyl chloride (5.6 mmol, 406 µL) was slowly added to a suspension of 5-fluoro-1H-indole-3-
carboxylic acid (1.12 mmol, 200 mg) in dry CH2Cl2 (10 mL) under argon, then the mixture was 
heated at reflux for 24h. After removal of the volatiles under reduced pressure, the residue was 
immediately put under argon atmosphere then taken off with dry CH2Cl2 (10 mL) and N-[2-[4-
(hydroxymethyl)-1-piperidinyl]ethyl]methylsulphonamide (1.10 mmol, 260 mg) was added. The 
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resulting mixture was heated at reflux under argon for 24h. After removal of the solvent under 
vacuum, the resulting brown solid was taken off with water (50 mL) and then the aqueous layer 
was saturated with NaCl and extracted with CH2Cl2 (5 x 50 mL). The combined organic layers 
were washed with brine, dried on Na2SO4, filtered and solvents were removed under vacuum. 
The resulting grey solid was purified on a 20 g normal phase silica column with eluent 
(CH2Cl2/MeOH 90/10 to 75/25) to afford the product as brown foam (0.34 mmol, 134 mg). Yield = 
30 %. The product was directly engaged in the next step.293 
General procedure 3 for the preparation of hydrochloride acid salt 
To a solution of (1-(2-(methylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-1H-indole-3-
carboxylate (0.16 mmol, 62 mg) in MeOH (3 mL) was slowly added acetyl chloride (0.48 mmol, 34 
µL). After removal of solvent under reduced pressure, the residue was taken off with CHCl3 (3 x 5 
mL) and evaporated 3 times then with Et2O (3 x 5 mL) to afford the title compound as a solid 
(0.16 mmol, 73 mg). Yield = quantitative. Chemical formula: C18H25FClN3O4S. Molecular weight: 
433.93 g.mol-1. LCMS (ESI): (2012/02/22) 96 % pure at 254 nm, m/z [M + H]+: 398.2. HRMS (ESI) m/z: 
calcd. for C18H26FClN3O4S: 398.1544; [M+H]+ found: 398.1536. 1H-NMR (400 MHz, DMSO-d6) δ = 
12.24 (s, 1H), 10.61 (s, 1H), 8.27 – 8.18 (m, 1H), 7.62 (dd, J = 2.8, 9.8, 1H), 7.51 (dd, J = 4.6, 9.1, 2H), 
7.06 (td, J = 2.7, 9.2, 1H), 4.23 – 4.07 (m, 2H), 3.53 (s, 3H), 3.15 (s, 2H), 2.98 (s, 3H), 2.11 – 1.84 (m, 
4H), 1.76 (d, J = 13.1, 2H), 1.35 (d, J = 5.8, 2H). 13C NMR (101 MHz, DMSO-d6) δ = 25.7, 26.7, 30.4, 
33.0, 34.4, 37.2, 51.7, 55.7, 66.2, 105.2, 106.4, 110.8, 113.8, 126.3, 133.1, 157.1, 159.5, 164.0. 
(1-(2-(Methylsulfonamido)ethyl)piperidin-4-yl)methyl 1H-indole-3-carboxylate (15b) 
N
H
O
O
N
NHSO
2
Me
 
The reaction was carried out according to the general procedure 2 with the corresponding 
scale: 1H-indole-3-carboxylic acid (1.67 mmol, 270 mg), SOCl2 (8.35 mmol, 606 µL), CH2Cl2 (10 mL), 
then N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]methylsulphonamide (1.58 mmol, 373 mg), 
CH2Cl2 (10 mL). The crude was purified without work-up on a normal phase silica gel 
chromatography (CH2Cl2/MeOH 90/10) to afford the title compound as brown foam (0.83 mmol, 
313 mg). Yield = 50 %. Chemical formula: C18H25N3O4S. Molecular weight: 379.48 g.mol-1. LCMS 
(ESI): 98 % pure, m/z [M + H]+: 380.2. HRMS (ESI) m/z: calcd. for C18H26N3O4S: 380.1639; [M+H]+ 
found: 380.1629. 1H NMR (400 MHz, DMSO-d6) δ = 1.75 (s, 2H), 1.83 – 1.94 (m, 2H), 1.93 – 2.05 (m, 
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1H), 2.92 (s, 2H), 2.97 (s, 3H), 3.07 (q, J = 7.7, 8.1, 2H), 4.14 (d, J = 5.9, 2H), 7.14 – 7.26 (m, 2H), 7.41 – 
7.54 (m, 2H), 7.96 – 8.02 (m, 1H), 8.15 (d, J = 3.0, 1H), 10.81 (s, 1H), 12.14 (d, J = 3.1, 1H).13C NMR 
(101 MHz, DMSO-d6) δ = 18.6, 33.2, 37.6, 38.9, 40.1, 40.2, 51.8, 56.0, 66.2, 106.2, 107.0, 112.4, 116.1, 
120.4, 121.4, 122.4, 125.6, 132.8, 136.5, 164.4. 
 
(1-(2-(Phenylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-1H-indole-3-carboxylate 
hydrochloride (15c) 
N
H
O
O
N
NHSO
2
Ph
F
.HCl
 
The reaction was carried out according to to the general procedure 2 with the corresponding 
scale: 5-fluoro-1H-indole-3-carboxylic acid (1.67 mmol, 300 mg), SOCl2 (8.35 mmol, 605 µL), CH2Cl2 
(10 mL), then N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]phenylsulphonamide (1.67 mmol, 498 
mg), CH2Cl2 (10 mL). For the purification, a normal phase silica gel column (CH2Cl2/EtOH/NH3(aq) 
95.5/4/0.5) was used to afford the product as a brown foam (0.65 mmol, 299 mg). Yield = 39 %. 
LC/MS (ESI): 86 % pure, m/z [M + H]+: 460.2 The product was directly engaged in the next step. 
The reaction was carried out according to the general procedure 3 with the corresponding 
scale: (1-(2-(phenylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-1H-indole-3-carboxylate (0.28 
mmol, 131 mg), MeOH (3 mL), acetyl chloride (0.86 mmol, 61 µL). After removal of solvent under 
reduced pressure, residue was washed with diethyl ether (3 x 3 mL). MeOH (3 mL) was added 
onto the resulting solid (120 mg) and heated at reflux for 15 min. The insoluble part was 
separated and washed with diethyl ether (2 x 3 mL). This operation was repeated two times to 
obtain the title compound as a white solid (64 mg, 0.13 mmol). Yield = 46 %. Chemical formula: 
C23H28FN3O4S. Molecular weight: 496.00 g.mol-1. LC/MS (ESI): 98 % pure at 254 nm, m/z [M + H]+: 
460.2. HRMS (ESI) m/z: calcd. for C23H29FN3O4S: 460.1701 [M+H]+; found: 460.1704. 1H-NMR (400 
MHz, DMSO-d6) δ = 1.74 (tt, J = 7.1, 13.6, 2H), 1.89 (d, J = 13.6, 2H), 1.93 – 2.07 (m, 1H), 2.97 (q, J = 
11.3, 2H), 3.07 – 3.27 (m, 5H), 3.40 – 3.54 (m, 2H), 4.13 (d, J = 5.9, 2H), 7.06 (td, J = 2.7, 9.2, 1H), 7.50 
(dd, J = 4.6, 8.9, 1H), 7.58 – 7.72 (m, 4H), 7.85 (dd, J = 1.8, 7.0, 2H), 8.18 (d, J = 5.6, 1H), 8.23 (d, J = 
3.1, 1H), 10.53 (s, 1H), 12.24 (d, J = 3.4, 1H). 13C NMR (101 MHz, DMSO-d6) δ = 25.5, 32.8, 37.1, 40.2, 
48.6, 51.6, 55.3, 66.1, 105.0, 105.2, 106.3, 106.4, 110.6, 110.8, 113.7, 113.8, 126.2, 126.3, 126.6, 126.6, 
129.4, 132.8, 133.1, 134.4, 139.7, 157.1, 159.4, 164.0. mp: 227-228°C 
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(1-(2-(Phenylsulfonamido)ethyl)piperidin-4-yl)methyl 5-nitro-1H-indole-3-carboxylate (15d) 
N
H
O
O
O
2
N
N
NHSO
2
Ph
 
The reaction was carried out according to the general procedure 2 with the corresponding 
scale: 5-nitro-1H-indole-3-carboxylic acid (1.45 mmol, 300 mg), SOCl2 (7.25 mmol, 526 µL), CH2Cl2 
(10 mL), then N-[2-[4-(hydroxymethyl)-1-piperidinyl]ethyl]phenylsulphonamide (1.45 mmol, 432 
mg), CH2Cl2 (10 mL). After the work-up, the resulting brown solid (512 mg) was taken off with 
MeOH (25 mL) and the insoluble part was removed by filtration. After removal of solvents, the 
resulting yellow solid was washed with EtOAc (3 x 20 mL) and Et2O (2 x 20 mL) to afford the title 
compound as a yellow solid (0.385 mmol, 187 mg). Yield = 26 %. Chemical formula: C23H26N4O6S. 
Molecular weight: 486.55 g.mol-1. LC/MS (ESI): 90 % pure, m/z [M + H]+: 487.2. HRMS (ESI) m/z: 
calcd. for C23H27N4O6S: 487.1646 [M+H]+; found: 487.1628. 1H-NMR (300 MHz, DMSO-d6) δ = 1.49 (s, 
2H), 1.83 (d, J = 13.4, 3H), 2.73 (t, J = 2.0, 2H), 3.01 (s, 4H), 4.17 (d, J = 6.0, 2H), 7.57 – 7.72 (m, 4H), 
7.83 (dd, J = 1.7, 8.0, 2H), 8.11 (dd, J = 2.4, 9.0, 1H), 8.40 (s, 1H), 8.86 (d, J = 2.3, 1H), 12.66 (s, 1H). 
13C NMR (101 MHz, DMSO-d6) δ = 26.4, 51.9, 67.0, 108.4, 113.3, 116.9, 117.8, 125.0, 126.6, 129.3, 
132.6, 136.3, 139.6, 140.1, 142.4, 163.5. mp: 201-202°C. 
 
 (1-(2-(Phenylsulfonamido)ethyl)piperidin-4-yl)methyl 1H-indole-3-carboxylate (15e) 
N
H
O
O
N
NHSO
2
Ph
 
The reaction was carried out according to the general procedure 2 with the corresponding 
scale: SOCl2 (4.65 mmol, 337 µL), 1H-indole-3-carboxilic acid (0.93 mmol, 150 mg), dry CH2Cl2 (10 
mL), N-{2-[4-(hydroxymethyl)piperidin-1-yl]ethyl}benzenesulfonamide (1.12 mmol, 333 mg). The 
resulting grey solid was purified on a 20 g normal phase silica column with eluent CH2Cl2/MeOH 
95/5 to give oil (154 mg) containing the product. This fraction was further purified on a 40 g 
normal phase silica column with eluent CH2Cl2/MeOH 97/3 to give the title compound as a white 
solid (0.068 mmol, 30 mg). Yield = 7 %. Chemical formula: C23H27N3O4S. Molecular weight: 441.55 
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g.mol-1. LC/MS (ESI): 80 % pure, m/z [M + H]+: 442.2. 1H-NMR (300 MHz, DMSO-d6) δ = 1.24 (d, J = 
9.1, 2H), 1.66 (d, J = 11.4, 3H), 1.87 (t, J = 11.1, 2H), 2.28 (t, J = 6.8, 2H), 2.72 (d, J = 10.6, 2H), 2.85 (t, 
J = 6.9, 2H), 4.07 (d, J = 5.9, 2H), 7.15 – 7.22 (m, 2H), 7.45 – 7.50 (m, 1H), 7.52 – 7.68 (m, 3H), 7.77 – 
7.85 (m, 2H), 7.94 – 8.00 (m, 1H), 8.07 (s, 1H), 11.94 (s, 1H). 
 
(1-(2-(Phenylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-2-methoxy-1H-indole-3-
carboxylate hydrochloride (16) 
N
H
O
O
N
F
O
NHSO
2
Ph
.HCl
 
To a solution of (1-(2-(phenylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-1H-indole-3-
carboxylate (0.32 mmol, 148 mg) in dry CHCl3 (7 mL) was added N-chlorosuccinimide (0.39 mmol, 
52 mg). The mixture was heated at reflux under argon for 4h. After removal of solvent under 
reduced pressure, the residue was taken off with MeOH (10 mL) and heated at reflux under 
argon for 12h. After removal of solvent under vacuum, the resulting brown foam (207 mg) was 
purified on a normal phase silica gel column (CH2Cl2/MeOH 9/1) to afford the product as brown 
foam (0.22 mmol, 109 mg). Yield = 56 %. LC/MS (ESI): 99 % pure at 254 nm, m/z [M + H]+: 490.2. The 
product was directly engaged in the next step. 
The reaction was carried out according to the general procedure 3 with the corresponding 
scale: (1-(2-(phenylsulfonamido)ethyl)piperidin-4-yl)methyl 5-fluoro-2-methoxy-1H-indole-3-
carboxylate (0.22 mmol, 109 mg), MeOH (3 mL), acetyl chloride (0.70 mmol, 50 µL). The crude oil 
was dissolved in boiling methanol (3 mL) and then cooled to -18°C overnight. A white precipitate 
occurred. After removal of MeOH, the resulting solid was washed with methanol (1 x 2 mL) and 
with diethyl ether (3 x 2 mL). MeOH (3 mL) was added to the resulting solid and heated at reflux 
for 15 min. The insoluble part was separated and then washed with diethyl ether (2 x 3 mL). This 
purification was repeated once to give the title compound as a white solid (0.07 mmol, 38 mg). 
Yield = 33 %. Chemical formula: C24H29FClN3O5S. Molecular weight: 526.03 g.mol-1. LC/MS (ESI): 99 
% pure at 254 nm, m/z [M + H]+: 490.2. HRMS (ESI) m/z: calcd. for C24H30FClN3O5S: 490.1806; [M+H]+ 
found: 498.1800. 1H-NMR (400 MHz, DMSO-d6) δ = 1.54 – 1.69 (m, 2H), 1.88 (d, J = 12.9, 2H), 1.97 (s, 
1H), 2.96 (q, J = 11.2, 2H), 3.11 (t, J = 5.6, 2H), 3.16 (s, 1H), 3.18 (d, J = 6.3, 2H), 3.40 (s, 2H), 3.48 (d, J 
= 12.0, 2H), 4.07 (d, J = 6.4, 2H), 4.11 (s, 3H), 6.88 (ddd, J = 2.7, 8.6, 9.6, 1H), 7.30 (dd, J = 4.7, 8.7, 
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1H), 7.45 (dd, J = 2.7, 10.2, 1H), 7.59 – 7.71 (m, 3H), 7.82 – 7.88 (m, 2H), 8.16 (t, J = 5.9, 1H), 10.42 (d, 
J = 67.8, 1H), 12.27 (s, 1H). 13C NMR (101 MHz, DMSO) δ = 25.8, 33.0, 37.1, 38.9, 39.1, 39.3, 39.5, 39.6, 
39.7, 39. 8, 39.9, 40.0, 40.2, 40.2, 48.6, 51.6, 55.4, 58.8, 65.6, 86.5, 86.5, 104.6, 104.9, 107.8, 108.1, 
112.1, 112.2, 126.6, 126.9, 127.1, 127.2, 129.4, 132.8, 139.7, 157.2, 158.5, 159.5, 163.2. mp: 195-196°C. 
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6.2 Biology 
 
6.2.1 Biology of the chapter 3.1 
 
Radiometric kinase assays  
CK2 radiometric kinase assay was performed as previously described in Prudent et al. 151. 
Production and purification of GST-rhCK2α mutants were performed as described in the paper of 
Moucadel et al. 150 and inhibitors were tested following the CK2 radiometric kinase assay 
procedure. ATP concentrations were 100 µM if not stated otherwise. Substrate dependent 
phosphorylation assays on nucleolin, Six1 and CK2β auto-phosphorylation were performed 
following the CK2 radiometric kinase assay with CK2α2β2, the reaction was quenched by 
Laemmli buffer and samples were submitted to electrophoresis in NuPAGE buffer (150 V for 75 
min) using pre-cast 4-12 % gradient gel (Bio-Rad). Proteins were stained using Coomassie blue 
(InstantBlueTM, Expedeon, Cambridfgeshire, UK) and phosphorylation status measured using a 
phosphorimager PMI (BIO-RAD) and quantified with ImageJ. 
Temperature-dependent circular dichroism (TdCD) 
All single Far-UV-CD spectra were recorded using a Jasco-1500 spectropolarimeter (Gross-
Umstadt, Germany). All spectra were recorded using a 1 mm path-length quartz cell, 1 nm 
bandwidth, 100 nm/min scan speed and 3 accumulations, within a wavelength range of 195 to 
250 nm. GST-CK2α protein was diluted at 5 µM with 10 mM KH2PO4 and 50 mM Na2SO4, pH 7.4. 
Ligand binding was tested at 50 µM for compound 5, 6.25 µM for compound 7 and 6.25 µM for 
CX-4945 with a final methanol concentration of 0.8 % (v/v). Compound 7 and CX-4945 
concentrations were limited by their solubility in the methanol stock. Spectra in absence of 
protein were recorded and subtracted from the experimental spectra. Temperature ramping 
experiments were performed from 20 °C to 86 °C, and prior to each recording point, the sample 
was allowed to equilibrate for 30 sec at ± 0.1 °C from the desired temperature. Midpoint 
unfolding temperatures (Tm) were determined using Thermal Denaturation multi-Analysis 
software.  
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Protein-ligand interactions by NMR 
NMR experiments were recorded on a 600 MHz spectrometer at 293 K in PBS pH 7.3, 10 mM NaCl, 
MgCl2 2 mM, 10 % D2O. 1D experiments were performed using a excitation sculpting pulse 
sequence. Saturation Transfer Difference was performed with on-resonance protein saturation at 
0.6 ppm using 2 s saturation time. 7-azaindole was used as a reference compound to test the 
STD-competition with CX-4945. STD experiments were performed using 5 µM CK2α protein in the 
presence of 4 mM MgCl2. STD factors were measured as previously reported 221, and the values 
were normalized by assigning the value 100 % to the highest STD factor. Concentrations of the 
molecules AMP-PNP, 7-azaindole and compound 5 were 500 µM, and concentration of CX-4945 
was 100 µM. 
 
Molecular modeling and docking 
Structures of the catalytic subunit of the human CK2 enzyme were retrieved from the Pocketome 
database 287. Including the multiple chains within each structure, there was a total of 72 
structures. Candidate ligand docking locations were delineated as shown in figure 3, one 
comprising the canonical ATP binding site, and another the proposed allosteric binding site. Prior 
to docking, the kinase structures were completed by rebuilding and optimization of the missing 
side-chains and the hydrogen atoms in the presence of co-crystallized ligands (if any). 
Compounds 1-7 presented here, as well as ATP and CX-4945 were docking to each of the two 
sites in each of the available structures using ICM (Molsoft L.L.C.) 288 (The ICM docking procedure 
and scoring are presented in the supporting procedures). 
Top ranking predicted ligand poses were inspected manually, taking into account the pose 
consistency between multiple compounds in the series as well as interactions with the residues 
highlighted by site-directed mutagenesis. From this analysis, it became clear that the backbone 
conformation with the largest distance between the αC-helix and the middle β-strand of the N-
terminal lobe is most compatible with the proposed model of binding. Based on this 
consideration, PDB 3JUH was selected as a backbone template for further studies. Val66Ala and 
Met163Leu mutations in the ATP binding pocket of this structure were reverted back to their wild-
type amino-acids. Residue side-chains in the allosteric pocket were conformationally optimized 
in the presence of docked compounds to resemble pocket shape observed in PDB 3FWQ. The 
optimized model was used for the second round of compound docking using the ICM grid 
potential based protocol described in the supporting procedures. Top-ranking poses of 
compounds (including CX-4945 and ATP) from this round are presented. 
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ICM docking procedure 
The ICM docking engine predicts ligand poses by stochastic global optimization of the flexible 
ligand molecule (represented in internal coordinates) inside a set of pre-calculated grid 
potential maps representing the binding pocket of the receptor 289–291 and including (i) van der 
Waals (represented as Lennard-Jones potential for hydrogen, carbon and “large atom” probes); 
(ii) electrostatic potential (calculated by the Coulomb formula with the distance-dependent 
dielectric constant of 4r); (iii) hydrogen bonding potential combining the donor and acceptor 
fields; (iv) apolar surface energy. Prior to sampling, multiple starting poses of the ligand were 
generated by exhaustively sampling the ligand in vacuo and overlaying each of the resulting 
conformations onto the binding pocket in four principal orientations. The sampling phase was 
performed using biased probability Monte Carlo optimization 288 of rotational, translational, and 
torsional variables of the ligandin an attempt to achieve the global minimum of the objective 
energy function that combines ligand interactions with the receptor grid potentials and the 
explicit (full-atom) interactions within the ligand itself (“ligand strain”). Top-ranking predicted 
poses of the ligand were combined with the full-atom representation of the receptor pocket and 
evaluated with ICM ligand binding score 292 calculated as Sbind = Eint + TΔSTor + Evw + 1 Eel + 
2Ehb + 3 Ehp + 4 Esf. Here Evw, Eel, Ehb, Ehp, and Esf are Van der Waals, electrostatic, hydrogen 
bonding, non-polar and polar atom solvation energy differences between bound and unbound 
states, Eint is the ligand internal strain, ΔSTor is its conformational entropy loss upon binding, T = 300 
K, and i are ligand- and protein-independent constants that have been previously optimized on 
a diverse screening benchmark. 
Cell culture  
The human kidney carcinoma cell line (786-O) was cultured in RPMI 1640 medium (Gibco) 
supplemented with 10 % (v/v) fetal calf serum, penicillin (100 U/mL) and streptomycin (100 
µg/mL) at 37 °C in 5 % CO2 atmosphere. Experiments were performed in RPMI 1640 (GIBCO) 
supplemented with 0.1 % or 0.5 % (v/v) fetal serum, penicillin (100 U/mL) and streptomycin (100 
µg/mL) 37 °C in 5 % CO2 atmosphere. 
Cell viability assay 
Cells were plated into 96-well plates at 1 x 104 cells/well. The following day, the culture medium 
was replaced with fresh medium containing the inhibitors at various concentrations. DMSO (0.25 
%) and cell free wells were used as control. After 24 h, 50 µL of (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (MTT) solution in PBS (5 mg/mL) were added in each well and the 
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plate incubated for 2 h at 37 °C in 5 % CO2 atmosphere. Then, 80 µL of SDS (10 %) containing 0.01 
M HCl were added in each well and gently stirred at RT for 4 h. Absorbance was measured at 
570 nm with a microplate reader (Infinite 200 Pro, Tecan). Results are the average of a triplicate 
experiment with a standard deviation lower than 10 %. EC50 was determined by linear 
interpolation after transformation to log[c] scale. 
CK2 inhibition in cells 
Cells were plated into 6-well plates at 3 x 105 cells/well. The following day, the culture medium 
was replaced with fresh medium containing the inhibitors at various concentrations or DMSO (0.5 
%) as reference. After incubation for 24 h, medium was removed, cells were washed with cold 
PBS and frozen at - -catenin 
and Akt1) was measured by Western Blot analysis of cell extracts. 
Western Blot analysis 
Primary antibodies were α-catenin (phospho-Ser641) antibody from SAB Signalway Antibody, 
Akt1-(phosphor-Ser129) antibody from Abgent, anti-GAPDH mAb from Ambion. Secondary 
antibodies were peroxidase-conjugated affinity pure Goat anti-rabbit IgG (#111035003) and 
peroxidase-conjugated affinity pure Goat anti-mouse IgG (#115035003) from Jackson Immuno 
Research. Cells were lysed in RIPA buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 % Triton X-100, 
0.1 % SDS, 0.5 % DOC and 1 mM EDTA) containing both protease- and phosphatase-inhibitor 
cocktails (Sigma-Aldrich; P8340, P2850, P5726). Cell homogenates were quantified using BCA 
protein Assay kit (Thermo Scientific). SDS-PAGE was performed using pre-cast 4-12 % gradient gel 
(Bio-Rad) and submitted to electrophoresis in NuPAGE buffer (150 V for 75 min). Separated 
proteins at 20 µg/lane were transferred to PVDF membranes (100 V for 60 min). Blotted 
membranes were blocked during 1 h at room temperature with saturation buffer (1 % BSA in Tris 
Buffer Saline 10 mM, Tween 0.1 % (TBST)), and then incubated with primary antibody diluted in 
saturation buffer, for 2 h or overnight. After 3 washes with TBST, secondary antibodies were 
added for 1 h. Luminata Forte Western HRP substrate (Millipore) was added and membranes 
were read with Fusion Fx7 (PerkinElmer). Anti-GAPDH was used as loading control. Images were 
analyzed and band intensities were quantified using ImageJ software. EC50 were determined by 
fitting band intensities in function of inhibitor concentration to a sigmoid equation using 
SigmaPlot. 
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Cell transfection and imaging 
The cDNA encoding GFP-CK2α was subcloned from pEGFP-CK2α vector 245 into pMSCV-puro 
plasmid. Viral particles were produced and stable expression of EGFP-CK2α was accomplished 
by transfection of 786-O cells followed by 1 µg/ml puromycin–mediated selection. 786-O pEGFP-
CK2α cells were seeded on Lab-TekTM slides. After treatment with DMSO, compound 7 (40 µM) or 
CX-4945 (8 µM) for 12 h, cells were washed twice with PBS and fixed with 4 % paraformaldehyde 
for 10 min at 20 °C. Nuclei were stained with Hoechst-33342 (Sigma-Aldrich) for 30 min and cells 
were washed with PBS (3 x 15 min). Images were acquired with a Zeiss ApoTome microscope and 
analyzed using Zen software. Fluorescence intensity, exposure times and post-acquisition 
modifications were kept identical for all the samples. 
Screening of compound selectivity against a kinase panel 
Kinase selectivity of compound 1 and 7 were assessed using the Kinase Profiler service offered by 
Life Technologies. The assays were performed with ATP concentration adjusted to the respective 
Km of each kinase in the presence of 50 μM inhibitor. Inhibition, expressed as the percent of 
activity determined in the absence of inhibitor, was calculated from the residual activity 
measured in the presence of 50 μM inhibitor. 
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6.2.2 Biology of the chapter 3.2 
Radiometric kinase assays  
CK2 radiometric kinase assay was performed as previously described in Prudent et al.151 
Production and purification of GST-rhCK2α mutants were performed as described in the paper of 
Moucadel et al.150 and inhibitors were tested following the CK2 radiometric kinase assay 
procedure. ATP concentrations were 100 µM if not stated otherwise.  
Cell culture  
The human kidney carcinoma cell line (786-O) was cultured in RPMI 1640 medium (Gibco) 
supplemented with 10% (v/v) fetal calf serum, penicillin (100 U/mL) and streptomycin (100 µg/mL) 
at 37 °C in 5% CO2 atmosphere. Experiments were performed in RPMI 1640 (GIBCO) 
supplemented with 0.1% or 0.5% (v/v) fetal serum, penicillin (100 U/mL) and streptomycin (100 
µg/mL) 37 °C in 5% CO2 atmosphere. 
Cell viability assay 
Cells were plated into 96-well plates at 1 x 104 cells/well. The following day, the culture medium 
was replaced with fresh medium containing the inhibitors at various concentrations. DMSO 
(0.25%) and cell free wells were used as control. After 24 h, 50 µL of (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) (MTT) solution in PBS (5 mg/mL) were added in each well and 
the plate incubated for 2 h at 37 °C in 5 % CO2 atmosphere. Then, 80 µL of SDS (10%) containing 
0.01 M HCl were added in each well and gently stirred at RT for 4 h. Absorbance was measured 
at 570 nm with a microplate reader (Infinite 200 Pro, Tecan). Results are the average of a 
triplicate experiment with a standard deviation lower than 10%. EC50 was determined by linear 
interpolation after transformation to log[c] scale. 
CK2 inhibition in cells 
Cells were plated into 6-well plates at 3 x 105 cells/well. The following day, the culture medium 
was replaced with fresh medium containing the inhibitors at various concentrations or DMSO 
(0.5%) as reference. After incubation for 24 h, medium was removed, cells were washed with 
cold PBS and frozen at -80°C. The phosphorylation status of two protein substrates of CK2 (α-
catenin and Akt1) was measured by Western Blot analysis of cell extracts. 
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Western Blot analysis 
Primary antibodies were α-catenin (phospho-Ser641) antibody from SAB Signalway Antibody, 
Akt1-(phosphor-Ser129) antibody from Abgent, anti-GAPDH mAb from Ambion, anti-Akt1, anti-α-
catenin, anti-PARP, anti-survivin. Secondary antibodies were peroxidase-conjugated affinity pure 
Goat anti-rabbit IgG (#111035003) and peroxidase-conjugated affinity pure Goat anti-mouse 
IgG (#115035003) from Jackson Immuno Research. Cells were lysed in RIPA buffer (10 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% DOC and 1 mM EDTA) containing both 
protease- and phosphatase-inhibitor cocktails (Sigma-Aldrich; P8340, P2850, P5726). Cell 
homogenates were quantified using BCA protein Assay kit (Thermo Scientific). SDS-PAGE was 
performed using pre-cast 4-12% gradient gel (Bio-Rad) and submitted to electrophoresis in 
NuPAGE buffer (150 V for 75 min). Separated proteins at 20 µg/lane were transferred to PVDF 
membranes (100 V for 60 min). Blotted membranes were blocked during 1 h at room 
temperature with saturation buffer (1 % BSA in Tris Buffer Saline 10 mM, Tween 0.1% (TBST)), and 
then incubated with primary antibody diluted in saturation buffer, for 2 h or overnight. After 3 
washes with TBST, secondary antibodies were added for 1 h. Luminata Forte Western HRP 
substrate (Millipore) was added and membranes were read with Fusion Fx7 (PerkinElmer). Anti-
GAPDH was used as loading control. Images were analyzed and band intensities were quantified 
using ImageJ software. 
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6.2.3 Biology of the chapter 3.3 
 
Cell culture  
The human kidney carcinoma cell line (786-O) was cultured in RPMI 1640 medium (Gibco) 
supplemented with 10 % (v/v) fetal calf serum, penicillin (100 U/mL) and streptomycin (100 
µg/mL) at 37°C in 5 % CO2 atmosphere. MCF10A and MCF10A-Δβ cells were cultured as 
described 293. HeLa cells were cultured in DMEM with 10 % (v/v) fetal calf serum, penicillin (100 
U/mL) and streptomycin (100 µg/mL) at 37°C in 5 % CO2 atmosphere. 
Monitoring of the CK2α/CK2β interaction in cells 
HeLa cells were seeded on Lab-TekTM. After treatment with DMSO, TAT-Pc (30 µM) or CX-4945 (12 
µM) for 6h, cells were washed twice with PBS and fixed with 4 % paraformaldehyde for 10 min at 
20° C, followed by permeabilization with 0.5% Triton X100. CK2α/CK2β interactions in cells were 
measured following the procedure of the DuoLinkTM kit (Olink Bioscience). Images were acquired 
with a Zeiss ApoTome microscope and analyzed using Zen software. Quantification was 
performed using the BlobFinder software 250.  
Cell immunostaining and imaging 
786-O, MCF10A or MCF10A-Δβ cells were seeded on Lab-TekTM. After treatment with DMSO, TAT-
Pc (30 µM) or CX-4945 (12 µM) for 12h, cells were washed twice with PBS and fixed with 4 % 
paraformaldehyde for 10 min at 20° C followed by permeabilization with 0.5% Triton X100. The 
following primary antibodies were diluted in TBS containing 0.1% Tween20. They were purchased 
from Santa Cruz Biotechnology for anti-CK2α sc6479 (1/200); anti-CK2β (6D5) sc-12739 (1/200); 
anti-CK2α′ (C-20) sc-6481 (1/200); anti-EGFR (1005) sc-03 (1/200); anti-p21 (C-19) sc-397 (1/200); 
and from BD Pharmingen™ for Anti-Human CD107a (LAMP1) Clone H4A3 (RUO) (1/500).  Cells 
were washed with PBS (3 x 15 min) and the secondary antibodies were Cy3-labeled donkey-anti-
goat, Dy649-labeled donkey-anti-mouse IgG, and Cy3-labeled goat-anti-rabbit IgG. Nuclei were 
stained with Hoechst-33342 (Sigma-Aldrich) for 30 min and cells were washed with PBS (3 x 15 
min). Images were acquired with a Zeiss ApoTome microscope and analyzed using Zen software. 
Fluorescence intensity, exposure times and post-acquisition modifications were kept identical for 
all the samples. 
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Cell viability assay 
Cells were plated into 96-well plates at 1 x 104 cells/well. The following day, the culture medium 
was replaced with fresh medium (90 µL) containing the inhibitors at various concentrations. 
DMSO (0.25 %) and cell free wells were used as control. After 24 h, 10 µL of PrestoBlue® solution 
were added in each well and the plate incubated for 1 h at 37° C in 5 % CO2 atmosphere. 
Results are the average of a triplicate experiment with a standard deviation lower than 10 %. 
Western Blot analysis 
Cells were plated into 6-well plates at 3 x 105 cells/well. The following day, the culture medium 
was replaced with fresh medium containing the inhibitors at various concentrations or DMSO (0.5 
%) as reference. After incubation for 48 h, medium was removed, cells were washed with cold 
PBS and frozen at -80°C. Primary antibodies were α-catenin (phospho-Ser641) antibody from SAB 
Signalway Antibody, anti-α-catenin, Akt1-(phosphor-Ser129) antibody from Abgent, anti-Akt1-
(phosphor-Ser473), anti-Akt1, anti-p21, anti-p21-(phosphor-Thr145), anti-GAPDH mAb from 
Ambion, anti-SNAIL1 from Cell signaling, anti-HSP90. Secondary antibodies were peroxidase-
conjugated affinity pure Goat anti-rabbit IgG (#111035003) and peroxidase-conjugated affinity 
pure Goat anti-mouse IgG (#115035003) from Jackson Immuno Research. Cells were lysed in 
RIPA buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 % Triton X-100, 0.1 % SDS, 0.5 % DOC and 1 mM 
EDTA) containing both protease- and phosphatase-inhibitor cocktails (Sigma-Aldrich; P8340, 
P2850, P5726). Cell homogenates were quantified using BCA protein Assay kit (Thermo Scientific). 
SDS-PAGE was performed using pre-cast 4-12 % gradient gel (Bio-Rad) and submitted to 
electrophoresis in NuPAGE buffer (150 V for 75 min). Separated proteins at 20 µg/lane were 
transferred to PVDF membranes (100 V for 60 min). Blotted membranes were blocked during 1 h 
at room temperature with saturation buffer (1 % BSA in Tris Buffer Saline 10 mM, Tween 0.1 % 
(TBST)), and then incubated with primary antibody diluted in saturation buffer, for 2 h or 
overnight. After 3 washes with TBST, secondary antibodies were added for 1 h. Luminata Forte 
Western HRP substrate (Millipore) was added and membranes were read with Fusion Fx7 
(PerkinElmer). Anti-HSP90 and/or anti-GAPDH were used as loading control.  
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6.2.4 Biology of the chapter 3.4 
 
CK2β-independent and CK2β(+)-dependent substrates  
The following peptide substrates were employed: a canonical CK2 peptide substrate 
RRREDEESDDEE phosphorylated equally by CK2α and CK2α2β2 (CK2β-independent peptide 
substrate), and MSGDEMIFDPTMSKKKKKKKKP (eIF2 peptide) exclusively phosphorylated by 
CK2α2β2 (CK2β-dependent peptide substrate.294 
CK2 kinase assays were performed in a final assay volume of 18 mL containing 3 mL of 
compounds, 3 mL of CK2α (36 ng) and a mixture of 100 µM peptide substrate, 10 mM MgCl2, and 
1 µCi [γ32P]-ATP. Final concentration of ATP was 100 µM if not specified otherwise. Assays were 
performed under linear kinetic conditions for 5 min at room temperature before termination by 
the addition of 60 µL of 4% TCA. 32P incorporation in peptide substrate was determined as 
previously described.295 
Surface Plasmon Resonance (SPR) 
SPR binding studies were performed using a Reichert SR7000DC instrument optical biosensor 
(Reichert Technologies) equipped with a CMD500m sensor chip obtained from XanTec 
Bioanalytics. CK2 was immobilized by a capturing approach using a monoclonal anti-GST 
antibody (27 kDa, Clone GST-R 6G9 produced in rat, SAB4200055 Sigma Aldrich). Prior to use, the 
anti-GST antibodies were purified twice by micro dialysis at 4°C (Membrane: dialysis tubing 
benzoylated, 9 mm, D2272-5FT) in 10 mM sodium acetate, pH = 5. Anti-GST antibodies were 
immobilized using amine-coupling chemistry at 12°C. The surfaces of all two flow cells were 
activated for 7 min with a 1:1 mixture of 0.1 M NHS (N-hydroxysuccinimide) and 0.1 M EDC (3-
(N,N-dimethylamino) propyl-N-ethylcarbodiimide) at a flow rate of 10 μl/min. The antibody at a 
concentration of 30 μg/ml in 10 mM sodium acetate, pH 5.0, was immobilized at a density of 
2000 RU on flow cell 2; flow cell 1 was left blank to serve as a reference surface. All the surfaces 
were blocked with a 3 min injection at 10 µL/min of 1 M ethanolamine, pH 8.0. GST tagged CK2α 
at a concentration of 50 µg/mL in 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) 
polysorbate 20, pH = 7.4 was captured at a density of 900 RU on flow cell 2.  
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SPR Kd determination 
To collect kinetic binding data, analytes in 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005 % (v/v) 
polysorbate 20, 1% DMSO (v/v), pH = 7.4 were injected over the two flow cells at concentrations 
of 100, 50, 25, 12.5, 6.25, 3.12, 1.56 µM at a flow rate of 25 μl/min and at a temperature of 25°C. 
The complex was allowed to associate and dissociate for 120 s. Duplicate injections (in random 
order) of each sample and a buffer blank were flowed over the two surfaces. Affinities were 
obtained after treatments (DMSO calibration, blank and references subtractions) using the 
software Scrubber 2.0c. 
Cell culture  
MCF10 were cultured as described.293 
Cell viability assay 
Cells were plated into 96-well plates at 1 x 104 cells/well. The following day, the culture medium 
was replaced with fresh medium (90 µL) containing the inhibitors at various concentrations. 
DMSO (0.25 %) and cell free wells were used as control. After 24 h, 10 µL of PrestoBlue® solution 
were added in each well and the plate incubated for 1 h at 37° C in 5 % CO2 atmosphere. 
Results are the average of a triplicate experiment with a standard deviation lower than 10 %. 
EC50 was determined by linear interpolation after transformation to log[c] scale. 
Western Blot analysis 
Cells were plated into 6-well plates at 3 x 105 cells/well. The following day, the culture medium 
was replaced with fresh medium containing the inhibitors at various concentrations or DMSO (0.5 
%) as reference. After incubation for 48 h, medium was removed, cells were washed with cold 
PBS and frozen at -80°C. Primary antibodies were anti-p21, anti-p21-(phosphor-Thr145), anti-
HSP90. Secondary antibodies were peroxidase-conjugated affinity pure Goat anti-rabbit IgG 
(#111035003) and peroxidase-conjugated affinity pure Goat anti-mouse IgG (#115035003) from 
Jackson Immuno Research. Cells were lysed in RIPA buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 
% Triton X-100, 0.1 % SDS, 0.5 % DOC and 1 mM EDTA) containing both protease- and 
phosphatase-inhibitor cocktails (Sigma-Aldrich; P8340, P2850, P5726). Cell homogenates were 
quantified using BCA protein Assay kit (Thermo Scientific). SDS-PAGE was performed using pre-
cast 4-12 % gradient gel (Bio-Rad) and submitted to electrophoresis in NuPAGE buffer (150 V for 
75 min). Separated proteins at 20 µg/lane were transferred to PVDF membranes (100 V for 60 
min). Blotted membranes were blocked during 1 h at room temperature with saturation buffer (1 
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% BSA in Tris Buffer Saline 10 mM, Tween 0.1 % (TBST)), and then incubated with primary antibody 
diluted in saturation buffer, for 2 h or overnight. After 3 washes with TBST, secondary antibodies 
were added for 1 h. Luminata Forte Western HRP substrate (Millipore) was added and 
membranes were read with Fusion Fx7 (PerkinElmer). Anti-HSP90 was used as loading control.  
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